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1. Introduction
1.1   About DANMAP
Antimicrobial resistance is considered a major threat to 
human health. While antimicrobial agents are essential for 
treating disease in humans and in animals, they are also the 
main contributors to the selection and spread of antimicrobial 
resistance. It is, therefore, essential to monitor trends in 
antimicrobial resistance and consumption of antimicrobial 
agents, in order to identify the risk factors that contribute to 
the dissemination of resistance, and the interaction between 
the risk factors. 
Humans and animals constitute over-lapping reservoirs of 
resistance and an integrated approach that takes this into account 
is therefore needed. The Danish Integrated Antimicrobial 
Resistance Monitoring and Research Programme, DANMAP, 
has implemented the One Health approach, comprising the 
entire chain from farm to fork to sickbed, since 1995. The 
organisation and collection of DANMAP data is presented in 
Figure 1.1.
DANMAP was established at the initiative of the Danish 
Ministry of Health and the Danish Ministry of Food, 
Agriculture and Fisheries. The programme participants are the 
National Food Institute and the National Veterinary Institute, 
both at the Technical University of Denmark (DTU), as well 
as Statens Serum Institut (SSI). The DANMAP programme 
is funded jointly by the Ministry of Health, the Ministry of 
Science, Innovation and Higher Education, and the Ministry 
of Food, Agriculture and Fisheries.
The objectives of DANMAP are:
•	 to monitor the consumption of antimicrobial agents in 
food animals and humans;
•	 to monitor the occurrence of antimicrobial resistance in 
bacteria isolated from food animals, food of animal origin 
(e.g. meat) and humans;
•	 to study associations between antimicrobial consumption 
and antimicrobial resistance; and
•	 to identify routes of transmission and areas for further 
research studies.
The monitoring of antimicrobial resistance is based on three 
categories of bacteria: 
•	 Human and animal pathogens that cause infections and 
are thought to reflect resistance caused by the use of 
antimicrobial agents in the respective reservoirs; 
•	 Zoonotic bacteria that can develop resistance in the animal 
reservoir, which may subsequently compromise treatment 
effect when causing infection in humans; 
•	 Indicator bacteria (enterococci and E. coli) due to their 
ubiquitous nature in animals, food and humans, and their 
ability to readily develop or transfer antimicrobial resistance 
in response to selective pressure in both reservoirs. 
All pathogens may be considered reservoirs of resistance 
determinants – genes – that may be disseminated independently 
of the bacterial hosts.
A web annex presenting Minimum inhibitory concentrations 
(MIC) distributions, detailed tables of antimicrobial 
consumption and other additional data are available for 
download at www.danmap.org. Current and previous 
DANMAP reports are also available at the website (PDF 
versions).
Public health risks
Bacteria become resistant either by spontaneous mutation or by transfer of resistance genes from other bacteria. Resistant 
strains are favoured when use of antimicrobial agents provide a selective pressure. This occurs in humans as well as in 
animals undergoing antimicrobial treatment. Resistant bacteria can spread between humans in the community, at healthcare 
centres and at hospitals. Furthermore, resistant bacteria from animals can be transmitted to humans either through direct 
contact with animals and their environment or through ingestion of contaminated food or other contaminated vehicles.
Antimicrobial treatment failure may occur if the ingested resistant bacteria are a direct cause of disease, or if resistance 
determinants are transferred to pathogenic bacteria causing the disease. Bacteria may be resistant to several – sometimes 
all – antimicrobial agents available for treatment, leading to life-threating illness.
Currently, there is only a limited number of antimicrobial agents, with novel modes of actions, under development by 
the pharmaceutical industry. Therefore, it is vital for public health organisations to ensure the continued effectiveness of 
compounds considered critically important to human treatment, by ensuring prudent use for both humans and animals. 
Prudent use should include the restriction of critical antimicrobial agents for use in humans only, as well as the elimination 
of over-use, i.e. only humans and animals suffering from an infection responsive to antimicrobial treatment should be 
exposed to antimicrobial agents.
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Figure 1.1. Organisation of DANMAP
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2. Summary
2.1 Sammendrag
DANMAP (Danish Antimicrobial Resistance Monitoring and 
Research Program) har siden 1995 beskrevet det årlige forbrug 
af antibiotika og forekomsten af antibiotikaresistens hos dyr og 
mennesker i Danmark. Denne udgave beskriver udviklingen i 
2012. 
Antibiotikaforbrug til dyr
Siden 2001 er al anvendelse af receptordineret medicin til dyr 
registreret i det offentlige register VetStat. 
I DANMAP 2012 introducerer vi to nye enheder som 
beskriver udviklingen i antibiotikaforbruget til dyr; DADD 
(defined animal daily dose) som er standard dosis pr dyr pr 
dag og DAPD som angiver DADD pr 1.000 dyr pr dag. DAPD 
er en statistisk måleenhed, der anslår andelen af en population 
(i tusinder), som dagligt behandles med en standard dosis 
antibiotikum. Disse nye enheder bliver primært introduceret 
for at sikre robusthed i analyserne således, at forbrugsdata 
er sammenlignelige over tid samt mellem den veterinære og 
humane sektor. 
I 2012 blev der brugt 112,3 tons antibiotika (aktivt stof) til dyr 
i Danmark. Størstedelen blev anvendt i svineproduktionen 
(76 %) og en mindre andel i kvæg (11 %), pelsdyr (5 %), fisk 
(3 %) og fjerkræproduktionen (1 %). De resterende 4 % blev 
blandt andet brugt til kæledyr og heste. Det totale forbrug (kg 
aktivt stof) til dyr i 2012 var 4 % højere end i 2011.
De overordnede ændringer i antibiotikaforbruget til dyr 
er primært styret af ændringer i forbrugsmønstret til svin. 
Svineproduktionen står for 80 % af den danske kødproduktion, 
men kun 43 % af den totale levende biomasse. Kvæg – primært 
malkekøer – står for 40 % af den levende biomasse. I det 
følgende benytter vi DAPD som enhed, når vi sammenligner 
antibiotikaforbruget mellem dyrearter, da denne enhed tager 
højde for forskelle i biomasse og levetid.
Svin: Det totale antibiotikaforbrug til svin i 2012 var på 86 tons 
aktivt stof. Dette er en stigning på 4 tons i forhold til 2011 og 
svarer til en stigning på 10 %, når forbruget udregnes i DAPD. 
Antibiotikaforbruget til svin har været faldende i perioden 
efter ”Gult kort-ordningen” blev bekendtgjort den 1. juli 
2010. Ordningen, som har til hensigt at reducere forbruget, er 
rettet specifikt mod de svinebesætninger, som har det højeste 
antibiotikaforbrug pr svin. Uagtet stigningen, var forbruget i 
2012 16 % lavere end i 2009 og på niveau med forbruget i 2007.
Stigningen i antibiotikaforbrug (DAPD) skyldtes især et 
øget forbrug af tetracykliner (15 %) og makrolider (19 %), 
som primært tilsættes til foder eller vand i forbindelse med 
mave-tarm lidelser. Visse typer antibiotika – især kinoloner 
og cefalosporiner – er kritisk vigtige i behandling af sygdom 
hos mennesker. I svin var forbruget af 3. og 4. generations 
cefalosporiner meget lavt (1 kg), hvilket er et resultat af, at 
svinebranchen i 2010 frivilligt indførte stop for brugen af 
disse stoffer. Brugen af fluorkinoloner var på det samme lave 
niveau (7 kg), som det har været siden 2003, hvor lovgivning 
om begrænsning af fluorkinolonforbruget trådte i kraft.
Kvæg: Det totale antibiotikaforbrug til kvæg har ligget relativt 
stabilt på ca. 14 tons aktivt stof om året siden 2005. Forbruget af 
beta-laktamase følsomme penicilliner udgjorde som tidligere 
år størstedelen af forbruget. 
Forbruget af 3. og 4. generations cefalosporiner til systemisk 
behandling af malkekvæg steg med 5 % til 47 kg i 2012, 
mens forbruget til intramammær behandling var 7 kg, et 
fald på 13 % i forhold til 2011. Forbruget af fluorkinoloner 
har siden 2003 været stort set nul. Det totale forbrug målt i 
standard doser (DADD) til intramammær behandling var på 
samme niveau som i 2011, men det dækker over ændringer 
i behandlingsmønstret, hvor forbruget til golddyrsbehandling 
steg med 20 %, hvorimod antallet af DADD til behandling af 
klinisk mastitis faldt med 9 %. 
Fjerkræ: Antibiotikaforbruget til fjerkræ var cirka 809 kg aktivt 
stof i 2012, hvilket er 5 % lavere end i 2011. Antibiotikaforbruget 
i den danske fjerkræproduktion, inklusiv avl og opdræt, er 
generelt meget lavt. Forbruget til slagtekyllinger (2 DAPD) faldt 
med hele 61 % efter nogle år med højt forbrug som følge af en 
række sygdomsproblemer i perioden 2008-2011. Bemærk dog, 
at en del af forklaringen på dette fald kan være en ufuldstændig 
rapportering af ordinationer til slagtekyllinger i 2012, men 
omfanget heraf er ikke klarlagt. I æglæggerproduktionen 
forblev antibiotikaforbruget lavt (0,4 DAPD), mens forbruget 
til kalkuner steg med 20 % til 21 DAPD. Det rapporterede 
forbrug af fluorkinoloner har været lavt siden 2006, og har 
ikke været brugt til slagtekyllinger, æglæggere eller kalkuner i 
2012, ligeledes er der ikke rapporteret brug af cefalosporiner til 
fjerkræ i mere end 10 år.
Fisk: Det totale antibiotikaforbrug til fisk i akvakultur var på 
2.900 kg aktivt stof i 2012. Forbruget i ferskvandsdambrug 
steg med 7 % til 11 DAPD, mens forbruget i havbrug steg med 
28 % til 29 DAPD. Antibiotikaforbruget til fisk er meget 
afhængig af vandtemperaturen, og den relativt kolde danske 
sommer i 2012, og især i 2011, har medført et lavere forbrug 
end de foregående år. Desuden har udbredt brug af vaccine 
i den marine produktion siden 2006 begrænset brugen af 
antibiotika.
Kæledyr: Oplysningerne i VetStat vedrørende antibiotikaforbrug 
til kæledyr er mindre detaljerede end oplysningerne vedrørende 
produktionsdyr. Derfor har vi i 2012 kun estimeret forbruget 
af antibiotika til oral behandling af kæledyr (primært katte 
og hunde), hvilket udgjorde ca. 12 DAPD. I 2011 blev det 
estimeret, at den orale behandling udgjorde cirka 70 % af det 
totale forbrug i kæledyr. Den stigning, som er set i det orale 
antibiotikaforbrug til kæledyr siden 2005, fortsatte ikke i 
2012 til trods for, at forbruget af ‘kombinationspenicillinet’ 
amoxicillin i kombination med clavulansyre fortsatte med 
at stige. Det orale forbrug af fluorkinoloner steg med 7 % til 
0,6 DAPD. Forbruget af 3. og 4. generations cefalosporiner til 
kæledyr var på 0,7 DAPD, et niveau som er højere end for nogen 
af produktionsdyrene.
Forbrug af bredspektrede antibiotika, som er kritisk vigtige til 
behandling af alvorlige infektionssygdomme hos mennesker, 
er højt i kæledyr sammenlignet med produktionsdyr og 
mennesker og giver stadig anledning til øget bevågenhed.
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Det totale forbrug til svin målt i kg aktivt stof steg med 5 % 
i 2012, hvilket svarer til en 10 % stigning i DAPD. 
Brugen af kritisk vigtige antibiotika i den danske 
svineproduktion er fortsat lav. Brugen af især bredspektret 
antibiotika til kæledyr er derimod høj sammenlignet med 
forbruget til produktionsdyr, og stigningen i forbruget af 
disse stoffer til kæledyr fortsatte i 2012.
Antibiotikaforbrug til mennesker 
Forbruget af receptordineret medicin på patientniveau er 
blevet overvåget siden begyndelsen af 1990erne.
Totalforbrug: I 2012 faldt det totale forbrug af antibiotika 
til systemisk brug (primærsektoren og hospitalssektoren 
sammenlagt) til mennesker med 2 % (18,90 DDD pr 1000 
indbyggere pr dag (DID) i 2011 sammenholdt med 18,48 DID 
i 2012). Primærsektoren udgjorde 90 % af forbruget. Fra 2003 
til 2012 er det totale forbrug af antibiotika i Danmark steget 
med 3,44 DID (23 %).
I denne DANMAP rapport beskriver vi for første gang forbruget 
af antibiotika samt incidensen af multiresistente bakterier i 
Grønland og på Færøerne (Textbox 1 og Textbox 2).
Primærsektor: Det totale antibiotikaforbrug i primærsektoren 
faldt (3 %) sammenlignet med 2011 (17,06 DID i 2011 og 16,47 
DID i 2012). Dog steg forbruget for nogle grupper af antibiotika. 
De mest udtalte stigninger fra 2011–2012 blev observeret 
for ’kombinationspenicilliner’ (0,16 DID) og tetracykliner 
(0,12 DID). 
I Textbox 5 beskrives forbruget af tetracykliner til henholdsvis 
unge og den samlede befolkning. Det viste sig, at størstedelen 
af tetracykliner i stor udstrækning bruges af unge, og mange 
af recepterne på tetracykliner var til behandling af hudlidelser 
som f.eks. akne. 
Som i de tidligere år udgjorde beta-laktamase følsomme 
penicilliner den største gruppe af antibiotika (29 %), efterfulgt 
af penicilliner med udvidet spektrum (21 %) og makrolider 
(14 %). Penicilliner udgjorde 65 % af det totale forbrug i 
praksis i 2012. Forbruget af bredspektrede antibiotika steg med 
0,3 DID (4 %) i forhold til 2011. 
I det seneste årti er forbruget af antibiotika i primærsektoren 
steget med 22 %, fra 13,53 DID i 2003 til 16,47 DID i 2012. 
I 2012 udgjorde bredspektrede antibiotika 42 % (6,85 DID) 
af det samlede antibiotikaforbrug i primærsektoren, hvilket 
er en stigning på 72 % sammenlignet med 2003 (3,98 DID, 
29 %). Denne stigning skyldes sandsynligvis til dels et øget 
antal DDD pr behandlet patient (definerede dagsdoser) og et 
øget antal DDD pr udskrevet medicinpakning. Sidstnævnte 
kan afspejle ændrede retningslinjer for behandling til kortere 
behandlingstider med højere doser.
På den Europæiske Antibiotikadag i november 2012 lanceredes 
en borgerrettet hjemmeside (www.antibiotikaellerej.dk) om 
anvendelse af antibiotika (Textbox 4).
Hospitaler: På somatiske hospitaler steg det totale 
antibiotikaforbrug opgjort i DDD pr 100 sengedage (DBD) 
med 3 % (2,28 DBD) fra 2011 til 2012. 
Fra 2011 til 2012 steg forbruget af ‘kombinationspenicilliner’ 
(3,49 DBD, 41 %), beta-laktamase resistente penicilliner 
(1,07 DBD, 15 %) og beta-laktamase sensitive penicilliner 
(0,81 DBD, 9 %), mens der sås et fald i forbruget af 
2. generations cefalosporiner (1,99 DBD, 12 %), 3. generations 
cefalosporiner (0,32 DBD, 23 %), carbapenemer (0,30 DBD, 
7 %) og fluorkinoloner (0,68 DBD, 6 %). Ændringerne var i 
overensstemmelse med den nationale vejledning om ordination 
af antibiotika udgivet af Sundhedsstyrelsen, som er beskrevet i 
Textbox 3.
Fra 2003–2012 steg det totale antibiotikaforbrug med 39,4 DBD 
(73 %). Denne stigning skyldtes en kombination af stigning i 
DDD og et fald i antallet af sengedage. I løbet af det seneste årti 
er forbruget af bredspektret antibiotika på somatiske hospitaler 
steget med 133 %, fra 27,11 DBD i 2003 til 63,14 DBD i 2012.
I 2012 faldt det totale forbrug af antibiotika til systemisk 
behandling af mennesker (primær- og hospitalssektoren 
sammenlagt) (2 %) sammenlignet med 2011. Forbruget i 
primærsektoren udgjorde 90 % af det totale forbrug, mens 
forbruget på hospitalerne udgjorde de resterende 10 %. 
Over en 10-årig periode fra 2003 til 2012 steg det totale 
forbrug af antibiotika til mennesker i Danmark med 23 %. 
Generelt steg antibiotikaforbruget i hospitalssektoren med 
3 % fra 2011 til 2012, mens forbruget af 2. og 3. generations 
cefalosporiner, fluorkinoloner og carbapenemer faldt, 
hvilket stemmer overens med den vejledning om 
ordination af antibiotika, som Sundhedsstyrelsen udstedte 
i november 2012.
Resistens i zoonotiske bakterier
Zoonotiske bakterier som Salmonella og Campylobacter 
er sygdomsfremkaldende bakterier, som kan overføres fra 
dyr til mennesker. Udvikles der resistens i disse bakterier i 
husdyrproduktionen, kan resistens overføres til mennesker 
via fødevarer og kan i visse tilfælde medføre behandlingssvigt 
ved sygdom. 
Salmonella Typhimurium er en af de mest almindeligt 
forekommende serotyper i danske svin, dansk svinekød og i 
humane Salmonella infektioner. Blandt S. Typhimurium fra 
svin var 65–67 % af isolaterne resistente overfor ampicillin, 
streptomycin, sulfonamid og tetracyklin, hvilket er en 
stigning i forhold til 2011. Dette kan primært tilskrives den 
stigende forekomst af monofasiske varianter, som ofte er 
multiresistente. I 2012 fandt vi, at 56 % af S. Typhimurium 
isolaterne fra svin var monofasiske. Vi fandt også høj forekomst 
af resistens blandt S. Typhimurium isolater fra dansk svinekød. 
Generelt fandt vi højere forekomst af multiresistens blandt S. 
Typhimurium isolater fra danske svin (66 %) og svinekød 
(59 %), end i Salmonella generelt (Salmonella spp.), hvor hhv. 
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34 % og 32 % var multiresistente. Der blev ikke påvist resistens 
overfor cefalosporiner (ceftiofur og cefotaxim) eller kinoloner 
(ciprofloxacin og nalidixansyre) blandt Salmonella isolaterne 
fra svin eller dansk svinekød. 
Ligesom for svin og svinekød steg den relative forekomst af 
de monofasiske S. Typhimurium varianter blandt isolater fra 
patienter, som havde erhvervet infektionen i Danmark (både 
sporadiske og udbrudstilfælde). Siden 2008 har forekomsten 
af multiresistens været stigende, og i 2012 blev der påvist 
multiresistens i 62 % af S. Typhimurium isolater fra sporadiske 
tilfælde erhvervet i Danmark. Blandt disse tilfælde steg andelen 
af isolater med resistens overfor fluorkinoloner (ciprofloxacin) 
og amfenikoler (fluorfenikol) også. 
Resistensforekomsten var højere for 7 ud af de 16 stoffer, 
som indgik i testpanelet, når man sammenligner isolater 
fra patienter med rejse-relaterede infektioner og isolater fra 
sporadiske infektioner erhvervet i Danmark. Det gælder også 
for fluorkinoloner, som bruges til behandling af patienter med 
alvorlige mave-tarm infektioner forårsaget af både Salmonella 
og Campylobacter.
Forekomsten af multiresistente S. Typhimurium er steget 
i både svin, svinekød og blandt humane infektioner. 
Dette kan hovedsageligt forklares med en øget forekomst 
af monofasiske S. Typhimurium, som har tendens til at 
være multiresistente. Tilsvarende er der set en stigning i 
niveauet af resistens overfor fluorkinoloner, som bruges 
til behandling af alvorlige mave-tarm infektioner.
Resistensforekomsten for 7 ud af de 16 stoffer, som indgik 
i testpanelet, var højere blandt de rejserelaterede tilfælde 
end blandt de hjemligt erhvervede infektioner, heriblandt 
for fluorkinoloner.
Resistensforekomsten i Campylobacter jejuni isolater fra 
kyllinger og kvæg og i Campylobacter coli isolater fra svin var 
på samme niveau som i 2011. Det bør bemærkes, at den stigende 
forekomst af fluorkinolon (ciprofloxacin) og tetracyklin-
resistens, som er observeret i C. jejuni fra slagtekyllinger 
de seneste ti år, ikke fortsatte i 2012. Dette har muligvis en 
sammenhæng med, at brugen af tetracyklin til slagtekyllinger 
faldt i 2012.
Siden 2007 har vi set en stigende forekomst af tetracyklin-
resistens i C. coli fra svin, og i 2012 var 15 % af isolaterne 
tetracyklin resistente. Dette stemmer overens med et generelt 
stigende forbrug af tetracyklin til svin i perioden.
Set i en europæisk sammenhæng er resistensforekomsten i C. 
jejuni fra danske slagtekyllinger og kyllingekød samt C. coli fra 
svin blandt Europas laveste. Fluorkinolon resistens i C. jejuni 
var også højere blandt isolater fra importeret kyllingekød 
(46 %) end fra dansk kyllingekød (29 %). 
Som i de foregående år var forekomsten af fluorkinolon resistens 
i C. jejuni isolater fra patienter med rejse-relaterede infektioner 
(80 %) højere end i isolater fra patienter, hvor infektionen var 
erhvervet i Danmark (35 %). Både blandt patienter med rejse-
relaterede og hjemligt erhvervede infektioner er der sket et fald 
i resistens overfor tetracyklin.
Fluorkinolon resistens i C. jejuni er fortsat højere blandt 
isolater fra importeret kyllingekød sammenlignet med 
dansk kyllingekød, og blandt C. jejuni fra patienter med 
rejse-relaterede infektioner i forhold til patienter, hvor 
infektionen var erhvervet i Danmark.
Clostridium difficile forårsager tarminfektioner hos mennesker 
og har forårsaget hospitalsudbrud både i Danmark og i udlandet 
[DANMAP 2009], hvorfor forekomsten af C. difficile i kvæg, 
svin og kød blev undersøgt. Fra 2010 til 2011 faldt forekomsten 
af C. difficile i svinebesætninger, hvilket muligvis kan forklares 
ved det kraftigt reducerede forbrug af cefalosporiner til svin i 
denne periode (til næsten nul) samt i nogen grad et generelt 
fald i forbruget til svin. Forekomsten af C. difficile var generelt 
lavt i kød (0 % – 7 %) og de mest virulente typer, som kan 
producere binært toksin, blev slet ikke fundet i kød, selv om 
de blev observeret i både kvæg og svin. Den højeste forekomst 
fandt vi i kyllingekød (7 %), men hvorvidt dette skyldes 
slagteprocessen, som adskiller sig meget fra slagteprocesserne 
for kvæg og svin, eller forskelle i forekomsten i de forskellige 
dyrearter kræver nærmere undersøgelse. Selvom der ikke 
blev påvist nogle af de mest virulente typer i prøverne fra kød, 
kan typer observeret med tcdA og tcdB potentielt forårsage 
infektioner hos mennesker, så den zoonotiske vigtighed af 
disse typer bør undersøges yderligere (Textbox 7).
Resistens i indikatorbakterier
Indikatorbakterier er inkluderet i DANMAP overvågningen for 
at kunne give et indblik i den generelle forekomst af resistens i 
raske husdyr og i kød.
Blandt Enterococcus faecium fra slagtekyllinger fandt vi høje 
forekomster af salinomycin-resistens (71 %). Salinomycin 
er et coccidiostika, som bruges i kyllingeproduktionen, men 
det bruges ikke til human behandling, hvorfor salinomycin-
resistens i sig selv ikke udgør en sundhedsrisiko for mennesker. 
Derimod kan kryds-resistens til andre antibiotika være af 
betydning, da 27 % af de salinomycin resistente isolater også var 
resistente overfor andre antibiotika, især erythromycin, som 
tilhører gruppen af antibiotika, som anses for kritisk vigtige 
i den humane behandling. I E. faecalis fra slagtekyllinger steg 
tetracyklin resistens til 43 %, selv om tetracyklinforbruget til 
slagtekyllingerne faldt i perioden. 
Tetracyklin resistens blandt E. faecium og E. faecalis fra svin 
var høj (hhv. 62 % og 87 %), og tetracykliner har været de mest 
benyttede antibiotika i den danske svineproduktion i mange år. 
Erythromycin resistens i E. faecium fra svin har været faldende 
siden 2007 og var i 2012 24 %. I E. faecalis har erythromycin 
resistens derimod været stigende og nåede i 2012 op på 56 %. 
Disse modsatrettede tendenser kunne ikke forklares ud fra de 
tilgængelige data.
I lighed med de foregående år var resistensforekomsten af flere 
testede antibiotika højere i både E. faecium og E. faecalis fra 
importeret kyllingekød end fra dansk produceret kyllingekød. 
Resistensforekomsten i E. faecium og E. faecalis fra dansk 
og importeret svinekød var på samme niveau, på nær for 
tetracyklin i E. faecalis, som var højere i importeret svinekød. 
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Set i et ’One Health’ perspektiv er der en direkte sammenhæng 
mellem antibiotikaforbruget i kyllingeproduktionen og 
forekomsten af antibiotikaresistente enterokokker i det danske 
kyllingekød. Derimod finder vi, at enterokokkerne fra svin 
er betragtelig mere resistente end isolaterne fra det danske 
svinekød. Mulige forklaringer kan være, at nogle af de mere 
følsomme typer er bedre til at overleve slagteprocessen end 
de resistente typer, og/eller at kødet krydskontamineres på 
slagteriet eller i opskæringsvirksomheden.
Vi fandt et højt niveau af resistens mod salinomycin – et 
coccidiostatika - blandt enterokok isolater fra kyllinger. 
Flertallet af disse isolater var fuldt følsomme for de fleste 
andre antibiotika i testpanelet, men det skal bemærkes, 
at 22 % af de salinomycin resistente isolater også var 
resistente for andre antibiotika, særligt erythromycin 
(18 %).
Indikator Escherichia coli fra slagtekyllinger var ofte 
resistente overfor sulfonamid (21 %) og ampicillin (20 %), 
som typisk bruges til slagtekyllinger. Vi påviste fluorkinolon 
(ciprofloxacin) resistens i 8 % af isolaterne, og resistens 
overfor 3. generations cefalosporiner (ceftiofur) blev påvist 
i to isolater fra slagtekyllinger. Resistensforekomsten i E. coli 
fra slagtekyllinger og dansk kyllingekød var sammenlignelig. 
Resistensforekomsten i isolater fra kvæg og dansk oksekød var 
som foregåede år ganske lav. Resistens i E. coli fra svin var den 
højeste blandt produktionsdyrene og forblev på samme høje 
niveau som i 2011, på nær et mindre fald i spectinomycin-
resistens. 
Blandt isolaterne fra kød havde isolaterne fra importeret 
kyllingekød generelt de højeste resistensforekomster – også 
når det gjaldt de kritisk vigtige antibiotika. Sammenlignet 
med dansk kyllingekød havde E. coli isolater fra importeret 
kyllingekød højere resistens overfor 13 af de 16 testede 
antibiotika. For svinekød havde E. coli isolater fra importeret kød 
højere resistensforekomst overfor ampicillin, chloramfenicol, 
ciprofloxacin og tetracyklin end isolaterne fra dansk svinekød.
ESBL-producerende bakterier er et af de hurtigst voksende 
resistensproblemer verden over. Flere nyere studier finder 
de samme ESBL gener, plasmider og kloner af E. coli isolater 
i både dyr og i mennesker med infektioner, hvilket tyder 
på et zoonotisk link. Forekomsten af Enterobacteriaceae 
bakterier, der er resistente overfor carbapenemer, er også en 
voksende trussel, idet carbapenemer er sidste mulighed for 
antibiotikabehandling af mennesker med infektioner, der 
skyldes multiresistente Gram-negative bakterier.
Otte procent af slagtesvinene havde ESBL-producerende E. coli, 
hvilket var højere end i 2011, men lavere end i 2010. Den højeste 
prævalens of ESBL-producerende E. coli i kødprøver blev fundet 
i importeret kyllingekød (61 %), hvilket også udgør en stigning 
i forhold til 2011. Forekomsten af ESBL-producerende E. coli i 
det importerede kyllingekød var også højere end i det danske 
kyllingekød, hvor vi fandt ESBL-producerende E. coli i 36 % 
af prøverne, hvilket er samme niveau som i 2011. I de andre 
kødtyper var forekomsten lav (0–2 %). ESBL-producerende 
E. coli fra produktionsdyr og kød fra 2011 og 2012 blev testet 
for carbapenem resistens, og ingen af de testede isolater var 
resistente overfor carbapenemer. Derfor er der ikke noget der 
tyder på at kød eller produktionsdyr i Danmark er kilde til 
carbapenemase gener i human kliniske bakterier (Textbox 8).
Indikator E. coli fra svin havde de højeste resistens-
forekomster blandt isolater fra produktionsdyr. I kød 
påviste vi de højeste resistensforekomster i isolater fra 
importeret svine- og kyllingekød. Forekomsten af ESBL-
producerende E. coli i svin steg, men var stadig under 
niveauet i 2010. Kyllingekød anses stadig for at være 
den vigtigste kilde til ESBL-producerende E. coli. Der 
blev ikke påvist carbapenem-resistente E. coli fra de 
undersøgte produktionsdyr eller kødprøver.
Resistens i bakterier fra diagnostiske indsendelser 
fra mennesker
Rapporteringen af antibiotikaresistens i bakterier fra 
diagnostisk indsendelser fra mennesker er baseret på frivillig 
indsendelse af data fra DANRES-gruppen, som dækker de 
Klinisk Mikrobiologiske Afdelinger (KMA) i Danmark. 
Undtagelser omfatter methicillin-resistente Staphylococcus 
aureus (MRSA) og invasive Streptococcus pneumoniae, som 
er anmeldepligtige. Data vedr. disse bakterier kommer fra 
referencelaboratorierne på SSI.
Blandt Escherichia coli isolater fra blod var forekomsten af 
3. generations cefalosporin resistens 7 % i 2012, hvilket er det 
samme niveau som i 2011, men højere end i de andre nordiske 
lande i 2011. Resistens for 3. generations cefalosporiner er kun 
rapporteret siden 2008; i denne periode er resistensen steget. 
Ciprofloxacin resistens var 14 % i 2012, dette var det samme 
niveau som i 2011. I løbet af det seneste årti er resistens for 
cefuroxim, ciprofloxacin og gentamicin steget. Ampicillin 
resistens faldt fra 48 % i 2011 til 45 % i 2012.
Blandt E. coli isolater fra urin fra patienter på hospital 
faldt forekomsten af ciprofloxacin resistens fra 13 % i 2011 til 
12 % i 2012, hvilket er et brud med den stigende tendens set 
siden 2003, hvor 2 % af isolaterne var ciprofloxacin resistente. 
Aminoglykosid (gentamicin) resistens steg fra 4 % i 2011 til 5 % 
i 2012. Sulfonamid resistens faldt fra 35 % i 2011 til 33 % i 2012.
Blandt E. coli isolater fra urin fra patienter i almen praksis 
steg forekomsten af ciprofloxacin resistens støt fra 2 % i 2003 til 
10 % i 2012. Sulfonamid resistens faldt fra 35 % i 2011 til 33 % i 
2012, og ampicillin resistens faldt fra 41 % i 2011 til 40 % i 2012.
I 2012 havde 2.511 patienter en urinvejsinfektion med en 3. 
generations cefalosporin resistent E. coli. Blandt E. coli urin-
isolater fra patienter på hospital steg forekomsten af både 
2. og 3. generations cefalosporin resistens fra 5 % i 2011 til 
6 % i 2012, og blandt E. coli urin-isolater fra patienter i praksis 
steg forekomsten af både 2. og 3. generations cefalosporin 
resistens fra 3 % i 2011 til 4 % i 2012. Den stigende forekomst af 
3. generations cefalosporin resistens blandt E. coli urin-isolater 
er beskrevet i Textbox 9.
Carbapenem (meropenem) resistens blev observeret i E. coli 
blod-isolater (n = 1) og urin-isolater fra både hospitaler (n = 
6) og praksis (n = 9). Blandt disse isolater blev identificeret 
den første NDM-4 producerende E. coli i Danmark samt to 
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VIM-4 producerende E. coli. Forekomsten af carbapenemase-
producerende bakterier i Danmark i 2012 er beskrevet i 
Textbox 11. Forekomsten af carbapenem resistens er ikke 
anmeldepligtig.
Blandt Klebsiella pneumoniae isolater fra blod var 
forekomsten af 3. generations cefalosporin resistens (9 %) og 
aminoglykosid (gentamicin, 6 %) resistens på samme niveau 
som i 2011, mens ciprofloxacin resistens faldt fra 12 % i 2011 
til 9 % i 2012. Niveauet var højere end i de andre nordiske lande 
og på samme niveau som i flere europæiske lande i 2011.
Blandt K. pneumoniae isolater fra urin var forekomsten af 3. 
generations cefalosporin resistens 8 % i isolater fra hospitaler 
og 5 % i isolater fra praksis, hvilket er samme niveau som i 
2011. Ciprofloxacin resistens faldt fra 11 % i 2011 til 9 % i 
2012 i urin-isolater fra hospitaler; i urin-isolater fra praksis 
var ciprofloxacin resistens 8 %, hvilket er samme niveau som 
i 2011. Mecillinam resistens faldt fra 12 % i 2011 til 11 % i 
2012 i isolater fra praksis; i urin-isolater fra hospitaler var 
mecillinam resistens også 11 %, hvilket er samme niveau som i 
2011. Sulfonamid resistens faldt fra 33 % i 2011 til 24 % i 2012 
i urin-isolater fra hospitaler og fra 35 % i 2011 til 26 % i 2012 i 
urin-isolater fra praksis.
Carbapenem (meropenem) resistens blev observeret i 
K. pneumoniae blod-isolater (n = 2) og urin-isolater fra 
både hospitaler (n = 3) og praksis (n = 2). Forekomsten af 
carbapenemase-producerende bakterier i Danmark i 2012 er 
beskrevet i Textbox 11.
I perioden januar–maj 2012 blev der udført en national 
undersøgelse af Bacteroides fragilis gruppe isolater fra 
bloddyrkninger fra 11 af landets 13 KMAer. I alt blev der 
inkluderet 118 blod-isolater fra B. fragilis gruppen. Ingen 
af isolaterne var resistente for metronidazol. Der sås en høj 
frekvens af nedsat følsomhed for piperacillin-tazobactam og 
clindamycin i B. thetaiotaomicron isolater og for meropenem i 
B. fragilis isolater (Textbox 10). 
Blandt Pseudomonas aeruginosa blod-isolater var niveauet af 
resistens for alle testede antibiotika ikke signifikant forskelligt 
fra niveauet i 2011, men der sås en stigende tendens for 
gentamicin resistens i perioden 2007–2012 og for meropenem 
resistens i perioden 2007–2011. Meropenem resistens blev 
observeret i 4 % af P. aeruginosa blod-isolater i 2012. I løbet af 
2012 blev der identificeret fire VIM-producerende P. aeruginosa 
isolater på SSI (Textbox 11).
I 2012 var forekomsten af resistens for penicillin og 
erythromycin stadig lav blandt Streptococcus pneumoniae og 
gruppe A, B, C og G streptokokker.
Forekomsten af ampicillin resistens i Enterococcus faecium 
isolater fra blod var 94 % i 2012, hvilket er samme niveau som 
i 2011. Vancomycin resistens var 1,8 % i E. faecium og 0,2 % i 
E. faecalis blod-isolater. I 2012 rapporterede to KMAer udbrud 
med vancomycin resistente E. faecium (vanA). To andre 
KMAer testede enterokokker fra blodinfektioner for højniveau 
gentamicin resistens (HLGR); 27 % af de testede E. faecalis 
isolater og 62 % af de testede E. faecium isolater var HLGR.
I løbet af det seneste årti er ciprofloxacinresistens i Neisseria 
gonorrhoeae steget støt fra 30 % i 2003 til 75 % i 2009, efterfulgt 
af et fald til 57 % i 2012. Penicillinase produktion blandt 
gonococcus isolater svingede mellem 12–24 % fra 2003–2012, 
og der blev ikke rapporteret hverken ceftriaxon resistente 
isolater eller tilfælde af ceftriaxon behandlingssvigt i denne 
periode. Fra 2009–2012 faldt azithromycin resistens fra 46 % til 
12 %, cefixim resistens svingede mellem 11–21 %, og der blev 
ikke detekteret spectinomycin resistente isolater (Textbox 12).
I 2012 blev der indrapporteret 1.528 tilfælde af Staphylococcus 
aureus bakteriæmi svarende til en incidens på 27,4 tilfælde pr 
100.000 indbyggere. Heraf var antallet af methicillin-resistente 
S. aureus (MRSA) 19 (1,2 %), hvilket er på samme niveau som 
tidligere år og blandt de laveste incidenser observeret i Europa. 
Den højeste resistensforekomst udover penicillin resistens 
var resistens for fusidinsyre (14 %), erythromycin (6 %), 
clindamycin (6 %) og norfloxacin (4 %). Niveauet af resistens 
for de testede antibiotika var det samme som i 2011.
Antallet af nye MRSA tilfælde (både koloniserede og inficerede 
personer) steg i 2012 til 1.556 sammenlignet med 1.292 i 
2011. Den stigning, der startede i 2010, fortsatte således i 
2012. Stigningen blev primært set i tilfælde kategoriseret som 
samfundserhvervede, 596 i 2011 vs. 726 i 2012. Andelen af 
patienter med infektion var på samme niveau i 2012 som i 
2011 (54 % vs. 53 %). Antallet af hospitalserhvervede tilfælde 
var fortsat lavt og udgjorde kun 4 % af det totale antal MRSA 
tilfælde i 2012.
Landbrugs-associerede MRSA (LA-MRSA) tilhører primært 
klonal kompleks CC398. Antallet af MRSA påvisninger hos 
mennesker tilhørende CC398, som er associeret med svin, steg 
fra 164 i 2011 til 232 i 2012. Den mest almindelige spa type 
relateret til CC398 var type t034 (n = 185), hvoraf 75 af t034-
tilfældene havde en egentlig MRSA infektion. MRSA isolater 
med den nye mecA homolog mecC blev fundet i 24 tilfælde (9 i 
2009, 21 i 2010 og 37 i 2011).
Svin ved slagtning og tankmælksprøver fra mælkeproducenter 
blev testet for MRSA. Prævalensen af MRSA hos svin ved slagtning 
var 77 %, hvilket er signifikant højere end tidligere år (13 % i 2009 
og 44 % i 2011, Textbox 13). Som i de tidligere år var t034 og t011 de 
mest almindelige spa typer. Der blev for første gang påvist MRSA 
i tankmælk. I alt 4 prøver var positive (2 %), og alle isolater var 
af MRSA mecA typen med spa typer korresponderede til CC398 
og CC1, typer der tidligere er fundet hos svin. MRSA med mecC 
typen blev ikke fundet blandt svin eller i tankmælk.
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I 2012 steg det totale antal af nye MRSA tilfælde til 1,556. 
Stigningen sås primært i tilfælde kategoriseret som 
samfundserhvervede. Antallet af hospitalserhvervede 
tilfælde var fortsat lavt og udgjorde kun 4 % af det totale 
antal MRSA tilfælde i 2012. Antallet af MRSA af typen 
CC398, som er associeret med svin, steg fra 164 i 2011 til 
232 i 2012. CC398 er nu den anden oftest forekommende 
CC gruppe blandt humane MRSA cases. Antallet af MRSA 
isolater, der indeholder mecC hos mennesker, ser ud til at 
være stabiliseret.
Prævalensen af MRSA hos svin ved slagtning steg kraftigt, 
men hvorvidt flere besætninger er MRSA positive vides 
ikke. Svin er stadig det vigtigste reservoir for MRSA CC398, 
men LA-MRSA CC398 blev også påvist i tankmælk, 
hvilket kan skyldes en spredning fra svineproduktionen.
 
I 2012 havde 2,511 patienter en urinvejsinfektion med 
en 3. generations cefalosporin resistent E. coli. I E. coli 
urin-isolater fra patienter på hospital steg resistens for 
3. generations cefalosporiner til 6 % i 2012, og i E. coli 
urin-isolater fra patienter i praksis steg resistens for 
3. generations cefalosporiner til 4 % i 2012.
Der blev observeret høj frekvens af nedsat følsomhed 
for piperacillin-tazobactam og clindamycin i isolater fra 
Bacteroides fragilis gruppen.
Der blev identificeret fire nye tilfælde af carbapenemase-
producerende Enterobacteriaceae (CPE) og fire 
carbapenemase-producerende (VIM) P. aeruginosa i 
2012. Endvidere sås et udbrud med carbapenemase-
producerende (OXA-23) A. baumanii i 2012.
I 2012 rapporterede to KMAer udbrud med vancomycin 
resistente E. faecium (vanA).
2.2  Summary
 
DANMAP (Danish Antimicrobial Resistance Monitoring and 
Research Program) has monitored antimicrobial resistance 
and consumption of antimicrobial agents in food animals 
and in humans in Denmark since 1995. This report describes 
changes and trends in 2012.
Antimicrobial consumption in animals
Data on all medicines prescribed by veterinarians have been 
registered at the farm and species level by the official VetStat 
programme since 2001.
In DANMAP 2012, we have introduced two new metrics to 
follow trends in antimicrobial consumption – defined animal 
daily doses (DADD) and DADD per 1,000 animals per day 
(DAPD). DAPD is a statistical measure, providing an estimate 
of the proportion of animals (in thousands) treated daily with 
a particular antimicrobial agent. These new metrics have been 
introduced primarily to ensure the robustness of the analyses 
over time and to facilitate comparisons between animal 
species, as well as comparisons between the veterinary and 
human sectors. 
The total consumption of antimicrobial agents in 2012 
amounted to 112.3 tonnes of active compounds, a 4% 
increase compared with 2011. Pigs accounted for 76%, cattle 
for approximately 11%, fur animals for 5%, aquaculture for 
3%, and poultry for 1% of the total veterinary consumption 
of antimicrobials measured in kg active compounds. The 
remaining 4% was used in companion animals and others. 
The overall changes in veterinary consumption are generally 
driven by changes in consumption in pig production. Pigs account 
for approximately 80% of the meat production in Denmark, but 
only 43% of the total live biomass, while adult cattle – mainly 
dairy cows - constitute another 40% of the total live biomass.
Pigs: The total consumption of veterinary antimicrobial agents 
in Danish pig production was 86 tonnes. This was an increase 
of 4 tonnes (5%) compared with 2011, corresponding to a 10% 
increase when measured in DAPD. This follows a decrease in 
2010–2011, which was probably the result of the introduction 
of legislation to reduce overuse of antimicrobials in the pig 
production. Even though antimicrobial consumption increased 
in 2012, it remained at a level 16% lower than in 2009, and 
similar to the 2007 level. 
In 2012, the increase in consumption (DAPD) was attributed 
mainly to an increase in prescriptions of tetracyclines (15%) 
and macrolides (19%) that are mostly used in feed or water 
medication for gastrointestinal disease. The use of 3rd and 4th 
generation cephalosporins in pigs remained close to zero (1 kg), 
as a result of a voluntary ban on cephalosporins introduced by 
the Danish pig industry in 2010. The use of fluoroquinolones 
remained at the same low level (7 kg) as has been observed 
since legal restrictions were enforced in 2003.
Cattle: Overall, the antimicrobial consumption in cattle has 
remained stable at around 14 tonnes since 2005, and beta-
lactamase sensitive penicillins account for the majority of 
the consumption. For critically important antimicrobials, the 
use of fluoroquinolones has been close to zero since 2003. In 
DANMAP 2012  
                                                                           
       16
SUMMARY2.
contrast, use of 3rd and 4th generation cephalosporins for 
systemic treatment increased by 5% to 47 kg, whereas the 
intramammary use decreased by 13% to 7 kg. The overall use of 
antimicrobials for intramammary treatment was unchanged, 
however, use of drying-off treatment increased by 20%, while 
therapeutic treatment of mastitis decreased by 9%. 
Poultry: In 2012, the overall consumption of antimicrobial 
agents in poultry was approximately 809 kg active compound, 
which represents a 5% decrease compared with 2011. The usage 
of antimicrobial agents in the broiler and layer production, 
including rearing and breeding, is generally very low. In 2012, 
the consumption in broilers (2 DAPD) decreased by 61%, 
following an increased consumption due to disease problems 
in 2008–2011. A part of this decrease may be explained by 
incomplete reporting of use in broilers during 2012, although 
the magnitude of underreporting is uncertain. In layers, the 
consumption remained very low (0.4 DAPD), whereas the 
antimicrobial consumption in turkeys increased by 20% 
(21 DAPD). The reported use of fluoroquinolones in poultry 
has been low since 2006, and they were not used in the 
production of broilers, layers or turkeys in 2012. Furthermore, 
use of cephalosporins has not been reported in Danish poultry 
production for more than a decade.
Aquaculture: The overall antimicrobial consumption in 
aquaculture was 2,900 kg in 2012. The consumption in fresh 
water fish increased by 7% to 11 DAPD, while the consumption 
in marine aquaculture increased by 28% to 29 DAPD, assuming 
an unchanged production.  However, the consumption in 
marine aquaculture 2011–2012 was very low compared to 
previous years probably due to cold summers in 2011–2012 and 
effects of improved vaccination schemes since 2006.
Pet animals: The information available on antimicrobial 
consumption in pet animals is not as detailed as for production 
animals. Therefore, we only estimated the consumption of 
antimicrobial agents used for oral treatment in pet animals 
(mainly cats and dogs), which amounted to 12 DAPD in 2012. 
In 2011, we estimated oral use to account for about 70% of the 
total consumption in pet animals. The increasing trend in oral 
treatment of pet animals observed since 2005 did not continue, 
however the use of the broad-spectrum combination penicillins 
(amoxicillin with clavulanic acid) continued to increase. The oral 
use of fluoroquinolones increased by 7% to 0.6 DAPD in 2012. 
The consumption of 3rd and 4th generation cephalosporins in 
pet companion animals was 0.7 DAPD, which is higher than for 
any production animal species.
The consumption in pet animals of broad-spectrum 
antimicrobials and the use of antimicrobial agents critical for 
treatment of human infections is high compared with both 
production animals and humans and are still a matter of 
concern.
The total consumption (kg active compound) in pigs 
increased by 5.4% in 2012 corresponding to a 10% 
increase in DAPD. 
Use of critically important antimicrobials in the pig 
production remains low. Use of critically important and 
broad-spectrum antimicrobial agents in pet animals 
is high compared with other species, and continued to 
increase in 2012.
Antimicrobial consumption in humans  
The use of prescription medicines at the level of the individual 
patient has been monitored since the early 1990s. 
Total consumption: In 2012, the total consumption of 
antimicrobial agents for systemic use (primary health care 
and hospital care) decreased by 2% (from 18.90 DDD per 
1,000 inhabitants per day (DID) in 2011 compared to 18.48 
DID in 2012). Primary health care contributed with 90% of 
the overall consumption. Since 2003, the total consumption of 
antimicrobial agents in humans in Denmark has increased by 
3.44 DID (23%). 
For the first time, we report consumption of antimicrobial 
agents and incidence of multi-resistant bacteria in Greenland 
and Faroe Islands (Textbox 1 and Textbox 2).
Primary health care: In 2012, the total consumption of 
antimicrobial agents for systemic use in primary health care 
decreased slightly by 3% compared with 2011 (from 17.06 
DID in 2011 to 16.47 DID in 2012). However, consumption 
of some classes of antimicrobial agents increased. The most 
pronounced increases from 2011–2012 were for ‘combination 
penicillins’ (0.16 DID) and tetracyclines (0.12 DID).
  
In Textbox 5, the consumption of tetracyclines from 2008–2011 
in young adults and the population as a whole is described. 
We found that tetracyclines are used to a great extent among 
adolescents, and many of the prescriptions with tetracyclines 
were given for skin disorders such as acne.
As in previous years, beta-lactamase sensitive penicillins 
represented the largest therapeutic group of antimicrobial 
agents consumed in 2012 (29%), followed by penicillins with 
extended spectrum (21%) and macrolides (14%). Penicillins 
accounted for 65% of the total consumption in 2012. 
Consumption of broad-spectrum agents increased by 0.3 DID 
(4%) compared with 2011.
During the past decade, antimicrobial consumption in primary 
health care has increased by 22%, from 13.53 DID in 2003 to 
16.47 DID in 2012. In 2012, broad-spectrum agents accounted 
for 42% (6.85 DID) of the total antimicrobial consumption 
which, compared with 2003 (3.98 DID, 29%), represents an 
increase of 72%. This increase is most likely driven by rises in 
DDDs per treated patient and number of DDDs per prescribed 
package. The latter may reflect a change in guidelines advising 
shorter treatment regimens at higher dosages. 
A citizen-centered website on how and when to use 
antimicrobial agents (www.antibiotikaellerej.dk) was launched 
on the European Antibiotic Awareness Day in November 2012 
(Textbox 4).
Hospitals: In somatic hospitals, the consumption of 
antimicrobial agents expressed in DDDs per 100 occupied bed-
days (DBD) increased by 2.28 DBD (3%) from 2011 to 2012. 
From 2011 to 2012, consumption increased for ‘combination 
penicillins’ (3.49 DBD, 41%), beta lactamase resistant penicillins 
(1.07 DBD, 15%), and beta lactamase sensitive penicillins 
(0.81 DBD, 9%). In contrast, consumption decreased for 2nd 
generation cephalosporins (1.99 DBD, 12%), 3rd generation 
cephalosporins (0.32 DBD, 23%), carbapenems (0.30 DBD, 
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7%), and fluoroquinolones (0.68 DBD, 6%). The changes were 
in agreement with the national guidelines on prescribing 
antibiotics from the Danish Health and Medicines Authority 
described in Textbox 3. 
From 2003–2012, the consumption of antimicrobial agents 
by humans in hospitals increased by 39.4 DBD (73%). This 
increase was due to a combination of increased DDDs and 
a decreased number of hospital bed-days. During the past 
decade, the consumption of broad-spectrum antimicrobial 
agents in somatic hospitals has increased by 133%, from 27.11 
DBD in 2003 to 63.14 DBD in 2012.
In humans, the overall consumption in 2012 of 
antimicrobial agents for systemic use decreased  (2%) 
compared with 2011. Antimicrobial consumption in 
the primary health care sector represented 90% of the 
total consumption and the hospital sector accounted 
for the remaining 10%. From 2003 to 2012, the total 
consumption of antimicrobial agents by humans in 
Denmark increased by 23%. In the hospital sector, the 
consumption of antimicrobial agents increased by 3% 
from 2011 to 2012, however a decreased consumption 
was observed for 2nd and 3rd generation cephalosporins, 
fluoroquinolones and carbapenems, which is in 
agreement with the national guidelines on prescribing 
antibiotics issued by the Danish Health and Medicines 
Authority in November 2012.
Resistance in zoonotic bacteria
Zoonotic bacteria such as Salmonella and Campylobacter 
can develop resistance in the animal reservoir. The resistant 
bacteria may be transferred to humans via food and may 
subsequently compromise treatment effect when causing 
infection in humans. 
Salmonella Typhimurium is one of the most common 
serovars in Danish pigs and pork. Among S. Typhimurium 
from pigs, 65–67% of the isolates were resistant to ampicillin, 
streptomycin, sulfonamide, and tetracycline; an increase 
compared with 2011. This can mainly be attributed to an 
increasing prevalence of monophasic S. Typhimurium that 
have a strong tendency to be multi-resistant. In 2012, 56% of 
the S. Typhimurium isolates from pigs were of the monophasic 
variants. We also found high levels of resistance in the tested S. 
Typhimurium isolates from pork. Generally, we found higher 
levels of multi-resistance among S. Typhimurium isolates 
from Danish pigs (66%) and pork (59%) compared with other 
Salmonella spp. isolates, where 34% and 32% were multi-
resistant, respectively. Notably, no resistance to cephalosporins 
(ceftiofur or cefotaxim) or quinolones (ciprofloxacin or 
nalidixic acid) was observed among Salmonella from Danish 
pigs or pork. 
As in isolates from pigs and pork, the occurrence of monophasic 
variants of S. Typhimurium in humans increased in prevalence 
among both domestic sporadic cases and outbreaks. This was 
also reflected in an increase in multi-resistance that has been 
seen since 2008. In 2012, multi-resistant isolates were recovered 
from 62% of the domestic sporadic cases. In S. Typhimurium 
from human domestic cases, resistance to fluoroquinolones 
(ciprofloxacin) and amphenicols (florfenicol) also increased. 
Resistance to 7 of the 16 tested compounds was higher among 
travel-associated cases than domestic human cases, including 
resistance to fluoroquinolones, which are used for empiric 
treatment of adults with severe bacterial gastroenteritis caused 
by both Salmonella and Campylobacter.
Resistance among Campylobacter jejuni isolates from Danish 
broilers and cattle and Campylobacter coli from Danish pigs 
remained at the same levels as in 2011. It is however noteworthy, 
that the increasing trend in fluoroquinolone (ciprofloxacin) 
and tetracycline resistance, which has been observed in C. 
jejuni from broilers for almost a decade, did not continue in 
2012. This corresponds to the decrease in consumption of 
tetracycline in the broiler production.
We have seen an increasing trend in tetracycline resistance in 
C. coli from pigs since 2007, and in 2012, 15% of the isolates 
were tetracycline resistant. This trend generally matches the 
growth in consumption of tetracycline in the pig production 
over the past years.
In a European context, Denmark reports the lowest levels of 
antimicrobial resistance among C. jejuni from broilers and 
broiler meat and for C. coli isolates obtained from pigs. 
For several years, the level of fluoroquinolone resistance in C. 
jejuni has been higher among isolates from imported broiler 
meat (46%), compared with isolates from Danish broiler meat 
(29%). 
In 2012, the C. jejuni isolates from the travel-associated cases 
continued to have a significantly higher level of fluoroquinolone 
resistance (80%) compared with domestic cases (35%). It is 
worth noting that the level of tetracycline resistance decreased 
in C. jejuni isolates from both domestic cases and cases 
associated with travel.
The level of multi-resistant S. Typhimurium increased in 
pigs, pork and humans. This can mainly be attributed to 
an increasing prevalence of monophasic S. Typhimurium 
that have a strong tendency to be multi-resistant. In human 
sporadic cases, resistance to fluoroquinolones, which is 
used for empiric treatment of adults with severe bacterial 
gastroenteritis, also increased. Resistance to 7 of the 16 
tested compounds was higher among travel-associated 
cases than domestic human cases, including resistance to 
fluoroquinolones.
The level of fluoroquinolone (ciprofloxacin) resistance 
in C. jejuni is still higher among isolates from imported 
broiler meat compared with isolates from Danish broiler 
meat, and among C. jejuni from travel-associated cases 
compared with domestic cases.
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Clostridium difficile is causing intestinal infections in humans 
and has caused outbreaks in hospitals in Denmark and in 
other countries [DANMAP 2009]. Therefore, the occurrence 
of C. difficile in cattle, pigs and meat was investigated. The 
occurrence of C. difficile decreased in pig farms from 2010 to 
2011, and this may be explained by a reduction close to zero 
of cephalosporin consumption and to some extent reduction 
in the total consumption in pigs during the same period. The 
prevalence of C. difficile was generally low in meat (0%-7%) 
and none of the most virulent types containing the binary 
toxin were observed in the meat, although present in cattle and 
pigs. The highest prevalence was observed in the broiler meat 
(7%), but whether this was due to differences in the slaughter 
processes for broilers compared to pigs and cattle or differences 
in occurrence in the animals requires further investigation. 
Although none of the most virulent types were detected in 
the meat samples, the types observed with tcdA and tcdB may 
contribute to human infections, so the zoonotic importance of 
these types should be further investigated (Textbox 7).
Resistance in indicator bacteria
Indicator bacteria, enterococci and Escherichia coli, are 
included in the DANMAP programme to provide information 
about the general levels of resistance in healthy production 
animals and meat.
In Enterocuccus faecium from Danish broilers, we observed 
high levels of salinomycin resistance (71%). Salinomycin is not 
used for treating humans, so salinomycin resistance in itself 
does not pose a public health problem. However, co-resistance 
with other antimicrobial agents can be of importance, and 
in 2012, 27% of the salinomycin-resistant isolates were also 
resistant to other antimicrobial agents, especially erythromycin, 
which belongs to the group of antimicrobial agents considered 
of critical importance in human medicine. In Enterocuccus 
faecalis from broilers, resistance to tetracycline increased 
to 43%, in contrast to the reduced usage of tetracyclines in 
broilers. 
Among E. faecium and E. faecalis from pigs, the highest 
occurrence of resistance was to tetracycline (62% and 87%, 
respectively). Tetracycline has been the most widely used 
antimicrobial agent in the Danish pig production for a decade. 
Erythromycin resistance in E. faecium from pigs was 24% and 
has been declining since 2007. However, in E. faecalis, resistance 
has increased, reaching 56% in 2012. These contrasting results 
could not be explained from the data available. 
Among isolates from broiler meat, the highest level of resistance 
to several compounds was observed in imported broiler meat, 
similar to previous years. In general, resistance to antimicrobial 
agents of critical importance for human treatment was low, but 
fluoroquinolone (ciprofloxacin) resistance was observed in two 
E. faecalis isolates from imported broiler meat. Occurrences 
of resistance were similar among E. faecium and E. faecalis 
from Danish and imported pork, except for a higher level of 
tetracycline resistance among E. faecalis from imported pork.
A high level of resistance to the coccidiostat salinomycin 
was observed in enterococci from broilers. Although 
most of these isolates were susceptible to all other 
compounds, 22% of the salinomycin-resistant isolates 
were also resistant to other antimicrobial agents, 
especially erythromycin (18%).
In a One Health perspective, the usage of antimicrobial 
agents in the broiler production can be directly linked to the 
prevalence of antimicrobial resistance in the Danish broiler 
meat. But Danish pork enterococcal isolates were in general 
more susceptible when compared with isolates from pigs, 
possibly due to better survival of more susceptible subtypes or 
due to cross contamination in the meat processing chain. 
Indicator Escherichia coli from broilers were most often 
resistant to sulfonamide (21%) and ampicillin (20%), which can 
be explained by the usage pattern. Resistance to fluoroquinolones 
was observed in 8% of the isolates and ceftiofur (3rd generation 
cephalosporin) resistance was observed in two E. coli isolates 
from broilers. Resistance in isolates from Danish broiler meat 
reflected the findings in the broilers. Resistance in isolates from 
cattle and beef was generally low. The highest occurrence among 
production animals was observed in pigs, and resistance was at 
the same level as in 2011 except for a decrease in resistance to 
spectinomycin. In isolates from meat, the highest occurrence 
of resistance, including resistance to critically important 
antimicrobials, was found in imported broiler meat. Compared 
with Danish broiler meat, we found higher levels of resistance 
for 13 of 16 tested antimicrobial agents from imported broiler 
meat. For E. coli from pork of domestic origin, resistance to 
ampicillin, chloramphenicol, ciprofloxacin and tetracycline was 
significantly lower than among isolates from imported pork.
Extended spectrum beta-lactamase (ESBL)-producing 
bacteria is one of the fastest emerging resistance problems 
worldwide. Lately, several studies have found the same ESBL 
genes, plasmids and clones of E. coli isolates originating from 
animals and isolates involved in human infections, suggesting 
a zoonotic link. The occurrence of Enterobacteriaceae resistant 
to carbapenems is a growing threat in human medicine 
because carbapenems are the last line of defence for treatment 
of infections caused by multidrug resistant Gram-negative 
bacteria in humans.
Eight percent of pigs at slaughter had ESBL-producing E. coli, 
which was higher than in 2011, but lower than in 2010. From 
meat samples, the highest occurrence of ESBL-producing E. 
coli was found among imported broiler meat (61%); an increase 
compared with 2011. The occurrence of ESBL-producing E. coli 
was higher in imported broiler meat when compared with Danish 
broiler meat. The occurrence of ESBL-producing E. coli in 
Danish broiler meat (36%) was at the same level as in 2011. In 
pork and beef, occurrence was generally low (0%–2%). ESBL-
producing E. coli obtained from production animals and meat 
in 2011 and 2012 was tested for carbapenem resistance, and 
none of the tested isolates were resistant to carbapenems. So 
at present, we have no indication that meat or food-producing 
animals in Denmark represent a source of carbapenemase 
genes found in human clinical bacteria (Textbox 8).
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The highest level of resistance in E. coli from production 
animals was observed in pigs. In meat, the high level of 
resistance was observed in imported pork and imported 
broiler meat. Occurrence of ESBL-producing E. coli in 
pigs increased in 2012, but was still significantly lower 
than in 2010. Broiler meat still seems to be the most 
important meat source for ESBL-producing E. coli. 
No carbapenem resistant E. coli were detected from 
production animals and meat.
Resistance in human clinical bacteria
Data on antimicrobial resistance in bacteria from diagnostic 
submissions from human patients were gathered by voluntary 
reporting from the DANRES group which covers the 
Departments of Clinical Microbiology (DCM) in Denmark. 
Exceptions were methicillin-resistant Staphylococcus aureus 
(MRSA) and invasive Streptococcus pneumoniae that are 
notifiable. Data on these bacteria were obtained from the 
reference laboratories at SSI.
In Escherichia coli blood isolates, resistance to 3rd generation 
cephalosporins was 7% in 2012, the same level as reported in 
2011, but above the 2011 level in the other Nordic countries. 
Resistance to 3rd generation cephalosporins has only been 
reported since 2008; in this period the resistance has increased. 
In 2012, ciprofloxacin resistance was 14%, the same level as 
in 2011. Over the last decade, resistance to cefuroxime, 
ciprofloxacin and gentamicin has increased. Ampicillin 
resistance decreased from 48% in 2011 to 45% in 2012.
In E. coli urine isolates from hospital patients, ciprofloxacin 
resistance decreased from 13% in 2011 to 12% in 2012, which is 
a change to the steady increase seen in ciprofloxacin resistance 
from 2% in 2003. Aminoglycoside (gentamicin) resistance 
increased from 4% in 2011 to 5% in 2012. Sulfonamide 
resistance decreased from 35% in 2011 to 33% in 2012.
In E. coli urine isolates from primary health care, 
ciprofloxacin resistance has increased steadily from 2% in 2003 
to 10% in 2012. Sulfonamide resistance decreased from 35% in 
2011 to 33% in 2012, and ampicillin resistance decreased from 
41% in 2011 to 40% in 2012.
In 2012, 2,511 patients had a urinary tract infection with 3rd 
generation cephalosporin resistant E. coli. In E. coli urine 
isolates from hospital patients, resistance to both 2nd and 
3rd generation cephalosporins increased from 5% in 2011 to 
6% in 2012, and in E. coli urine isolates from primary health 
care, resistance to both 2nd and 3rd generation cephalosporins 
increased from 3% in 2011 to 4% in 2012. The increased 
occurrence of 3rd generation cephalosporin resistance among 
E. coli urine isolates is described in Textbox 9.
Carbapenem (meropenem) resistance was observed in E. coli 
blood (n = 1) and urine isolates from both hospitals (n = 6) 
and primary health care (n = 9). Among these, the first NDM-
4 producing E. coli in Denmark was identified as well as two 
VIM-4 producing E. coli. The occurrence of carbapenemase-
producing bacteria in Denmark in 2012 is described in 
Textbox 11. The occurrence of carbapenem resistance is not 
mandatory reportable. 
In Klebsiella pneumoniae blood isolates, resistance to 
3rd generation cephalosporin (9%), and aminoglycoside 
(gentamicin 6%) was the same level as reported in 2011, 
whereas ciprofloxacin resistance decreased from 12% in 2011 
to 9% in 2012. The level was above the level reported by the 
other Nordic countries and corresponded to the occurrence 
reported by several other European countries in 2011. 
In K. pneumoniae urine isolates, 3rd generation cephalosporin 
resistance was 8% in isolates from hospitals and 5% in 
isolates from primary health care, the same level as in 2011. 
Ciprofloxacin resistance decreased from 11% in 2011 to 9% 
in 2012 in urine isolates from hospitals; in urine isolates from 
primary health care, ciprofloxacin resistance was 8%, the same 
level as in 2011. Mecillinam resistance decreased from 12% 
in 2011 to 11% in 2012 in isolates from primary health care; 
in urine isolates from hospitals, mecillinam resistance was 
also 11%, the same level as in 2011. Sulfonamide resistance 
decreased from 33% in 2011 to 24% in 2012 in urine isolates 
from hospitals and from 35% in 2011 to 26% in 2012 in isolates 
from primary health care.
Carbapenem (meropenem) resistance was observed in K. 
pneumoniae blood (n = 2) and urine isolates from both hospitals 
(n = 3) and primary health care (n = 2). The occurrence of 
carbapenemase-producing bacteria in Denmark in 2012 is 
described in Textbox 11. 
A national study of Bacteroides fragilis group isolates from blood 
cultures at 11 of the 13 DCM was performed January–May 2012. 
In total, 118 blood isolates were included from the B. fragilis 
group. None of the isolates were resistant to metronidazole. 
High rates of reduced susceptibility towards piperacillin-
tazobactam and clindamycin were seen in B. thetaiotaomicron 
and towards meropenem in B. fragilis (Textbox 10). 
In Pseudomonas aeruginosa blood isolates, resistance to all the 
tested antimicrobial agents was not significantly different from 
the level in 2011, but an increasing trend has been observed for 
gentamicin resistance during 2007–2012 and for meropenem 
resistance during 2007–2011. Meropenem resistance was 
observed in 4% of the P. aeruginosa blood isolates in 2012. 
During 2012, four VIM-producing P. aeruginosa isolates were 
identified at SSI (Textbox 11).
Resistance to penicillin and erythromycin in Streptococcus 
pneumoniae and in group A, B, C and G streptococci 
remained low in 2012.
In 2012, resistance to ampicillin was 94% in Enterococcus 
faecium isolates from blood, the same level as in 2011. 
Vancomycin resistance was 1.8% in E. faecium and 0.2% 
in Enterococcus faecalis blood isolates. During 2012, two 
DCM reported outbreaks with vancomycin resistant E. 
faecium (vanA). Two other DCM tested all enterococci from 
bloodstream infections for high-level gentamicin resistance 
(HLGR); 27% of the E. faecalis isolates and 62% of E. faecium 
isolates were HLGR.
Through the last decade, ciprofloxacin resistance in Neisseria 
gonorrhoeae increased steadily from 30% in 2003 to 75% in 2009, 
followed by a decrease to 57% in 2012. Penicillinase production 
among gonococcus isolates fluctuated between 12%–24% from 
2003–2012, and no ceftriaxone-resistant isolates, or cases of 
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ceftriaxone treatment failure, were reported in this period. 
From 2009–2012, azithromycin resistance decreased from 46% 
to 12%, cefixime resistance fluctuated between 11%–21%, and 
no spectinomycin resistant isolates were detected (Textbox 12).
In 2012, 1,528 cases of Staphylococcus aureus bacteraemia 
were reported, corresponding to 27.4 cases per 100,000 citizens. 
Of these cases the number of methicillin-resistant S. aureus 
(MRSA) was 19 (1.2%), a level similar to previous years and 
among the lowest incidences recorded in Europe. The highest 
frequency of resistance in addition to penicillin was observed 
for fusidic acid (14%), erythromycin (6%), clindamycin (6%) 
and norfloxacin (4%). Susceptibility to the tested antimicrobial 
agents was at the same level as in 2011.
The number of new cases of MRSA (both infected and 
colonized persons) increased in 2012 to 1,556 compared with 
1,292 in 2011. Thus, the increase starting in 2010 continued 
into 2012. The increase was primarily seen in cases categorised 
as community-acquired (CA), 596 in 2011 vs. 726 in 2012. The 
proportion of cases presenting with infection was similar in 
2012 to 2011 (54% vs. 53%). The number of hospital-acquired 
(HA) cases continued to be low and constituted only 4% of the 
total number of MRSA cases in 2012.
Livestock associated MRSA primarily belong to clonal complex 
398 (CC398). The number of MRSA belonging to CC398, which 
is associated with pigs, increased in humans from 164 in 2011 
to 232 in 2012. The most frequent spa type related to CC398 
was type t034 (n = 185). Seventy-five t034 cases represented 
infections. MRSA isolates carrying the new mecA homologue 
mecC were demonstrated in 24 cases (9 in 2009, 21 in 2010, 
and 37 in 2011).
Pigs at slaughter and bulk milk samples from dairy farms were 
tested for MRSA. The prevalence of MRSA in pigs at slaughter 
was estimated to be 77% which was higher than in previous years 
(13% in 2009 and 44% in 2011) (Textbox 13). As in previous years, 
spa types t034 and t011 were the most common types. For the first 
time, MRSA was detected in bulk milk from dairy farms. The 
four (2%) MRSA isolates found were of the mecA type with 
spa types corresponding to CC398 and CC1, types that have 
previously been detected in pigs. MRSA isolates of mecC type 
were not found among pigs or bulk milk.
In 2012, the total number of new human MRSA cases 
increased to 1,556. This increase was primarily seen in 
community-acquired cases. The number of hospital-
acquired cases remained low and accounted for only 
4% of the total number of MRSA cases in 2012. The 
number of MRSA type CC398, which is associated with 
pigs, increased from 164 cases in 2011 to 232 in 2012. 
CC398 now constitutes the second most common CC 
group among human MRSA cases. The number of MRSA 
isolates in humans carrying the mecC gene seems to have 
stabilised.
The prevalence of MRSA in pigs at slaughter increased 
dramatically, but whether more herds are MRSA positive 
compared to previous years is unknown. Pigs still seem 
to be the most important reservoir for MRSA CC398, 
but detection of LA-MRSA CC398 in bulk milk depicts a 
spread possibly from the pig production. 
In 2012, 2,511 patients had a urinary tract infection 
with 3rd generation cephalosporin resistant E. coli. In 
E. coli urine isolates from hospital patients, resistance to 
3rd generation cephalosporins increased to 6% in 2012, 
and in E. coli urine isolates from primary health care, 
resistance to 3rd generation cephalosporins increased to 
4% in 2012. 
High rates of reduced susceptibility towards piperacillin-
tazobactam and clindamycin  in isolates from the 
Bacteroides fragilis group were observed.
Four new cases of carbapenemase producing 
Enterobacteriaceae (CPE) and four carbapenemase 
producing (VIM) P. aeruginosa isolates were identified 
in 2012. Furthermore, an outbreak of carbapenemase 
producing (OXA-23) A. baumanii was seen in 2012.
During 2012, two DCM reported outbreaks with 
vancomycin resistant E. faecium (vanA).
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3. Background information
Figure 3.1 The five health care regions and 13 Departments of Clinical Microbiology (DCM) of Denmark
DANMAP 2012
The following sections present general information about  the 
human population in Denmark in 2012, and the production 
of food animals and the amount of meat available for human 
consumption in Denmark, over the past decade. It also 
provides an overview of the antimicrobial agents for systemic 
and intramammary therapeutic use in humans and animals in 
2012. 
3.1  Populations
 
The distribution of the Danish human population, which could 
potentially have received antimicrobial treatment in 2012, is 
displayed in Figure 3.1, together with the 5 healthcare regions 
and the 13 Departments of Clinical Microbiology (DCM).
In 2012, the number of slaughtered cattle and pigs was 1%– 
2% lower than in 2011; however, the volumes (kg) of beef and 
pork produced were reduced by 5% (Table 3.1). The number of 
fattening pigs (15–50 kg) exported increased by 15%, and the 
export has increased by five-fold since 2004. As in the previous 
years, an increase in the number of dairy cows (1%) and milk 
produced (3%) occured.     
There was a 4% reduction in the Danish broiler production 
from 2011 to 2012 (Table 3.1). The export of live broilers for 
slaughter has increased markedly; from 0.1% in 2003 to 10% 
of the broilers produced in 2012. The annual production of 
turkeys has fluctuated considerably over the last decade. Since 
2006, more than 99% of the turkeys produced have been exported 
for slaughter, thus all turkey meat available in Denmark is listed 
as imported.
The amounts of meat available for consumption in Denmark 
during 2008–2012 are presented in Table 3.2. The amount 
of domestically produced meat available for consumption in 
Denmark is estimated as production minus export, and includes 
chilled and frozen fresh meat as well as natural-marinated 
broiler meat. Approximately 3.1 million tonnes of pork and 1.7 
million tonnes of beef meat were available for consumption in 
Denmark during 2012, where 72% of the pork and 48% of the 
beef was of Danish origin. Statistics on export of broiler meat 
was incomplete, for 2011 and 2012, thus, the correct amount 
of Danish broiler meat available for consumption in Denmark 
could not be accurately calculated, however import of broiler 
meat continued to increase. 
North Denmark Region
No. of inhabitants  580,273
No. of inhabitants/km2 73
No. of inhabitants/GP 1727
Central Denmark Region
No. of inhabitants  1,271,223
No. of inhabitants/km2 97
No. of inhabitants/GP 1522
The Capital Region of Denmark
No. of inhabitants  1,729,952
No. of inhabitants/km2 675
No. of inhabitants/GP 1584
The Sealand Region
No. of inhabitants  816,670
No. of inhabitants/km2 112
No. of inhabitants/GP 1617
Region of Southern Denmark
No. of inhabitants  1,201,547
No. of inhabitants/km2 98
No. of inhabitants/GP 1483
Source: Statistics Denmark (www.dst.dk) and the Danish Medical Association (www.laeger.dk) GP=general practitioner
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Table 3.1. Production of food animals and the production of meat and milk, Denmark DANMAP 2012
Source: Statistics Denmark (www.dst.dk) and The Danish AgriFish Agency. Production data for farmed fish was not available for 2012. Live 
animals exported prior to slaughter are included in number of animals and amount of meat produced. Export data for poultry from Statistics 
Denmark (personal communication) and export of 15-50 kg live pigs from Danish Agriculture and Food
a) The production of farmed fish includes fish transferred from one production facility to another. In 2011, this included 4 tonnes transferred 
between freshwater facilities (14% of the freshwater production), and 2.9 tonnes transferred from freshwater to marine facilities, corresponding 
to 25% of the marine aquaculture production
b) Assume a final slaughtered weight of 1.51 kg per broiler produced (Danish Agriculture and Food, 2013)
c) Export of 15-50 kg live pigs. These are included in total number of heads, but antimicrobial use after export until slaughter is not registered 
as it takes place outside of Denmark
d) Increase from 2011 to 2012
Year Broilers Turkeys Cattle(slaughtered) Dairy cows Pigs
 Farmed fish(a) 
Fresh 
water Marine
1,000 
heads
mill. 
kg(b)
1,000 
heads
mill. 
kg
1,000 
heads
mill. 
kg
1,000 
heads
mill. 
kg
milk
1,000 
heads
Export
1,000
heads(c)
mill. 
kg
mill. 
kg
mill. 
kg
2003 129861 197 777 11.2 625 161 596 4540 24434 - 1898 34 8
2004 130674 198 1086 19.6 632 165 569 4434 25141 1712 1967 34 9
2005 122179 183 1237 17.4 549 145 559 4449 25758 2720 1988 31 8
2006 106182 161 785 11.3 509 140 556 4492 25763 3204 1957 29 8
2007 107952 163 1009 14.4 512 141 545 4515 26311 3522 2046 31 10
2008 107595 163 1068 12.3 509 138 559 4585 27078 4943 1985 30 10
2009 108851 165 1175 11,1 507 137 569 4734 27603 6642 1898 29 11
2010 117653 178 1184 14,0 519 142 574 4830 28505 7074 1974 28 10
2011 115454 175 960 9,4 551 145 575 4801 29399 7632 2008 28 11
2012 111080 168 1103 12,4 539 138 580 4928 29047 8794 1902 - -
Increase(d) -4% -4% 15% 31% -2% -5% 1% 3% -1% 15% -5% - -
DANMAP 2012
Pork Beef Broiler meat(a) Turkey meat
Danish Import Danish Import Danish Import Import
2008 216 83 83 81 48 32 8
2009 187 83 84 89 51 30 7
2010 185 90 97 101 56 44 9
2011 105 85 85 92 - 51 8
2012 230 88 84 91 - 60 7
Table 3.2. Danish and imported chilled and frozen fresh meat available for consumption (mill kg), Denmark
Note: Source Danmarks Statistik (www,dst.dk). Data from 2011 and 2012 are extracted on March 25th  2013. Data from 2012 are preliminary 
and will be updated in the 2013 report. The amount of Danish meat for consumption is estimated as production minus export
a) Natural-marinated broiler meat included. Statistics on export of broiler meat was incomplete for 2011 and 2012, and the amounts of Danish 
broiler meat availiable for consumption in Denmark could therefore not be accurately calculated
3.2  Marketed antimicrobial agents
Table 3.3 shows the antimicrobial agents that are registered to 
treat bacterial infections in humans and animals. Some of these 
antimicrobial agents are considered critically important for 
humans by WHO. An antimicrobial agent is considered critically 
important if it is the only compound, or one of limited available 
therapy, to treat serious human disease. Critically important 
antimicrobial agents are also used in food animals and pets to 
treat veterinary diseases, and bacteria that are resistant to these 
critically important agents may be transmitted to humans. 
Bacteria that cause human disease may acquire resistance genes 
from bacteria of animal origin. Fluoroquinolones, 3rd and 4th 
generation cephalosporins, macrolides and glycopeptides are 
among the antimicrobial agents considered critically important 
for humans [AGISAR, WHO 2009].
Growth promoters, which are no longer used for animals in 
Denmark, are shown in parentheses in Table 3.3. Most of the 
antimicrobial agents used for growth promotion in Denmark 
had effects on Gram-positive bacteria. Since 1995, the indicator 
enterococci from animals and meat (and in some years from 
healthy humans) have been used as a measure of resistance to 
growth promoters.
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Table 3.3.  Antimicrobial agents marketed for systemic and veterinary intramammary therapeutic use in animals and humans, 
Denmark 2012
a) ATCvet codes starts with a Q
b) Animal growth promoters used before 1999 are listed in parentheses
c) Although intestinal antiinfectives (A07AA) and imidazole derivatives for protozoal diseases (P01AB) are used to treat human patients, they 
are not reported by DANMAP
ATC / ATCvet codes (a) Therapeutic group Antimicrobial agents within the therapeutic groups
Animals Humans
J01AA / QJ01AA,QJ51AA Tetracyclines Chlortetracycline, doxycycline, oxytetracycline
Doxycycline, lymecycline, 
oxytetracycline, tetracycline, 
tigecycline
J01BA / QJ01BA Amphenicols Florfenicol
J01CA / QJ01CA Penicillins with extended spectrum Ampicillin, amoxicillin
Ampicillin, pivampicillin, 
amoxicillin, pivmecillinam, 
mecillinam
J01CE / QJ01CE Beta-lactamase sensitive penicillins
Benzylpenicillin, 
phenoxymethylpenicillin, procaine 
penicillin, penethamate hydroiodide
Benzylpenicillin, 
phenoxymethylpenicillin
J01CF / QJ51CF Beta-lactamase resistant penicillins Cloxacillin, nafcillin Dicloxacillin, flucloxacillin
J01CR / QJ01CR Comb. of penicillins, incl. beta-lactamase inhibitors Amoxicillin/clavulanate
Amoxicillin/clavulanate, 
piperacillin/tazobactam
J01DB / QJ01DB,QJ51DB First-generation cephalosporins Cefalexin, cefadroxil, cefapirin Cefalexin
J01DC Second-generation cephalosporins Cefuroxime
J01DD / QJ01DD,QJ51DD Third-generation cephalosporins Cefoperazone, ceftiofur, cefovecin Cefotaxime, ceftazidime, ceftriaxone
J01DE / QJ51DE Fourth-generation cephalosporins Cefquinome
J01DF Monobactams Aztreonam
J01DH Carbapenems Meropenem, ertapenem, imipenem/cilastatin, doripenem
J01EA Trimethoprim and derivatives Trimethoprim
J01EB / QJ01EQ Short-acting sulfonamides Sulfadimidine Sulfamethizole
J01EE / QJ01EW Comb.of sulfonamides and trimethoprim, incl. derivatives
Sulfadiazine/trimethoprim, 
sulfadoxine/trimethoprim Sulfamethoxazole/trimethoprim
J01FA / QJ01FA Macrolides
Spiramycin, tylosin, tilmicosin, 
tylvalosintartrat, tulathromycin, 
gamithromycin, tildiprocin
Erythromycin, roxithromycin, 
clarithromycin, azithromycin
J01FF / QJ01FF Lincosamides Clindamycin, lincomycin Clindamycin
J01FG / QJ01XX (b) Streptogramins (Virginiamycin)
J01G / QJ01RA,QA07AA Aminoglycosides Streptomycin, dihydrostreptomycin, gentamicin, neomycin, apramycin Tobramycin, gentamicin
J01MA / QJ01MA Fluoroquinolones
Enrofloxacin, marbofloxacin, 
difloxacin, ibafloxacin, 
pradofloxacin
Ofloxacin, ciprofloxacin, 
moxifloxacin
QJ01MB Other quinolones Oxolinic acid
QJ01MQ (b) Quinoxalines (Carbadox, olaquindox)
J01XA,A07AA / Not in 
ATCvet (b,c) Glycopeptides (Avoparcin) Vancomycin, teicoplanin
J01XB / QA07AA (b) Polypeptides (incl. polymyxins) Colistin, (bacitracin) Colistin
J01XC Steroid antibacterials Fusidic acid 
J01XD,P01AB (c) Imidazole derivatives Metronidazole
J01XE Nitrofurane derivatives Nitrofurantoin 
J01XX / QJ01FF Other antibacterials Spectinomycin Methenamine, linezolid, daptomycin
QJ01XQ Pleuromutilins Tiamulin, valnemulin
QP51AG04 Antiprotozoals, sulfonamides Sulfaclozine
Not in ATCvet (b) Oligosaccharides (Avilamycin)
Not in ATCvet (b) Flavofosfolipols (Flavomycin)
DANMAP 2012
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4. Antimicrobial consumption in animals
4.1  Introduction
The use of antimicrobial agents in humans and animals has 
been monitored by the DANMAP programme since 1995. 
Since the early 1990s there has been both political and public 
focus on the use of antimicrobial agents in the Danish animal 
production. This has resulted in discontinued use of several 
antimicrobial agents used for growth promotion from 1994-
1999, and recently a voluntary ban of use of cephalosporins 
in the pig production and regulatory legislation regarding 
therapeutic use [DANMAP 2010]. 
Since the end of the 1990s, an increase in the antimicrobial 
consumption for both humans and animals has been 
observed. While the increase in consumption for humans 
has been gradual throughout the period, the consumption 
in animals has fluctuated notably. The increase in veterinary 
consumption can partly be explained by the increase in pork 
production, which constitutes approximately 80% of the  meat 
production in Denmark (Table 3.1). Figure 4.1 shows the total 
antimicrobial consumption in animals and humans since 1994 
and 1997, respectively.
The prescription pattern has been clearly influenced by 
implemented legislation. For example, a steep decrease in 
antimicrobial consumption from 1994 to 1995 was likely the 
result of 1) limitation of veterinarians profit from sales of 
medicine [Directive (DK) 60/1995], and 2) enforcement of the 
so called “cascade rule” [Order (DK) 142/1993], which limits 
the use of (cheaper) extemporaneously produced medicines 
- this particularly affected the use of tetracyclines from 1994. 
Another important intervention was the restriction on the 
use of fluoroquinolones in production animals, through 
legislation implemented in 2002 and 2003. Furthermore, in 
July 2010, the pig industry imposed a voluntary ban on use 
of cephalosporins, due to concerns regarding extended beta-
lactamase resistance (ESBL).
From 2010 to 2011, consumption decreased following the 
introduction of  threshold values for antimicrobial consmuption 
adopted within the “yellow card initiative”. This enforces legal 
actions on pig farmers with high antimicrobial agent use per pig 
[DANMAP 2010].  
Effects from other parts of the legislation may be less obvious, 
but are important to keep in mind, when interpreting the 
veterinary prescription patterns. 
Official guidelines for the selection of antimicrobial agents 
that veterinarians may choose from for pigs and cattle have 
been available since 1996. The guidelines provide specific 
recommendations for the selection of the appropriate 
antimicrobial agents for treatment of all common indications 
in major production animal species. Initially, guidelines were 
developed by the National Veterinary Serum Laboratory 
(presently, DTU National Veterinary Institute). Since 2005, 
the guidelines have been updated by the Danish Veterinary 
and Food Administration (DVFA) in collaboration with DTU 
National Veterinary Institute, DTU National Food Institute, the 
Practicing Veterinarians Organization, university experts, the 
Danish Association of the Veterinary Pharmaceutical Industry 
and the Danish Agriculture and Food Council. The latest update 
was in 2010, when new dynamic evidence-based treatment 
guidelines for pigs were launched [DANMAP 2010, www.fvst.
dk]. In 2012, the Danish Veterinary Association published 
treatment guidelines to promote prudent use of antimicrobials 
in dogs and cats, prepared by clinical specialists and expert 
scientists from the Veterinary Faculty at Copenhagen University 
and DTU National Food Institute.
DANMAP 2012
Figure 4.1. Prescribed antimicrobial agents for humans and for animals compared to the number of pigs produced, Denmark
Sources: Human therapeutics: The Danish Medicines Agency. Veterinary consumption: Until  2001, data are based on reports from the 
pharmaceutical industry of total annual sales from the Federation of Danish pig producers and slaughterhouses (1994-1995) and Danish 
Medicines Agency and Danish Plant Directorate (1996–2000). Data from 2001–2011 originate from VetStat
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4.1.1  Data sources
Data on antimicrobial use at the product level have been 
collected in Denmark since 1996, including historical data back 
to 1990. In Denmark, all therapeutic medicine is prescription-
only, and since 2001, data on all medicine prescribed for use in 
animals has been collected (at prescription level) in a national 
database (VetStat). Data on consumption of antimicrobial feed 
additives, including coccidiostatic agents (non-prescription) 
and antimicrobial growth promoters (no longer used), are also 
collected by VetStat. 
Consumption data for 2012 - for use in DANMAP - were 
extracted from Vetstat by the Danish Veterinary and Food 
Administration (DVFA) on 22 March 2013. DTU National 
Food Institute has carried out no further validation of the 
received data. This is in contrast to previous years, where 
efforts were made to determine, for example, target species 
for antimicrobial agent sold to veterinary practitioners, but 
where target animals were not reported to VetStat. Therefore, 
the proportion of consumption in ‘species unknown’ is larger 
in this year’s report than previous reports, for further details see 
Chapter 10, Materials and Methods.
4.1.2  Methods
Metrics of antimicrobial consumption are numerous, each 
with its own advantages and limitations. Therefore, the chosen 
measures must depend on the purpose and the available 
information. 
The overall amount of antimicrobial agents is measured in kg 
active compound and is used in Section 4.2 for the purpose of an 
overall crude comparison of antimicrobial use in the veterinary 
and human sectors and to enable international comparisons 
(Figure 4.1). 
In DANMAP 2012, we introduce two new metrics to follow 
trends in antimicrobial consumption to ensure the robustness 
of the analyses over time and to facilitate comparisons between 
animal species, as well as comparisons between the veterinary 
and human sectors. The new metrics are defined below, and for 
more information on methodology, please refer to Chapter 10 
and the web annex.
DADD (Defined animal daily dose)
DADD is the average maintenance dose per day for a drug used 
for its main indication in the appropriate animal species. 
The DADD is not defined at product level but for each 
antimicrobial agent, administration route and animal species; 
and when appropriate, also age group. DADD has been 
specifically defined for use in DANMAP and does not always 
completely match the prescribed daily dose or the recommended 
dosage in the Summaries of Product Characteristics (SPC). 
In DANMAP 2012, the DADD replaces the ADD (as defined in 
VetStat), which has been used since DANMAP 2003. For more 
details, see Chapter 10, Materials and Methods. The DADDs 
used in DANMAP 2012 are presented in the web annex. 
DAPD (DADD per 1,000 animals per day) - estimated 
treatment proportion.
Trends in veterinary consumption, both within and across 
species, are presented in DAPD, allowing for comparison 
between sectors and adjusting for changes in live biomass. The 
estimated live biomass is expressed as the number of standard 
animals with an estimated average weight on a given day. This 
may also be referred to as the ‘standard-animals-at-risk’, and 
takes into account species differences in body-mass and life-
span. 
DAPD or estimated treatment proportion is a statistical 
measure, providing a rough estimate of the proportion of 
animals treated daily with a particular antimicrobial agent. 
For example, 10 DAPDs indicate that an estimated 1% of 
the population (e.g. broiler population), on average, receives 
a certain treatment on a given day (Section 4.3 and Chapter 
10, Materials and Methods). Furthermore, presenting the 
veterinary consumption in DAPD allows comparisons to the 
antimicrobial consumption in the human sector as expressed 
in defined daily dose per 1,000 inhabitants per day (DID), see 
Chapter 11, Terminology for a description of DID. 
At European level, the ESVAC (European Surveillance of 
Veterinary Antimicrobial Consumption) project monitors 
veterinary usage in a number of countries. ESVAC monitoring 
is based on the quantity by weight of antimicrobials, using a 
“population correction unit” (PCU) as denominator to adjust 
for changes in size of the production animal population 
within the respective countries over time. A description of the 
methodology used by ESVAC is contained in the first report 
“Trends in the sales of veterinary antimicrobial agents in nine 
European countries 2005-2009” [www.ema.europa.eu]. 
In the context of DANMAP, we base our comparison on dosages 
in order to keep in focus the newer, potent antimicrobials such 
as fluoroquinolones and cephalosporins that are critically 
important in treatment of human infections. Further, the 
biomass of the live population is used as denominator to 
allow for comparisons of selection pressure between animal 
populations. 
In the text that follows, unless otherwise stated, DAPD will 
be used to describe patterns in the veterinary antimicrobial 
consumption. 
4.2  Total antimicrobial consumption
In 2012, the total veterinary consumption of antimicrobial 
agents, including agents used for companion animals, 
amounted to 112.3 tonnes active compound (Table 4.1), 
representing a 4% increase compared with 2011. The increase 
was mainly attributed to a 5% increase in amounts (tonnes) 
used in pigs. The two major species, cattle and pigs, comprise 
equal proportions of live biomass. However, the vast proportion 
of cattle biomass consists of dairy cows, which have a very low 
consumption of antimicrobial agents compared with growing 
animals. In 2012, the antimicrobial consumption in pigs, 
cattle and poultry comprised 76%, ~11%, and ~1% of the total 
veterinary consumption, respectively (Figure 4.2).
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Historically, the overall consumption – measured as kg active 
compound - was 46% lower in 2012 compared with 1994 
-while the total meat production increased by 12% during this 
period (Table 3.1 and Figure 4.1). A major part of the decrease 
in consumption can be explained the by discontinued use of 
growth promoters (1994-1999). 
However, from 2001 to 2009, the antimicrobial consumption 
in production animals increased by 36% (Figure 4.1). This 
increase was driven mainly by an increase in consumption 
in pigs and should be seen in the context that the number of 
pigs produced increased by 19% (Table 3.1). At the same time 
the proportion of live pigs (approx. 30 kg) being exported has 
increased and thus resulted in a 2% decrease in the biomass of 
the pig population. 
Figur 4.2. Live biomass (mill kg) and antimicrobial consumption (kg) in main animal species, Denmark
DANMAP 2012
4.3  Antimicrobial consumption by animal 
species
For comparison between species, kilograms of meat produced 
has been used in many international comparisons; however, 
this measure overestimates the selection pressure in species 
with long lives (e.g. cattle), while underestimating the selection 
pressure in species slaughtered at an early age (e.g. poultry). 
A comparison of trends in the consumption of antimicrobial 
agent, by species, is shown in Figure 4.3. Previous comparisons 
between species were based on gram active compound per 
kilogram of meat produced, and the consumption in aquaculture 
was very high compared with all other species [DANMAP 
2011]. However, comparisons based on the DAPD provide a 
very different picture, with similar levels for pigs and marine 
aquaculture, and similar levels for freshwater aquaculture and 
poultry. There are two reasons for this: firstly, the typical drug 
of choice in aquaculture needs high dosages (in all species), 
and secondly, the lifespan of fish is very long compared to both 
pigs and poultry. Similarly, the difference between pig and 
poultry production also becomes less pronounced when using 
DAPD (Figure 4.3). 
Note:  The DAPD is calculated as the number of standard doses for one 
kg animal divided by the estimated live biomass in the age group at the 
total population (in tonnes)
DANMAP 2012
Figure 4.3. Antimicrobial consumption in pigs, broilers, turkey, 
aquaculture and pet animals, Denmark
The consumption in dairy cattle is very low, measured in 
DAPD, compared with the antimicrobial consumption in 
calves (half of which are for slaughter), pig production and 
turkey production. 
In 2011, antimicrobial sales for use in pet animals amounted to 
more than 15 DAPD (~10% underestimation, see DANMAP 
2011). Thus, the consumption in pet animals was higher than 
for cattle and poultry, but lower than for pigs. The trends in 
consumption of medicines for oral use in pets indicate a similar 
level (2% decrease) in antimicrobial use for pets in 2012.
Note: The live biomass is estimated from census data (pigs, cattle and pet animals) and production data (poultry, fur animals, aquaculture). The 
estimation procedures are described in Chapter 10. For poultry: the figures comprise only the biomass and antimicrobial consumption for the 
main production types (turkey and broiler production)
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Table 4.1. Antimicrobial agents sold (kg active compound) by animal species and age group, Denmark  
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Pigs, total 164 4716 1 7 - 2284 11203 7505 15896 7408 7622 28652 412 85870
- Sows and piglets 139 1970 0 7 - 455 540 637 8418 3645 6029 2068 57 23964
- Weaners 21 2437 1 0 - 806 6925 2869 1566 2573 1348 16602 352 35500
- Finishers 4 308 0 0 - 1022 3736 3999 5911 1190 244 9981 3 26398
- Age not given 0 1 0 0 - 0 3 0 2 0 1 1 0 8
Cattle, total (c) 509 648 120 - - 7 201 - 7339 990 1382 1675 9 12881
- Intramammaries - 19 73 - - 2 - - 195 163 5 - 2 460
- Cows and bulls 15 308 43 - - 2 127 - 6634 630 1048 1240 1 10047
- Calves<12   months 476 276 2 - - 2 65 - 360 181 294 384 7 2046
- Heifers, Steers 18 45 2 - - 1 10 - 150 16 35 51 0 328
Poultry, total(d, e) 5 28 - - 1 14 278 6 29 157 126 163 2 809
- Turkeys 5 26 - - - 13 247 0 16 27 1 127 2 463
- Broiler production 0 0 - - - 0 15 0 10 111 105 12           - 253
- Species unknown 0 3 - - 1 1 16 6 3 18 21 23 0 93
Other production animal 
species 166 411 0 3 532 204 679 0 1 2179 3434 749 1 8358
- Fur animals 5 411 0 3 0 204 679 0 1 2172 1240 733 1 5448
- Aquaculture 161 0 0 0 532 0 0 0 0 7 2194 16 0 2910
Companion animals 
(pharmacy) - 5 272 12 - 67 7 - 64 645 408 52 43 165
- Pet animals - oral use (f) - 1 270 12 - 67 7 - 27 643 293 50 42 1411
- Pet animals - other (g) - 3 3 0 - 0 0 - 23 2 5 1 2 38
- Horses - 1 0 - 0 0 - 14 0 111 1 0 127
Target species not reported (h) 1 261 5 5 3 11 18 14 924 156 947 179 8 2843
Total 844 6069 398 27 536 2587 12386 7526 24254 11536 14128 31469 476 112338
Note: Only the ATCvet group contributing mostly to the antimicrobial group is mentioned. Combination drugs are divided into active compounds
a) Penicillins with extended spectrum, cloxacillin and amoxicillin/clavulanic acid
b) Sulfaclozin (a prescription coccidiostat) is included in the sulfonamide/trimethoprim group
c) Fluoroquinolones reported for use in pigs were used in a clinical trial approved by the Danish Medicine Agency [Source: DVFA]
d) Approximately half of the prescribed antimicrobials for cattle was purchased of the animal owner at pharmacies; half was either administered 
or handed out by veterinary practitioners. In previous reports, reporting from large animal practice on medicines for cattle was validated against 
data on medicines sold from pharmacies to cattle practice (not mixed practice), but this was not performed for this report. Thus, the part of 
antimicrobial used for cattle not reported cannot be estimated
e) An important part of antimicrobial agents prescribed for poultry are sold in practice. Potential underreporting from practice has not been 
validated for 2012 and the magnitude can therfore not be estimated
f) In 2012, 103 kg sulfamethoxazole was used in poultry on special license, due to problems with resistance in E.coli infections. Sulfamethoxazole 
for use in poultry was not included in VetStat until January 2013, and thus target poultry species prior to this date is unknown. According to the 
practitioners it was mainly in young broilers, and therfore included under the broiler category in this table  used, but not reported to the Vetstat 
database. According to the practitioners it was mainly in young broilers, and included under the broiler category in the table
g) Includes all medicines approved for oral treatment of dogs and cats, plus all oral medicines handed out to pet owners from the pharmacy
h) Includes parenteral and topical medicines sold from the pharmacies directly to the animal owner. Parenteral and topical medicines sold for use 
in practice are not included
i) Part of the medicines sold from pharmacy to practice, not reported to by veterinarian. Contains medicines mainly to companion animals and 
ruminants, see also d) and e)
                                                                           
       30 DANMAP 2012  
ANTIMICROBIAL CONSUMPTION IN ANIMALS4.
0
20
40
60
80
100
120
03 04 05 06 07 08 09 10 11 12
Sows Weaners
Finishers Total, adjusted
D
A
P
D
 (D
A
D
D
 p
er
 1
00
0 
an
im
al
s 
pe
r d
ay
)
4.3.1  Antimicrobial consumption in pigs 
In 2012, the total antimicrobial consumption in pigs was 85.9 
tonnes active compound (Table 4.1), representing an increase 
of 4.4 tonnes (5%) compared with 2011. Measured in DADD, 
the consumption increased by 6%. 
The treatment proportions (DAPD) in the pig population 
overall and by age group are presented in Figure 4.4 and in the 
web annex (Table A4.2).
On average, of the antimicrobial agents used for the production 
of a pig until slaughter, 22% is used in the sow section, 36% 
during weaning and 42% in the finisher section. The treatment 
proportion (DAPD) is much higher in the weaning pigs, 
compared with finishers and sows (Figure 4.4). However, the 
biomass of the weaning pigs is very small (7.2-30 kg, 4 weeks), 
compared with the finishers (31-107 kg, 12 weeks) and the 
sows. 
The DAPD of the total population should reflect the trends in 
selection pressure in the population. Due to the differences in 
treatment proportion between age groups, the DAPD of the total 
population is affected by changes in population structure, e.g. 
increased export of live pigs at 30 kg. The increase in the export 
would in itself cause an increase in DAPD for the remaining 
population, because the DAPD for slaughter pigs is relatively 
low. Thus, a true impression of the antimicrobial consumption 
pattern and selection pressure in the pig production requires 
that changes in export and productivity are taken into account.
The antimicrobial consumption in pigs increased by 10% from 
26 DAPD in 2011 to 30 DAPD in 2012 (Figure 4.4) when 
adjusted for changes in export, i.e. representing the change in 
treatment incidence of a pig from birth to slaughter. This 10% 
increase in DAPD was related to an increased consumption 
of almost 6%. The number of pigs produced decreased by 
1.2% (Table 3.1). An additional decrease in biomass related to 
increased productivity and underestimation of weight of sows 
accounts for a minor part (~1%) of the increase in DAPD. 
Overall, the best estimate for the increase in antimicrobial 
use for the production of a slaughter pig would be an 8%-9% 
increase in 2012.
The DAPD increased the most in weaners (15%) and finishers 
(10%) and less in sow herds (2.9%), and this was almost 
entirely (97%) associated with an increasing use of primarily 
tetracyclines and macrolides in all age groups (Figure 4.5). 
Tetracyclines, macrolides and pleuromutilins have been the 
most commonly used antimicrobial agents in the Danish pig 
production for a decade (Figure 4.5). They are almost entirely 
administered orally, and particularly used for treatment of 
gastrointestinal disease in weaning pigs and finishers. The 
overall treatment proportion (DAPD) of tetracycline increased 
by 15%, while the use of macrolides increased by 19%.
Figure 4.4. Antimicrobial consumption (a) in the pig production, 
and the distribution on age groups, Denmark
DANMAP 2012
Note:  The" adjusted total" is adjusted for the increasing export of 
pigs at 30 kg (see text). "Sows” includes treatment in piglets pre-
weaning
a) The DAPD is calculated as the number of standard doses for one 
kg animal divided by the estimated live biomass in the age group or 
the total population (in tonnes)
For the critically important antimicrobial agents, the use 
of flouroquinolones increased, however remains at a very 
low level, constituting only 0.7% of the total consumption 
in pigs. A clinical trial aiming at eliminating infections with 
Actinobacillus pleuropneumoniae by flouroquinolone treatment 
was carried out in 2012, and may explain the observed increase 
in fluoroquinolone consumption for pigs [DVFA].  The use of 
cephalosporins in pigs was close to none (1 kg) corresponding 
to 0.2% of the total consumption in this species (in DAPD).
Over the last decade, the treatment proportion (DAPD) 
increased by 49% from 2003 to 2009. However, in 2010 and 2011, 
a decrease in DAPD by 23% compared with 2009 was observed, 
probably as a response to the DFVA’s implementation of the 
“yellow card initiative” – a special provision for reduction of 
antimicrobial consumption in pig production (See DANMAP 
2010 for further details). The reductions in antimicrobial use 
were associated with increasing use of vaccines and a slight 
decrease in productivity in some herds, but disease outbreaks 
did not increase [Danish Veterinary Bulletin no. 6, 2012]. With 
the increase in antimicrobial consumption in pigs in 2012, the 
consumption is still 16% lower than in 2009, and similar to the 
2007 level.
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Figure 4.5. Antimicrobial consumption(a) in the total pig production(b), and in finishers, weaners, sows and piglets, Denmark
Note: Amphenicols, colistin, fluoroquinolones, intramammaries, gynecologicals and topical drugs are not included in the figure. Data from 
veterinary practice are not included (<1% of the consumption in pigs)
a) The DAPD is calculated as the number of standard doses for one kg animal divided by the estimated live biomass in the age group or the 
total population (in tonnes)
b) Total pigs produced includes pigs exported at 30 kg, which has increased in numbers from 1.7 million in 2004 to 8.8 million in 2012,
comprising an 26%, although consumption in these pigs is included only from birth to 30 kg body weight. See discussion in the DANMAP 2011 
c) Lincosamide/spectinomycin combinations comprise 65% of this group
d) Beta-lactamase sensitive penicillins
DANMAP 2012
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4.3.2  Antimicrobial consumption in poultry
In Denmark, poultry production comprises mainly the broiler 
production (Gallus gallus), followed by egg layers (Gallus 
gallus) and turkey production. In addition, there is a small 
production of ducks, geese, and game birds. Consumption of 
antimicrobial agents for systemic use in poultry (2003–2012), 
given as defined animal daily dose (DADD) to the different 
species, are presented in the web annex (Table A4.3).
In 2012, the total antimicrobial consumption in poultry was 809 
kg active compound, including 103 kg sulfamethoxazole used 
on special license, representing a 5% decrease compared with 
2011. Sulfamethoxazole for use in poultry was not included 
in VetStat until January 2013, and thus target poultry species 
prior to this date is unknown (Table 4.1). Sulfamethoxazole 
is primarily prescribed to treat E. coli or Staphylococci (joint) 
infections in young broilers [Personal communication, S. 
Kabell, Danish Agriculture and Food Council].
In the period 2002–2008, the annual consumption fluctuated 
between 400–600 kg. However, disease problems caused a 
steep increase in antimicrobial consumption for poultry in 
2009 (Figure 4.6, see also DANMAP 2009). For the layers, 
broiler rearing, and the turkey production, the decrease in 
antimicrobial consumption seems to indicate that these disease 
problems were under control in 2010 and 2011. In 2012, a 
steep decrease in reported treatment proportion (DAPD) in 
broilers was observed. However, it is not known whether this 
is altogether a true decrease in antimicrobial consumption 
in broilers, or partly due to incomplete reporting, because 
reporting has not been validated for 2012. However, during 
2012, ESBL-producing  bacteria became a much discussed issue, 
thus the poultry industry made a serious effort to minimize the 
use of antibiotics.
In Denmark, the antimicrobial consumption in the broiler 
production is generally low compared with other species 
(Figure 4.3). Therefore, a few disease outbreaks in some 
farms will seriously affect the national consumption, causing 
considerable fluctuations in annual consumption data. In 2012, 
the consumption decreased to 2.3 DAPD in broilers, indicating 
that the disease problems observed in 2009-2011 are almost 
solved by other means. In the broiler production in total 
(including rearing flocks), the consumption fell to 1.8 DAPD, 
corresponding to a 61% reduction. However, for broilers this is 
2.5 times higher than the level in 2003-2008 (Figure 4.6). 
In 2012, an estimated 9% of the antimicrobial agents prescribed 
for the broiler production were used for parent and grandparent 
flocks.
For broilers, amoxicillin has been the most commonly used 
antimicrobial agent for at least a decade. However, during the 
period with higher consumption (2009-2011), tetracyclines 
(mainly doxytetracycline) were also important (Figure 4.6). 
Fluoroquinolones were the second most commonly used 
antimicrobial agent until 2007 (when new medicines were 
approved for poultry), but has not been used in broilers in 
2010-2012.
 
The antimicrobial consumption in the layer production is 
low with large annual fluctuations. The treatment proportion 
in 2012 (0.4 DAPD) was about 50% higher than in 2011, 
and twice the average consumption during the past decade. 
Amoxicillin and tetracycline have comprised the vast majority 
of antimicrobial agents used in the layer production, but during 
2010-2012, pleuromutilins comprised 12% of the consumption 
(web annex, Table A4.3).
In turkeys, both the annual consumption and the production are 
highly variable (Figure 4.6). In 2012, the treatment proportion 
was 21 DAPD, corresponding to a 20% increase compared with 
2011. Reviewing the past decade, the consumption in 2012 
was twice the average annual consumption than the previous 
nine years (Figure 4.3). The peak in 2009 was mainly due to 
Pasteurella multocida infections (according to the poultry 
practitioners), and a vaccination campaign was conducted to 
control the disease in April–October 2009. Also, vaccination 
against haemorrhagic enteritis (viral) in turkeys was initiated 
in April 2010.
Please note that the estimation of biomass is very difficult 
for the turkey production due to variability in slaughter age 
and weight, and the trends must be interpreted with caution. 
Measured in standard doses (DADDs), without relating to 
population size, the consumption increased by 51% in 2012 
(web annex Table 4.3).
Tetracyclines comprised a significant part (50%–70%) of 
antimicrobial use in turkeys since 2008, but the overall 
increase in 2012 was mainly related to increasing use of 
macrolides. Prior to 2007, amoxicillin constituted 73%–99% 
of the antimicrobial consumption in turkeys (Figure 4.6). The 
changes in prescription practice occurred after the marketing 
of tetracyclines and other agents for use in poultry during 
2007–2008. As for broilers, fluoroquinolones were commonly 
used previously but have not been used for turkeys since 2008. 
Cephalosporins have not been used for at least 12 years (if 
ever). 
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Figure 4.6. Consumption of antimicrobial agents in the poultry production, Denmark
Note: Amphenicols, colistin, fluoroquinolones, intramammaries, gynecologicals and topical drugs are not included in the figure. Data from 
veterinary practice are not included 
a)  The DAPD is calculated as the number of standard doses for one kg animal divided by the estimated live biomass in the age group or the total 
population (in tonnes)
b) Includes mainly sulfaclozin registered as a coccidiostat
c) Lincosamide/spectinomycin combinations comprise 65% of this group
d) Beta-lactamase sensitive penicillins
DANMAP 2012
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4.3.2  Antimicrobial consumption in cattle
Data on antimicrobial consumption in cattle are not as 
accurate as data in the other major species because a large 
proportion of the antimicrobial agents are sold via veterinary 
practice, and reporting from practices is incomplete. In 
contrast to previous years, we have not attempted to estimate 
the proportion of medicines from veterinary practices that 
were used for cattle in 2012. 
Pharmacy data, including sales to veterinary cattle practices, 
indicate that the overall consumption in cattle has been stable, 
around 14 tonnes per year from 2005–2012. During this 
period, the veal and beef production has fluctuated around 
a consistent level, and the milk production has increased 
slightly. In 2012, the beef production was 2% lower, and the 
milk production 6% higher compared with the average from 
2005–2011 (Table 3.1).
In general, the majority of the parenteral use in cattle is for cows 
(Table 4.1), and is mainly prescribed for mastitis. The systemic 
use of fluoroquinolones in cattle was only 0.04 kg active 
compound in 2012, and has been at a low level since 2003. In 
2012, systemic use of 3rd and 4th generation cephalosporins 
in cattle increased by 5% to 47 kg and intramammary use 
decreased by 13% to 7 kg compared with 2011. To note, the 
use of 3rd and 4th generation cephalosporins for systemic use 
peaked in 2008, and for intramammary use in 2007 (Figure 
4.7).
Table  4.2. Number of treatments with antimicrobial agents for intramammary application in cattle, Denmark  DANMAP 2012
2005 2006 2007 2008 2009 2010 2011 2012
Total doses per indication DADDs (1000's)
Drying off treatment  (4 teats) 73 75 71 76 82 99 97 117
Therapeutic treatment (2 teats) 420 408 388 377 378 350 307 279
Data on intramammary use, based on pharmacy data show 
an unchanged overall level of intramammary treatment from 
2001 to 2012. However, drying-off treatment increased by 20% 
while therapeutic treatment decreased by 9% in 2012 (Tables 
4.2 ). From 2005 to 2012, the overall intramammary treatments 
per cow per year decreased by 12%, while the proportion of 
intramammary medicines containing only penicillins increased 
from 35% to 63% (Table 4.3). The use of antimicrobial agents 
for treatment of mastitis in cattle has been regulated since 2006 
[Order (DK) 1045/2006 and 785/2010], and simple penicillins 
should be used, unless resistance testing indicates otherwise. 
However, these trends are probably also a result of a “milk 
quality campaign” run by the cattle association (Agriculture 
and Food Council) since 2010. The goals of the campaign are 
to reduce treatment of clinical mastitis by 50%, mainly through 
a reduction of treatment of subclinical mastitis, but also by 
increasing the frequency of cell counts to determine the need 
for treatment. 
The Agriculture and Food Council does accept some degree of 
increase in drying-off treatment in cases where it is a consequence 
of refraining to treat during lactation. Furthermore, Order (DK) 
785/2010 provides legal regulations of use of antimicrobial 
agents for mastitis in cattle (recommending using simple 
penicillins) and the industry has also emphasized that farmers 
should use narrow spectrum penicillins to treat mastitis caused 
by Gram-positive bacteria, unless sensitivity testing expresses 
resistance towards these antimicrobials. 
DANMAP 2012Table  4.3. Use of of antimicrobial agents for intramammary application in cattle, Denmark 
Note: For intramammary application, 1 DADD is defined as the dose to treat two teats for 24 hours
a) Includes benzylpenicillin, cloxacillin, and cloxacillin-ampicillin combinations (QJ51CE, QJ51CF, QJ51RC)
b) Mainly dihydrostreptomycin-benzyl benicillin combinations; includes also combinations of penicillin/aminoglycoside with bacitracin or 
nafcillin (QJ51RC)
c) Lincosamides, neomycin-lincomycin combinations and trimethoprim-sulfonamide combinations
2005 2006 2007 2008 2009 2010 2011 2012
Doses per antimicrobial class DADDs (1000's)
Penicillins(a) 201 211 211 236 282 314 318 324
Aminoglycoside-benzylpenicillin 
combinations(b) 130 104 101 101 110 93 48 47
Cephalosporins,1st generation 103 98 89 85 89 89 99 105
Cephalosporins, 
3rd and 4th generation 110 124 127 112 76 51 34 30
Others(c) 21 20 16 15 14 12 9 8
Total 566 558 544 549 570 559 508 514
Total DADD per cow per year 1.0 1.0 1.0 1.0 1.0 1.0 0.9 0.9
Note: For intramammary therapeutic treatment, 1 DADD is defined as the dose to treat two teats for 24 hours. For drying off treatment, 1 DADD 
is defined as the dose to treat 4 teats. One product used for both indications is included as half drying off and half therapeutic treatments
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4.3.4  Antimicrobial consumption in 
aquaculture, fur animals and companion 
animals
The antimicrobial consumption in aquaculture increased by 8% 
to 2,900 kg in 2012 compared with 2011 (Table 4.1). Measured 
in standard doses (DADD), the major class of antimicrobial 
used was sulfonamide/trimethoprim, comprising 53% of the 
consumption in aquaculture in 2012. The consumption of 
quinolones (oxolinic acid) comprised 39% and florfenicol 8%.
Assuming an unchanged production volume, the treatment 
proportion in marine aquaculture was 29 DAPD in 2012, 
representing a 28% increase compared with 2011 (Figure 4.3). 
This increase is partly related to an increase in production. 
However, the antimicrobial consumption in both 2012 and 2011 
was very low compared to previous years, probably due to cold 
summers in 2011–2012. Fish immunology and infection is very 
sensitive to water temperatures. Improved vaccination against 
furunculosis between 2006–2010 may also have contributed to 
the observed decrease in antimicrobial consumption. [personal 
communication: N.H. Henriksen, Danish Aquaculture].
In freshwater fish, the antimicrobial consumption fluctuates 
less than in the marine aquaculture. In 2012, the treatment 
proportion in freshwater aquaculture increased by 7%, to 
11 DAPD, assuming the same production volume as in 
2011. There has been an increasing trend in antimicrobial 
consumption since 2009. Some structural changes in the 
production could be a partial explanation but at present, the 
cause is unknown [personal communication: N.H. Henriksen, 
Danish Aquaculture].
In 2012, the production of mink increased to 17 million 
mink from 15 million in 2011 (Source: Kopenhagen Fur). 
Antimicrobial consumption in fur animals increased to 5.4 
tonnes, representing a 13% increase in kg active compound 
compared with 2011 (Table 4.1). Aminopenicillins remained 
the most commonly used antimicrobial class in fur animals, 
comprising 40%. The use of fluoroquinolones increased from 
0.4 kg in 2010 to 3 kg in 2012, when it was prescribed for 
enteritis in May-June 2012, presumably for the kits. During 
the past five-year period, the antimicrobial use has gradually 
increased by 60%, while the production of mink has increased 
by 21%, from 14 million since 2008. This increase may partly be 
explained by an increased focus on animal welfare in the mink 
production by both the Industry (Kopenhagen Fur) and  the 
Authorities (DVFA).
The information available on antimicrobial consumption in pet 
animals is not as detailed as for production animals. Therefore, 
in 2012, we only estimated the consumption of antimicrobial 
agents used for oral treatment in pet animals (mainly cats and 
dogs).
In 2011, antimicrobial sales for use in pet animals amounted to 
more than 15 DAPD; this estimate does not include parenteral 
and topical antimicrobial use in mixed practice, causing an 
underestimation of approximately 10%-15%. Consumption 
of antimicrobial agents for oral use amounted to 12 DAPD in 
2012, corresponding to a 2% decrease in treatment proportion 
compared with 2011 (Figure 4.8). 
The use of the broad-spectrum agent amoxicillin/clavulanic acid 
increased by 2%. This is part of a continuous increase of 91% 
since 2005. The use of fluoroquinolones for oral use increased 
by 7% in 2012, compared with 2011, whereas the use of 1st 
generation cephalosporin decreased by 12%. In pet animals 
(mainly cats and dogs), the prescription for oral treatment 
measured in DAPD has increased by 30% since 2005. 
The treatment proportion of 3rd and 4th generation 
cephalosporins was estimated at 0.7 DAPD in 2012, similar to 
2011. The use of fluoroquinolones for oral use was 0.6 DAPD in 
2012. For comparison, the use of cephalosporins for systemic 
use was 0.2 DAPD in cattle in 2011, while the use in pigs is now 
close to none, and it has not been used in poultry for at least 12 
years. 
The use of fluoroquinolones for oral use in pet animals was 12 
kg in 2012. This means that the total use of fluoroquinolones 
in pet animals is about half of the total veterinary use (kg) of 
fluoroquinolones. Regarding amoxicillin/clavulanic acid, 91% 
of the veterinary consumption (kg) was used in pet animals; 
this combination has a very broad spectrum and should be 
reserved for infections caused by bacteria that are resistant to 
more narrow spectrum agents, or as a potential empirical choice 
for severe infections where instant effect is essential. 
In conclusion, the treatment proportion for critically important 
antimicrobial agents is much higher for pet animals compared 
with food animals. 
Considering the close contact between pet animals and humans, 
and the increasing evidence for transfer of resistance between 
the pet reservoir and humans, the high consumption of broad 
spectrum antimicrobial agents in pets is a matter of concern. 
The new national guideline from the Danish Health and 
Medicines Authority aim to ensure that the critically important 
antibiotics are reserved for severely ill people or are only used 
when there are no alternatives, including especially targeting 
the use of carbapenems, and cephalosporins (Textbox 3).
A large proportion of antimicrobials used for pet animals are 
prescribed for treatment chronic or recurrent disease, mainly 
dermatitis. Particularly the consumption of critically important 
antimicrobial agents in pet animals could pose an important 
risk to owners of diseased dogs that are frequently treated. 
Presently, there is no information available concerning the 
prevalence of antimicrobial resistance in pet animals. 
Vibeke Frøkjær Jensen and Birgitte Borck Høg
Figure 4.7. Consumption of 3rd and 4th generation 
cephalosporins in pigs and cattle, Denmark
DANMAP 2012
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DANMAP 2012
Figure 4.8 Antimicrobial consumption (oral treatments) in pets(a), Denmark
Note: The DAPD is calculated as the number of standard doses for one kg animal divided by the estimated live biomass in the age group or the 
total population (in tonnes)
a) The live biomass for pets only include dogs (average weight: 20 kg), and cats (average weight: 4 kg). Census data are available only for 2000 
(Statistics Denmark), and the population size was assumed to be constant (in accordance with data in the Danish Dog register; personal 
communication), while the cat population may have increased. The vast majority of antimicrobials for pets are used in dogs
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5. Antimicrobial consumptions in humans
5.1  Introduction
In Denmark, systemic antimicrobial agents for humans are 
available only on prescription. In November 2012 a new set of 
national guidelines for use of antimicrobial agents especially 
concerning the use of the “critical important antibiotics”: 
fluoroquinolones, cephalosporins and carbapenems was 
published (Textbox 3). Some of the Danish Regions already 
had made new guidelines which were in agreement with the 
recommendation before it was published, in order to reduce 
the number of multi-resistant bacteria (e.g. ESBL-producing 
bacteria, MRSA and Clostridium difficile).  
Throughout this section, the antimicrobial consumption 
in 2012 is compared to that of 2011 and of the last decade 
(2003). Combinations of penicillins, including beta-lactamase 
inhibitors (J01CR), are referred to as ‘combination penicillins’. 
In this section, the term ‘antimicrobial agents’ covers only 
antibacterial agents for systemic use in humans, agents used 
for treatment of  infections caused by virus or fungi are not 
included. Currently available antimicrobial agents for systemic 
treatment in humans (and in animals) are listed in Table 3.3.
Antimicrobial agents have been classified as either narrow-
spectrum or broad-spectrum agents according to the spectrum 
of the activity (Table 5.1).
5.2  Total consumption in both primary health 
care and hospital care
Consumption in both primary health care, hospital care and 
the overall total consumption is presented in DID, and can be 
used  for comparison between sectors and for illustration of 
the consumption in hospital care without taking account of 
hospital activity (discharges) (Figure 5.1). 
In 2012, the total consumption of antimicrobial agents for 
systemic use (primary health care and hospital care) decreased 
with 2% (18.48 DID in 2012 compared to 18.90 DID in 2011, 
Figure 5.1). The total consumption of broad-spectrum agents 
increased in 2012 (8.21 DID in 2012 compared to 7.80 DID in 
2011, Figure 5.2). Primary health care represented 90% of all 
prescribed DDDs in Denmark in 2012 (Figure 5.1). 
The distribution of DIDs between primary health care and 
hospital care differed between antimicrobial agents (Figure 
5.3). For most of the antimicrobial agents, the consumption 
was higher in primary health care, with exception of 
cephalosporins and related substances, aminoglycosides and 
imidazole derivatives. 
Since 2003, the overall consumption of antimicrobial agents 
has increased by 23%, or 3.44 DID (Figure 5.1). During the 
same period, broad-spectrum agents have increased by 3.5 
DID (74%), comprising 31% of the overall consumption in 
2003 and 44% in 2012. The proportion of DDDs prescribed 
in primary health care remained relatively constant during the 
last decade, between 89%–90%. 
The detailed distribution of DIDs among antimicrobial groups 
in primary health care and hospital care is presented in Table 
5.2 and Table A5.1 in the web annex. 
In 2012, 48.7 tonnes of antimicrobial agents for systemic use 
were used in humans in Denmark. This level is approximately 
2.5 tonnes less than reported in 2011 but still represents an 
increase of  4.8 tonnes (10%) compared to 2003 (Table A5.2 in 
web annex). 
Table 5.1. Classification of antimicrobial agents for systemic use 
in humans into narrow-spectrum and broad-spectrum agents, 
Denmark
ATC 
group(a) Therapeutic group
Narrow-spectrum
J01CE            Beta-lactamase sensitive penicillins     
J01CF            Beta-lactamase resistant penicillins     
J01DB
First-generation cephalosporins (included in data from 
primary health care as a broad-spectrum agent in the 
group J01D)
J01DF Monobactams
J01EA            Trimethoprim and derivatives   
J01EB            Short-acting sulfonamides       
J01FA            Macrolides                  
J01FF                        Lincosamides                
J01XA Glycopeptides
J01XC            Steroid antibacterials (fusidic acid)     
J01XD            Imidazol derivatives
J01XE Nitrofuran derivatives (nitrofurantoin)
J01XX Other antibacterials
Broad-spectrum
J01AA            Tetracyclines               
J01CA            Penicillins with extended spectrum
J01CR            Combinations of penicillins, incl. beta-lactamase inhibitors   
J01D                        Cephalosporins and related substances (primary health care only)         
J01DC Second-generation cephalosporins
J01DD Third-generation cephalosporins
J01DH Carbapenems
J01EE            Combinations of sulfonamides and trimethoprim, incl. derivatives 
J01GB Aminoglycosides
J01MA            Fluoroquinolones            
J01XB            Polymyxins                 
DANMAP 2012
a) From the 2012 edition of the Anatomical Therapeutic Chemical 
(ATC) classification system
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Figure 5.1. Total consumption of antimicrobial agents (J01) in humans by sector, Denmark
Figure 5.2. Total consumption of antimicrobial agents (J01) in humans by narrow-spectrum and broad-spectrum agents, Denmark
Note: “Narrow-spectrum” includes: beta-lactamase sensitive penicillins, beta-lactamase resistant penicillins, trimethoprim, sulfonamides, 
macrolides, lincosamides, glycopeptides, fusidic acid, imidazol derivatives, nitrofuran derivatives, and ‘other antibiotics’
“Broad-spectrum” includes: tetracyclines, penicillins with extended spectrum, combinations of penicillins incl. beta-lactamase inhibitors, 
cephalosporins and related substances, combinations of sulfonamides and trimethoprim, aminoglycosides, fluoroquinolones, and polymyxins
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Figure 5.3. Distribution of DIDs between primary health care and hospital care, Denmark
0.00 0.25 0.50 0.75 1.00 1.25 1.50
J01XX Other antibacterials
J01XE Nitrofuran derivatives (nitrofurantoin)
J01XD Imidazol derivatives
J01XC Steroid antibacterials (fusidic acid)
J01XB Polymyxins
J01XA Glycopeptides
J01MA Fluoroquinolones
J01G Aminoglycosides
J01E Sulfonamides and trimethoprim
J01D Cephalosporins and related substances
J01CR Penicillins, incl. beta-lactamase inhibitors
DDD/1000 inhabitant-days
Primary health care
Hospitals
0 1 2 3 4 5 6
J01F Macrolides, lincosamides and
streptogramins
J01CF Beta-lactamase resistant penicillins
J01CE Beta-lactamase sensitive penicillins
J01CA Penicillins with extended spectrum
J01AA Tetracyclines
DDD/1000 inhabitant-days
Primary health care
Hospitals
                                                                           
       41DANMAP 2012  
ANTIMICROBIAL CONSUMPTION IN HUMANS 5.Textbox 1
Consumption of antimicrobial agents and incidence of multi-resistant bacteria in 
Greenland
Background: Greenland has a population of 56,749 inhabitants (January 2012) and Nuuk is the capital with 
around 16,000 inhabitants. Greenland has its own Ministry of Health and the country is divided into five health 
regions: Qeqqa (the former health districts Sisimiut and Maniitsoq), Disko (the former health districts Aasiaat, 
Kangaatsiaq, Qeqertarsuaq and Qasigiannguit), Avannaa (the former health districts Uummannaq, Upernavik and 
Qaanaaq), Sermersooq (the former health districts Nuuk, Paamiut/Ivittuut, Tasiilaq and Illoqqortoormiut), and 
Kujataa (the former health districts Qaqortoq, Nanortalik and Narsaq). The largest hospital, Dronning Ingrids 
Hospital, is situated in Nuuk (185 beds). There are several smaller hospitals and health care centers in the five 
health regions. Around 15-16,000 persons are admitted to hospital once or several times a year. The primary health 
care is organized different from that in Denmark; there are no general practitioners with private practice, and the 
hospital clinics are used for patients from the primary health care. In Nuuk, a large health care center has combined 
function as medical clinic, emergency room and primary health care with doctors and nurses. The settlements have 
nursing stations (supervised by doctors via phone or telemedicine and doctors visiting three to four times a year). 
Medication on prescription is free of charge. Patients with specific/serious diseases are transferred to Denmark or 
Iceland for further treatment (e.g. hemodialysis, cancer treatment, brain surgery etc.).
Resistant bacteria: From 2004 to 2012, eight patients have been diagnosed with MRSA, 23 patients with ESBL-
producing Enterobacteriaceae, and 24 patients with Clostridium difficile 027. Most of these resistant bacteria 
were imported from Denmark or abroad, but in some cases, especially in patients with an ESBL-producing 
Enterobacteriaceae, treatment with broad-spectrum antimicrobial agents in Greenland has probably selected for 
these bacteria.
Consumption of antimicrobial agents: There are no exact figures for consumption of antimicrobial agents in 
Greenland, only for purchased agents. Figure 1 shows the total purchase of selected antimicrobial agents in DDD 
per 1,000 inhabitants per day (DID) from 2007 to 2012. From 2007–2012, an increase in purchase of narrow-
spectrum (18%) and broad-spectrum penicillins (11%) has been seen. From 2011 to 2012, an increase in the sale 
of piperacillin-tazobactam (18%) and a decrease in broad-spectrum antimicrobial agents such as macrolides (7%), 
fluoroquinolones (12%), and meropenem (40%) have been seen. The sale of cephalosporins (mainly ceftriaxone) 
has been at the same level from 2011 to 2012. 
Conclusion: Continued focus on resistant microorganisms and use of broad-spectrum antimicrobial agents in 
Greenland is important in the future. 
Anne Kjerulf, Jette Holt, Anne Birgitte Jensen, Turid B. Skifte, Peter Poulsen, Inge Mortensen
For further information: Anne Kjerulf (alf@ssi.dk)
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(b)
Figure 1. Consumption of selected antimicrobial agents in humans in Greenland (DDD/1,000 inhabitants/day) 2007–
2012: (a) consumption of narrow- and broad-spectrum penicillins, macrolides and tetracyclines; and (b) consumption 
of cephalosporins, meropenem, fluoroquinolones, piperacillin/tazobactam and gentamicin. (Note: Narrow-spectrum 
penicillins include benzylpenicillin, phenoxymethylpenicillin and dicloxacillin, and broad-spectrum penicillins include 
ampicillin, pivampicillin, amoxicillin and amoxicillin with enzyme inhibitor)
(a)
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Increased focus on the use of antimicrobial agents in the Faroe Islands
Background: The Faroe Islands (FI) consists of 18 islands, inhabited by approx. 48,000 inhabitants, 19,000 of whom live 
in the capital Tórshavn. The main hospital (Landssjúkrahúsið, LS, with 170 beds) is located in Tórshavn, and there are 
two smaller hospitals in Klaksvik (36 beds) and Súðuroy (26 beds). The healthcare system is comparable to the Danish 
healthcare system with general practitioners responsible for primary care and secondary care provided by the hospital. 
LS has a local as well as a centralized function. In the case of specified diseases, patients are referred to hospitals in 
Denmark or other foreign hospitals. The healthcare staff is well educated and constitutes a stable workforce. However, 
consultants, mainly from Denmark, perform specialized treatment where the number of patients is too small to support 
full-time specialist employment.
 
Food is either locally produced or similar to what can be bought in Danish supermarkets (same origin), although with 
a greater share of products from Iceland and Norway.
Data and data sources: Data for antimicrobial consumption for FI and for LS were supplied by the Chief Pharmaceutical 
Office. Bed days and data on MRSA and ESBL-producing bacteria were obtained from LS.
Results: Since the first case of MRSA in 2004, a total of 32 cases of MRSA have been identified (21 with infection and 
11 carriers). From 2006–2012, 13 ESBL-producing Escherichia coli and 4 ESBL-producing Klebsiella pneumoniae have 
been detected, furthermore one patient had both an ESBL-producing E. coli and an ESBL-producing K. pneumoniae. 
The total consumption of antibacterial agents in primary health care (defined by individual prescriptions) was 14.17 
DID in 2012. An almost total stop in the use of pivampicillin and pivmecillinam and a rise in the use of amoxicillin 
with enzyme inhibitor (251%) as well as ciprofloxacin (47%) have been detected from 2007 to 2012 (Figure 1). This 
change reflects a ban of the use of pivampicillin and pivmecillinam due to identification of a potentially fatal carnitine 
transporter gene defect in 1/3.600 inhabitants of the Faroe Islands [Joensen F et al. 2006. Ugeskr Laeg 168: 667-670]. 
Screening is possible and it is considered to lift the ban in order not to stimulate quinolone use further. 
For many years, LS has had a policy of rational use of antimicrobial agents. However, a rise in the use of broad-spectrum 
antimicrobial agents from 2007–2012 has been detected, exemplified by cefuroxime (41%), ciprofloxacin (413%), 
and meropenem (102%) (Figure 2). LS has therefore increased the focus on reduction of the use of broad-spectrum 
antimicrobial agents. This will be done by performing regular audits in all clinical wards, and securing continued 
compliance with infection control guidelines in order to prevent transmission of possible resistant bacteria. 
Conclusion: Increased focus on the use of broad-spectrum antimicrobial agents and resistant bacteria is the current 
strategy of the Faroe Islands. 
Elsebeth Tvenstrup Jensen, Anne Kjerulf, William Smith, Niels Joensen and Hjørdis Reinert 
For further information: Elsebeth Tvenstrup Jensen (etj@ssi.dk)
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Figure 1. All primary health care prescriptions for pivampicillin, pivmecillinam, amoxicillin and enzyme inhibitor, and 
ciprofloxacin (DDD/1,000 inhabitants/day)
Figure 2. Use of cefuroxime, ciprofloxacin, and meropenem at the LS hospital (DDD/100 bed-days)
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New guidelines on prescribing antibiotics in primary health care and hospitals
Background: In November 2012, The Danish Health and Medicines Authority issued a new set of guidelines that outline 
the standards required for physicians in prescribing antibiotics. Below is a short description of the guidelines, the full 
length version can be found at: http://www.sst.dk/~/media/English/Guidelines%20on%20Antibiotics.ashx
The guidelines aim to change the pattern of prescription of antibiotics to become more rational - including ensuring 
that unnecessary use is reduced - with the aim of preventing the development of antibiotic resistance; and to ensure that 
the critically important antibiotics are reserved for severely ill people or are only used when there are no alternatives, 
including especially targeting the use of carbapenems, fluoroquinolones and cephalosporins.
The basic rules that apply to physicians’ prescription of antibiotics for systemic use are as follows:
•	 Antibiotic treatment must be expected to prevent severe or life-threatening events or to reduce the period of illness 
considerably.
•	 Clinical and diagnostic testing must be carried out such that it at least determines that bacteria are the likely cause 
of illness.
•	 The antibiotic selected must be as narrow-spectrum as possible and influence the normal bacterial flora as little as 
possible in accordance with the general and local guidelines for the use of antibiotics.
•	 If the initial treatment is not successful, the choice of antibiotic must be reassessed and perhaps changed based on 
microbiological testing.
•	 The treatment must be as brief as possible and be in accordance with the evidence available in the field.
•	 The diagnosis that results in the prescription must be specifically outlined in the prescription system, including on 
the prescription and in the medical records.
General rules on prescribing antibiotics at hospitals:
•	 Each department or hospital must have instructions for prescribing and using antibiotics.
•	 If there is a reason to deviate from these instructions, the reason for this must be entered into the medical records in 
connection with prescription.
•	 The department or hospital should always take samples for microbiological testing before initiating antibiotic 
treatment. Occasional exceptions might include cholecystitis and erysipelas.
•	 For all treatment with antibiotics, the indication, dose and expected duration of treatment must be entered in the 
person’s medical record.
•	 A physician must reassess the indication, choice of medicine, dose and duration of treatment within 48 hours and 
should assess this at least every 3 days thereafter.
•	 Critically important antibiotics should be primarily used when the person has or may be expected to have life-
threatening illness or relevant microbiological test results are available.
Specific rules for carbapenems, fluoroquinolones and cephalosporins:
The recommendation outlines specific rules for the use of carbapenems, fluoroquinolones and cephalosporins.
For the primary sector applies: 
Regarding use of antimicrobial agents by general practitioners and other physicians in the primary sector, the use of 
carbapenems is not allowed at all, and the use of fluoroquinolones and cephalosporins should be minimized and only 
used when microbiological diagnostics indicate that other antibiotics cannot be used. 
Treatment with fluoroquinolones before the microbiological test results are available may only be initiated among:
•	 people allergic to penicillin who have acute exacerbation of chronic obstructive pulmonary disease, are clinically 
affected and fulfil the following criteria: increased dyspnoea, increased expectoration and increasing purulent 
expectorate;
•	 people allergic to penicillin who have pyelonephritis;
•	 people with severe gastroenteritis who have a higher risk of complications (such as those older than 60 years, with 
arteriosclerosis or with immune suppression) and among whom Salmonella infection is suspected; and
•	 men older than 35 years with epididymitis.
Cephalosporins can be prescribed for patients with one of two indications:
•	 Pregnant women with penicillin allergy who require treatment for a proven infection (fluoroquinolones and 
macrolides are not recommended for pregnant women).
•	 Patients with penicillin allergy and suspected meningococcal disease, see Health Protection Agency guidelines 
treatment of meningococcal disease No. 9235 of 23 May 2012. 
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For hospitals applies:
•	 Carbapenems as fi rst-line treatment should only be used empirically when septic shock or severe sepsis, synergistic 
gangrene or a similar life-threatening acute infection is suspected.
•	 Carbapenems may be used as second-line treatment if the symptoms progress during treatment with another less 
broad-spectrum antibiotic treatment for infections of unknown cause.
•	 For microbiologically verifi ed infections, carbapenems should only be used if the paraclinical results indicate that 
less broad-spectrum treatment is inadequate.
•	 Fluoroquinolones should only be used in connection with microbiological testing demonstrating that other 
antibiotics cannot be used or if the pharmaceutical properties of fl uoroquinolones are especially suitable and/or 
if the person is allergic to penicillin.
•	 Cephalosporins may be used empirically aft er samples have been obtained for microbiological testing from 
normally aff ected people suspected of having an infectious disease with unknown bacterial origin.
•	 Cephalosporins may be used for surgical prophylaxis in accordance with the local instructions on the use of 
antibiotics if they are validated as being the best choice: that is, more narrow-spectrum antibiotics or combinations 
thereof would not have the same eff ect.
•	 Cephalosporins should otherwise only be used in connection with microbiological testing demonstrating that 
penicillin products or other less broad-spectrum medicines cannot be used.
Jenny Dahl Knudsen and Niels Frimodt-Møller
For further information: Jenny Dahl Knudsen (inge.jenny.dahl.knudsen@regionh.dk)
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5.3  Primary health care
5.3.1  Total consumption in primary health care
In 2012, the total consumption of antimicrobial agents for 
systemic use in primary health care decreased with 3% 
compared to 2011 (17.06 in 2011 to 16.47 DID in 2012) and thus 
deviating from the general upwards tendency observed since 
1995. Several changes were observed from 2011 to 2012 (Table 
5.2). Increases were observed for ‘combination penicillins’ 
(0.16 DID), tetracyclines (0.12 DID), beta-lactamase resistant 
penicillins (0.07 DID) and trimethoprim and derivatives (0.02 
DID). Consumption decreased notably within two groups: 
beta-lactamase sensitive penicillins (0.63 DID) and macrolides 
(0.28 DID).  
Compared to 2011, each patient treated in primary health care 
used a higher number of DDDs in 2012 (20.6 DDD vs. 19.4 
DDD) (Table 5.3), as discussed in section 5.3.2. 
As observed during previous years, the consumption of 
antimicrobial agents was markedly larger in the second half 
of the year, particularly for macrolides and beta-lactamase 
sensitive penicillins. This pattern is most likely caused by the 
generally increased burden of lower respiratory tract infections 
(LRTIs) in the winter months of 2012 as illustrated by the 
incidence of Mycoplasma pneumoniae infections (Figure 5.4).
According to national guidelines, LRTIs of suspected bacterial 
origin are treated with beta-lactamase sensitive penicillins 
and suspected or confirmed M. pneumoniae infections with 
macrolides. 
As in previous years, beta-lactamase sensitive penicillins 
represented the largest therapeutic group of antimicrobial 
agents consumed in 2012 (29%), followed by penicillins with 
extended spectrum (21%) and macrolides (14%) (Figure 5.5). 
Penicillins accounted for 65% of the total consumption in 2012. 
Consumption of broad-spectrum agents increased by 0.3 DID 
(4.1%) compared to 2011 (Figure 5.6). 
From 2003 to 2012, antimicrobial consumption increased by 
21.7% from 13.53 to 16.47 DID (Table 5.2). Broad-spectrum 
agents represented 6.85 DID (42%) of the total consumption 
in 2012 compared to 3.98 DID (29%) in 2003; representing an 
increase of 72% (Figure 5.6 and 5.7). 
5.3.2  Measures at treated patient level
The total number of DDDs per treated patient was 20.6 
compared to 19.4 in 2011. This can be explained by the fact 
that, although fewer patients were treated, more DDDs were 
prescribed for each package than in 2011 (Table A5.3 and Table 
A5.4 in web annex). 
5.2. Consumption of antimicrobial agents for systemic use in primary health care (DDD/1000 inhabitant-days), Denmark
a) From the 2012 edition of the Anatomical Therapeutic Chemical (ATC) classification system
ATC 
group(a) Therapeutic group
Year
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
J01AA            Tetracyclines               1.07 1.17 1.28 1.38 1.48 1.54 1.61 1.69 1.64 1.76
J01CA            Penicillins with extended spectrum 2.52 2.63 2.79 2.95 3.25 3.26 3.29 3.47 3.41 3.40
J01CE            Beta-lactamase sensitive penicillins     5.07 5.20 5.28 5.40 5.67 5.30 5.12 5.25 5.31 4.68
J01CF            Beta-lactamase resistant penicillins     0.85 0.92 0.97 1.05 1.09 1.12 1.13 1.17 1.14 1.21
J01CR            Combinations of penicillins, including beta-lactamase inhibitors   0.05 0.06 0.08 0.12 0.19 0.27 0.45 0.68 0.89 1.05
J01D                        Cephalosporins and related substances          0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
J01EA            Trimethoprim and derivatives   0.38 0.41 0.44 0.47 0.49 0.49 0.48 0.51 0.50 0.52
J01EB            Short-acting sulfonamides       0.36 0.36 0.35 0.35 0.31 0.28 0.27 0.26 0.24 0.22
J01EE            Combinations of sulfonamides and trimethoprim, including derivatives 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
J01FA            Macrolides                  2.13 2.23 2.41 2.31 2.42 2.28 2.21 2.44 2.47 2.19
J01FF            Lincosamides                0.01 0.01 0.01 0.02 0.02 0.03 0.03 0.04 0.04 0.04
J01GB Aminoglycosides 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02
J01MA            Fluoroquinolones            0.25 0.28 0.33 0.37 0.44 0.51 0.52 0.57 0.57 0.55
J01XA Glycopeptides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XB            Polymyxins                 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02
J01XC            Steroid antibacterials (fusidic acid)     0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01
J01XD            Imidazole derivatives                  0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XE Nitrofuran derivatives (nitrofurantoin) 0.42 0.43 0.45 0.46 0.47 0.47 0.49 0.51 0.50 0.49
J01XX            Other antibacterials (methenamine >99%)                0.32 0.30 0.28 0.27 0.26 0.27 0.26 0.27 0.26 0.25
J01 Antibacterial agents for systemic use (total) 13.53 14.06 14.75 15.23 16.17 15.91 15.95 16.93 17.06 16.47
DANMAP 2012
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For the leading groups of antimicrobial agents each treated 
patient received 11.7–22.3 DDDs in 1.5–1.7 packages with the 
exception of tetracyclines (47.6 DDDs in 2.1 packages) (Table 
5.3). The large number of DDDs prescribed for tetracyclines 
are primarily due to acne treatment which requires higher 
dosages for longer periods (Textbox 5).
Three different indicators of antimicrobial consumption at 
treated patient level in primary health care are available (Figure 
5.8). From 2003 to 2012, the largest decreases were observed 
in DDDs per treated patient (29%) and DDDs per prescribed 
package (24%) (Table 5.3). 
The reasons for the changes at treated patient level are still 
unclear. However, following the removal of broad codes of 
indication on prescriptions for antimicrobial agents in early 
2012, it is expected that future editions of DANMAP will be 
able to shed light on the disease-or pathogen-specific reasons 
for upward or downward trends in consumption of certain 
antimicrobial agents. 
5.3.3  Tetracyclines 
In 2012, the overall consumption of tetracyclines increased 
by 0.12 DID (7.2%) compared to 2011 (Table 5.2). The most 
commonly used substance was tetracycline (0.78 DID, 44%) 
followed by doxycycline (0.60 DID, 34%) and lymecycline 
(0.38 DID, 22%) (Figure 5.9). Compared to 2011, consumption 
of doxycycline increased while consumption of tetracycline, 
lymecycline and oxytetracycline remained relatively constant.
Since the early 2000s, a considerable increase in the 
consumption of tetracyclines has been observed (Table 5.2). 
This topic is further highlighted in Textbox 5. 
5.3.4  Penicillins 
The overall consumption of penicillins in 2012 showed a small 
decrease of 0.41 DID (3.8%) compared to 2011 (Table 5.2). 
Increases in consumption were observed for ‘combination 
penicillins’ (18%) and beta-lactamase resistant penicillins (6%). 
For the individual substances, the consumption of flucloxacillin, 
amoxicillin and enzyme inhibitor, and pivmecillinam increased. 
The consumption of phenoxymethylpenicillin decreased 
by 29% (Figure 5.10). The use of ‘combination penicillins’ 
(primarily amoxicillin/clavulanic acid) is currently advocated 
for broad treatment of respiratory infections, particularly in 
patients with exacerbation of chronic obstructive pulmonary 
disease. 
During the past decade (2003–2012), the consumption of 
penicillins increased by 1.85 DID (22%). This increase was 
apparent for penicillins with extended spectrum, ‘combination 
penicillins’ and beta-lactamase resistant penicillins (Table 5.2). 
Phenoxymethylpenicillin continues to be the most commonly 
consumed penicillin; however the order has changed among 
the other substances during the last decade (Figure 5.10).
Table 5.3. Number of DDDs and packages per treated patient among leading groups of antimicrobial agents in primary health care, 
Denmark
a) From the 2012 edition of the Anatomical Therapeutic Chemical (ATC) classification system
ATC 
group(a) Therapeutic group Indicator
Year
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
J01AA Tetracyclines               
DDDs / patient 34.4 36.9 39.0 40.9 43.0 44.4 45.2 45.9 44.0 47.6
Packages / patient 1.9 1.9 2.0 1.9 2.0 2.0 2.0 2.0 1.9 2.1
DDDs / package 18.1 19.0 19.6 21.0 22.0 22.7 22.7 22.7 22.6 23.1
J01CA Penicillins with extended spectrum
DDDs / patient 13.4 13.6 13.9 14.2 14.4 14.7 14.8 14.9 14.8 16.1
Packages / patient 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.7
DDDs / package 8.2 8.4 8.5 8.9 9.0 9.2 9.2 9.0 9.2 9.7
J01CE Beta-lactamase sensitive penicillins     
DDDs / patient 10.7 11.1 11.3 11.5 11.7 11.8 11.8 11.8 11.8 11.8
Packages / patient 1.5 1.5 1.5 1.4 1.4 1.4 1.4 1.4 1.4 1.4
DDDs / package 7.3 7.5 7.7 8.0 8.2 8.2 8.4 8.4 8.4 8.4
J01CF Beta-lactamase resistant penicillins     
DDDs / patient 11.8 12.4 12.7 13.0 13.4 13.7 13.9 14.2 13.8 15.5
Packages / patient 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.5 1.4 1.6
DDDs / package 7.4 7.8 8.0 8.6 8.7 9.0 9.1 9.3 9.6 9.7
J01CR Combinations of 
penicillins, incl. beta-
lactamase inhibitors   
DDDs / patient 16.6 17.2 16.8 19.3 19.1 19.9 20.4 21.1 21.9 22.3
Packages / patient 1.8 2.0 2.0 1.8 1.6 1.6 1.5 1.5 1.6 1.6
DDDs / package 9.1 9.1 9.3 10.7 11.7 12.4 13.3 13.7 14.1 14.3
J01FA Macrolides                  
DDDs / patient 12.1 12.4 12.4 12.6 12.4 12.5 12.5 12.2 11.5 12.4
Packages / patient 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5
DDDs / package 7.8 7.9 8.0 8.3 8.1 8.1 8.1 8.1 7.9 8.0
J01MA Fluoroquinolones            
DDDs / patient 10.3 9.5 9.6 10.3 10.6 11.0 11.2 11.2 11.5 11.7
Packages / patient 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
DDDs / package 6.6 6.4 6.5 6.9 7.0 7.5 7.6 7.6 7.7 7.8
J01 Antibacterial agents for systemic use (total)
DDDs / patient 16.4 17.0 17.5 17.9 17.3 18.9 19.2 19.6 19.4 20.6
Packages / patient 2.1 2.1 2.1 2.0 1.9 2.1 2.1 2.1 2.1 2.1
DDDs / package 7.9 8.1 8.3 8.7 8.9 9.1 9.3 9.3 9.3 9.7
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Figure 5.4. Monthly consumption in 2012 of macrolides and beta-lactamase sensitive penicillins and PCR positive 
Mycoplasma pneumoniae tests in primary health care, Denmark
Figure 5.5. Distribution of the total consumption of antimicrobial agents in primary health care, Denmark
DANMAP 2012
Note: Bold highlights indicate broad-spectrum antimicrobial agents
Note: Derived from weekly data representing only those tests sent for analysis at Statens Serum Institut, not national totals
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DANMAP 2012
Figure 5.6. Consumption of antimicrobial agents (J01) in primary health care by narrow-spectrum and broad-spectrum agents, 
Denmark
Note: "Narrow-spectrum" includes: beta-lactamase sensitive penicillins, beta-lactamase resistant penicillins, trimethoprim, sulfonamides, 
macrolides, lincosamides, glycopeptides, fusidic acid, imidazol derivatives, nitrofuran derivatives, and 'other antibiotics'
“Broad-spectrum” includes: tetracyclines, penicillins with extended spectrum, combinations of penicillins incl. beta-lactamase inhibitors, 
cephalosporins and related substances, combinations of sulfonamides and trimethoprim, aminoglycosides, fluoroquinolones, and polymyxins
DANMAP 2012
Figure 5.7. Consumption of leading antimicrobial groups for systemic use in primary health care, Denmark
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Figure 5.8. Indicators of antimicrobial consumption (J01) in primary health care, Denmark
Figure 5.9. Consumption of tetracyclines in primary health care, Denmark
DANMAP 2012
Figure 5.10. Consumption of leading penicillins in primary health care, Denmark
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5.3.5  Macrolides 
From 2011–2012, the consumption of macrolides decreased by 
0.28 DID (11.4%) (Table 5.2). A decreased consumption was 
observed for all substances apart from clarithromycin (Figure 
5.11). The consumption of roxithromycin decreased for the 
first time since 2008. The high consumption of macrolides in 
2010 and 2011 may be explained by two epidemic waves of M. 
pneumoniae infection (DANMAP 2010 & 2011) and the return 
to a generally lower consumption in 2012 may be explained by 
a more normal incidence of M. pneumoniae infection in 2012 
(Figure 5.4).
From 2003 to 2012, the consumption of roxithromycin 
increased by 0.47 DID, with smaller increases also observed 
for clarithromycin (0.13 DID) and azithromycin (0.09 DID) 
(Figure 5.11). The consumption of erythromycin decreased 
substantially (0.62 DID), most likely in response to changes 
in national guidelines which in 2004 substituted the first-
choice macrolide in primary care from erythromycin to 
roxithromycin and subsequently also to clarithromycin in 2007. 
These two substances are now the recommended first choices 
for treatment of respiratory infections in people with penicillin 
allergy or suspected M. pneumoniae infection. During the 
whole period, azithromycin has been the recommended 
treatment for urethritis/cervicitis and epididymitis.  
  
5.3.6  Fluoroquinolones 
The consumption of fluoroquinolones in 2012 (0.55 DID) 
remained at almost the same level as observed in 2011 (0.57 
DID) (Table 5.2). Ciprofloxacin accounted for the majority 
of the fluoroquinolone consumption (94%), followed by 
moxifloxacin (4.1%) and ofloxacin (1.6%) (Figure 5.12). 
During the past decade, the consumption of fluoroquinolones 
has increased by 0.30 DID (120%), most likely driven by the 
introduction of generic versions in Denmark in late 2001 
[Jensen et al. 2010. J Antimicrob Chemother. 65: 1286–91]. 
As ciprofloxacin is strongly associated with resistance, this 
increase is particular grounds for concern.
DANMAP 2012
Figure 5.11. Consumption of macrolides in primary health care, Denmark
Figure 5.12. Consumption of leading fluoroquinolones in primary health care, Denmark
DANMAP 2012
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From 2011 to 2012, increased consumption was seen for 
‘combination penicillins’ (3.49 DBD, 41%), beta lactamase 
resistant penicillins (1.07 DBD, 15%), and beta lactamase 
sensitive penicillins (0.81 DBD, 9%), while decreased 
consumption was observed for 2nd generation cephalosporins 
(1.99 DBD, 12%), 3rd generation cephalosporins (0.32 DBD, 
23%), carbapenems (0.30 DBD, 7%), and fluoroquinolones 
(0.68 DBD, 6%) (Table 5.4). The changes were in agreement 
with the guidelines from the Danish Health and Medicines 
Authority described in Textbox 3. 
Furthermore, tetracyclines increased with 0.40 DBD (34%). 
This could in part be explained by purchase of a large amount 
of a tetracycline for prophylactic treatments after Brucella 
exposures in the Capital Region, but in the end only a minor 
part of the tetracycline was used for treatment (Jenny Dahl 
Knudsen, personal communication).
Consumption (DBD) in somatic hospitals - the last decade 
From 2003–2012, the total consumption of antimicrobial 
agents increased by 39.4 DBD (73%) (Table 5.4). This increase 
was due to a combination of increased DDDs and a decreased 
number of hospital bed-days. During the past decade, the 
consumption of broad-spectrum antimicrobial agents in the 
somatic hospitals has increased by 133%, from 27.11 DBD in 
2003 to 63.14 DBD in 2012 (Table 5.4).
The changes in leading groups of antimicrobial agents used 
in hospitals during 2003–2012 are shown in Figure 5.15. 
The consumption of fluoroquinolones in somatic hospitals 
increased by 6.12 DBD (157%) and the consumption of 
carbapenems increased by 3.18 DBD (468%) during the past 
decade. Consumption of cephalosporins increased by 8.29 
DBD (118%) from 2003–2012 (Table 5.4). 
5.4  Hospital care
5.4.1  Introduction
The consumption of antimicrobial agents in the hospital 
sector is presented as DDD per 100 occupied bed-days 
(DBD). Furthermore, data are also presented as DDD per 
100 admissions (DAD) to account for hospital activity and as 
DID to enable comparison with primary health care and to 
document the consumption across the entire hospital sector, 
irrespective of hospital activity.
The hospital sector encompasses all hospitals in Denmark, 
i.e. rehabilitation centres, hospices, private-, psychiatric-, 
specialized-, and somatic hospitals. Somatic hospitals account 
for the majority (97%) of the antimicrobial consumption in 
the hospital sector. Antimicrobial consumption is therefore 
correlated only to bed-days and admissions in somatic 
hospitals and not to bed-days and admissions in other hospital 
types since psychiatric hospitals contribute a large proportion 
of bed-days and admissions but only a small proportion of the 
antimicrobial consumption. 
The hospitalization pattern in Denmark has changed 
significantly during the past decade: more people are 
admitted to somatic hospitals but average length of stay has 
been shortened (Figure 5.13, Table A5.5 in web annex) and 
outpatient treatment has increased considerably. Therefore, 
the hospital activity and subsequent selection pressure for the 
emergence of resistance were higher in 2012 than in 2003.  
5.4.2  Somatic hospitals - DDD per 100 
occupied bed-days (DBD)
Consumption (DBD) in somatic hospitals compared to 
2011 
The consumption of antimicrobial agents in somatic hospitals 
increased with 2.28 DBD (3%) from 90.84 DBD in 2011 to 
93.12 DBD in 2012 (Table 5.4). The distribution of the different 
antimicrobial agents is shown in Figure 5.14. 
Figure 5.13. Number of bed-days and admissions in somatic hospitals, Denmark
DANMAP 2012
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Figure 5.14. Distribution of the total consumption of antimicrobial agents in somatic hospitals, Denmark
Table 5.4. Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 occupied bed-days), Denmark
a) From the 2012 edition of the Anatomical Therapeutic Chemical (ATC) classification system
ATC 
group(a) Therapeutic group
Year
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
J01AA                        Tetracyclines               0.30 0.32 0.33 0.39 0.63 0.78 1.04 1.09 1.18 1.58
J01CA                        Penicillins with extended spectrum 11.55 11.51 12.90 13.00 13.42 13.96 15.37 14.61 14.41 14.90
J01CE                        Beta-lactamase sensitive penicillins     11.85 12.02 12.17 10.67 10.79 9.98 9.90 9.49 9.32 10.13
J01CF                        Beta-lactamase resistant penicillins     6.54 6.78 6.71 6.51 6.70 6.81 7.40 7.71 7.30 8.37
J01CR                        Combinations of penicillins. incl. beta-lactamase inhibitors   0.49 0.84 1.16 1.83 2.95 4.00 5.65 7.13 8.51 12.00
J01DB                  First-generation cephalosporins 0.14 0.17 0.15 0.14 0.13 0.18 0.13 0.13 0.13 0.12
J01DC Second-generation cephalosporins 6.24 6.91 8.39 9.38 12.31 13.32 15.76 16.21 16.14 14.15
J01DD Third-generation cephalosporins 0.67 0.67 0.83 0.83 1.03 1.25 1.42 1.26 1.39 1.07
J01DF Monobactams 0.01 0.00 0.00 0.00 0.04 0.07 0.06 0.09 0.19 0.15
J01DH Carbapenems 0.68 0.85 1.16 1.38 2.13 2.70 3.15 4.02 4.16 3.86
J01EA                        Trimethoprim and derivatives   0.43 0.41 0.41 0.42 0.44 0.44 0.44 0.36 0.36 0.38
J01EB                        Short-acting sulfonamides       1.14 1.06 0.99 0.75 0.34 0.35 0.35 0.33 0.25 0.20
J01EE                        Combinations of sulfonamides and trimethoprim. incl. derivatives 1.54 1.86 2.11 2.12 1.52 1.95 2.28 3.04 4.11 3.33
J01FA                        Macrolides                  2.95 2.85 2.89 2.83 3.08 3.06 3.42 3.52 3.69 3.56
J01FF                        Lincosamides                0.22 0.23 0.24 0.31 0.35 0.41 0.50 0.47 0.53 0.62
J01GB Aminoglycosides 1.71 2.00 1.95 1.81 1.79 1.64 1.56 1.71 1.91 2.14
J01MA            Fluoroquinolones            3.90 4.93 6.14 6.74 8.16 9.53 10.71 10.44 10.70 10.02
J01XA Glycopeptides 0.42 0.47 0.52 0.56 0.63 0.68 0.99 1.07 1.24 1.29
J01XB                        Polymyxins                 0.03 0.06 0.12 0.12 0.05 0.05 0.07 0.10 0.09 0.09
J01XC                        Steroid antibacterials (fusidic acid)     0.22 0.22 0.25 0.28 0.28 0.26 0.31 0.34 0.27 0.23
J01XD                 Imidazole derivatives 2.32 2.43 2.62 2.78 2.62 3.27 3.84 3.93 4.19 4.16
J01XE Nitrofuran derivatives (nitrofurantoin) 0.30 0.28 0.29 0.29 0.28 0.29 0.36 0.31 0.33 0.34
J01XX05 Methenamine 0.08 0.10 0.08 0.11 0.09 0.10 0.09 0.08 0.10 0.09
J01XX08 Linezolid 0.04 0.07 0.15 0.20 0.16 0.21 0.22 0.22 0.32 0.32
J01XX09 Daptomycin 0.00 0.00 0.00 0.00 0.01 0.02 0.02 0.02 0.02 0.02
J01 Antibacterial agents for systemic use (total) 53.77 57.04 62.58 63.47 69.94 75.28 85.03 87.72 90.84 93.12
DANMAP 2012
Note: Bold highlights indicate broad-spectrum antimicrobial agents
DANMAP 2012
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5.4.3 Other measures of somatic hospital 
consumption 
DDD per 100 admissions (DAD)
In Denmark, the hospitalization pattern has changed over the 
last decade. Today, more patients are admitted to the somatic 
hospitals but each length of stay has been shortened. It can 
therefore be relevant to measure the hospital consumption in 
relation to admissions.
When expressed as DAD (DDD per 100 admissions), the total 
consumption of antimicrobial agents in Danish somatic hospitals 
increased by 8% from 2011 to 2012 (Table 5.5). Increases in 
consumption were partly observed for the same therapeutic 
groups as when expressed in DBD: ‘combination penicillins’ 
(12.67 DAD, 48%), beta lactamase resistant penicillins (4.59 
DAD, 20%), beta lactamase sensitive penicillins (4.06 DAD, 
14%), penicillins with extended spectrum (3.83 DAD, 9%) 
and tetracyclines (1.49 DAD, 41%). A decreased consumption 
was observed for 2nd generation cephalosporins (4.02 DAD, 
8%), fluoroquinolones (0.63 DAD, 2%) and 3rd generation 
cephalosporins (0.83 DAD, 19%).
From 2003–2012, the consumption of antimicrobial agents 
increased by 19%, from 255.59 DAD in 2003 to 303.71 DAD 
in 2012. As observed in previous years, this increase was 
primarily driven by an increase in the number of DDDs but 
counterbalanced by an increase in the number of hospital 
admissions. 
DDD per 1,000 inhabitants per day (DID)
The consumption of antimicrobial agents in somatic hospitals 
has increased by 0.50 DID (33%) from 2003 to 2012. Broad-
spectrum agents have increased by 0.60 DID (79%), comprising 
68% of the total consumption in 2012 compared to 50% in 2003 
(Figure 5.16). 
Katrin Gaardbo Kuhn, Maja Laursen, Stefan S. Olsen, 
Line Skjøt-Rasmussen and Anette M. Hammerum
Table 5.5. Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 admitted patients), Denmark
ATC 
group(a) Therapeutic group
Year
2003 2004 2005 2006 2007 2008(b) 2009 2010 2011 2012
J01AA                        Tetracyclines               1.43 1.45 1.45 1.67 2.59 3.19 3.63 3.55 3.66 5.15
J01CA                        Penicillins with extended spectrum 54.88 52.22 56.43 55.13 55.39 57.18 53.76 47.46 44.77 48.60
J01CE                        Beta-lactamase sensitive penicillins     56.33 54.53 53.20 45.26 44.55 40.90 34.61 30.83 28.98 33.04
J01CF                        Beta-lactamase resistant penicillins     31.11 30.77 29.33 27.60 27.64 27.89 25.86 25.04 22.71 27.30
J01CR                        Comb. of penicillins. incl. beta-lactamase inhibitors   2.35 3.82 5.09 7.77 12.17 16.37 19.74 23.15 26.47 39.14
J01DB                  First-generation cephalosporins 0.67 0.76 0.67 0.60 0.55 0.72 0.46 0.43 0.41 0.40
J01DC Second-generation cephalosporins 29.66 31.36 36.70 39.76 50.81 54.55 55.12 52.65 50.19 46.17
J01DD Third-generation cephalosporins 3.17 3.06 3.62 3.53 4.24 5.10 4.98 4.10 4.33 3.50
J01DF Monobactams 0.02 0.02 0.02 0.00 0.18 0.27 0.21 0.29 0.60 0.48
J01DH Carbapenems 3.24 3.85 5.05 5.86 8.78 11.08 11.01 13.07 12.55 12.60
J01EA                        Trimethoprim and derivatives   2.05 1.86 1.78 1.78 1.81 1.80 1.56 1.17 1.11 1.23
J01EB                        Short-acting sulfonamides       5.44 4.82 4.32 3.18 1.41 1.43 1.21 1.09 0.78 0.63
J01EE                        Comb. of sulfonamides and trimethoprim. incl. derivatives 7.32 8.44 9.21 8.98 6.28 7.98 7.96 9.88 12.79 10.87
J01FA                        Macrolides                  14.03 12.92 12.64 12.01 12.70 12.53 11.97 11.45 11.47 11.61
J01FF                        Lincosamides                1.05 1.04 1.05 1.31 1.46 1.69 1.74 1.52 1.63 2.01
J01GB Aminoglycosides 8.14 9.07 8.55 7.68 7.39 6.71 5.45 5.56 5.95 6.99
J01MA            Fluoroquinolones            18.53 22.38 26.87 28.58 33.66 39.04 37.45 33.92 33.30 32.67
J01XA Glycopeptides 1.97 2.12 2.28 2.38 2.61 2.77 3.48 3.47 3.87 4.20
J01XB                        Polymyxins                 0.14 0.27 0.54 0.53 0.22 0.21 0.24 0.32 0.28 0.30
J01XC                        Steroid antibacterials (fusidic acid)     1.04 1.01 1.11 1.19 1.17 1.05 1.09 1.12 0.85 0.76
J01XD                 Imidazole derivatives 11.03 11.02 11.47 11.81 10.83 13.39 13.43 12.76 13.03 13.55
J01XE Nitrofuran derivatives (nitrofurantoin) 1.41 1.26 1.28 1.24 1.17 1.19 1.27 1.01 1.02 1.12
J01XX05 Methenamine 0.37 0.45 0.36 0.46 0.38 0.43 0.31 0.27 0.32 0.28
J01XX08 Linezolid 0.21 0.34 0.64 0.86 0.68 0.84 0.76 0.72 0.99 1.04
J01XX09 Daptomycin 0.00 0.00 0.00 0.00 0.03 0.06 0.06 0.07 0.05 0.06
J01 Antibacterial agents for systemic use (total) 255.59 258.81 273.67 269.18 288.70 308.39 297.36 284.89 282.53 303.71
DANMAP 2012
a) From the 2012 edition of the Anatomical Therapeutic Chemical (ATC) classification system
b) The number of admissions was affectedly low in 2008 due to a major hospital strike
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Figure 5.16. Consumption of antimicrobial agents (J01) in hospital care by narrow-spectrum and broad-spectrum agents, Denmark
Note: "Narrow-spectrum" antibiotics includes: beta-lactamase sensitive penicillins, first-generation cephalosporins, beta-lactamase resistant 
penicillins, monobactams, trimethoprim, sulfonamides, macrolides, lincosamides, glycopeptides, fusidic acid, imidazol derivatives, nitrofuran 
derivatives, and 'other antibiotics'
“Broad-spectrum” includes: tetracyclines, penicillins with extended spectrum, combinations of penicillins incl. beta-lactamase inhibitors, 
second-generation cephalosporins, third-generation cephalosporins, carbapenems, combinations of sulfonamides and trimethoprim, 
aminoglycosides, fluoroquinolones, and polymyxins
DANMAP 2012
Figure 5.15. Total somatic hospital consumption (DBD) by leading groups of antimicrobial agents (J01), Denmark
DANMAP 2012
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Citizen-centered website on how and when to use antimicrobial agents  
Furthermore, the website describes two case stories with patients infected with multi-resistant bacteria. Th e website 
has information about what the patient can do to get well, as well as a sub-site with frequently asked questions.
 
Line Skjøt-Rasmussen, Katrin G. Kuhn, Berit Jørgensen, Lars Bjerrum, 
Tove Rønne, Grith Strøbæk, Anette M. Hammerum and Robert L. Skov
 
For further information: Robert L. Skov (rsk@ssi.dk)
At the European Antibiotic Awareness Day in November 2012, the website antibiotikaellerej.dk about antimicrobial 
agents and resistance was launched in cooperation between the Ministry of Health, the Danish Health and Medicines 
Authority, the Danish College of General Practitioners, the Danish Medical Association, and Statens Serum Institut. 
Th e purpose of the website is to focus on our use of antimicrobial agents and help to raise awareness about when it is 
appropriate to get antimicrobial agents.
On the citizen-centered website one may fi nd answers on when and when not there is a need for antimicrobial agents as 
well as why it is important to only use antimicrobial agents when necessary.
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Excessive use of tetracylines for acne treatment among young Danish adults
Background: Acne vulgaris is a disease of the sebaceous glands, caused either by infection with Propionibacterium acnes, 
sebaceous gland hyperplasia or excessive production of sebum. In Northern Europe, acne affects between 80-85% of 
teenagers and the most severe cases are observed in 17–19 year old males. Tetracyclines are used as treatment for acne 
vulgaris in adolescents worldwide. 
In Denmark, a large increase in consumption of antimicrobial agents in primary health care was recently shown to be 
driven by 15–19 year olds, with particular increases for tetracyclines [Textbox 3, DANMAP 2011]. 
In this study, we investigated the consumption of tetracylines in young adults and the population as a whole by collecting 
consumption data and codes of indication from tetracycline prescriptions from 2008 to 2011. 
Methods: Consumption data for antimicrobial agents and indication codes from general practitioner tetracycline 
prescriptions from 2008 to 2011 were obtained from National Register of Medicinal Products Statistics. Prescription 
indication codes specify the disease/infection for which the antimicrobial agent has been prescribed, including the two 
broad options ‘against infection’ and ‘against inflammation’. Completing the indication code field on a prescription was 
not mandatory for Danish general practitioners in the period 2008–2011. 
Data were analysed by descriptive statistics and two-tailed t-tests using the STATA™ software 11.0 (Statacorp., Lakeway, 
TX, USA). 
Results: In 2008, tetracyclines accounted for 4.5 DID (29%) of all antimicrobial agents prescribed to 15–19 year olds 
(Figure 1). By 2011, this had increased to 5.4 DID (33%). For all age groups (including 15–19 year olds), tetracyclines 
accounted for 1.6 DID (10%) of all prescribed antimicrobial agents in 2008 and 1.7 DID (9.6%) in 2011. For 15–19 year 
olds, penicillins accounted for 7 DID (45%) of all prescribed antimicrobial agents in 2008 and 7.3 DID (45%) in 2011. In 
the whole population, penicillins accounted for 10 DID (63%) in 2008 and 11 DID (63%) in 2011 (Figure 1). 
In 2008, 47% of tetracycline for 15–19 year olds were prescribed with an indication code of acne and 55% with codes 
indicating any skin disorder (acne, ‘skin problems’, ‘unclean skin’ or ‘skin disorders’) (Figure 2). By 2011, 53% of 
tetracyclines in 15–19 year olds were prescribed against acne and 59% against skin disorders in total. During 2008–2011, 
indication codes were missing on 21–28% of the tetracycline prescriptions (Figure 2).
Discussion: From 2008 to 2011, tetracyclines accounted for 29–33% of all antimicrobial consumption in young Danish 
adults but only around 10% in the general population. In comparison, penicillins, which are the most common used 
antimicrobial agents in Denmark, accounted for 45% of the consumption in 15–19 year olds and 63% of antimicrobial 
consumption in all age groups during the study period. These numbers confirm that tetracyclines are used to a great extent 
among adolescents, reaching almost the same consumption level as penicillins. Further, the consumption of tetracyclines 
remained at a constantly high level during the four years of interest. Even though all prescriptions did not have codes of 
indication, many of the prescriptions with tetracyclines were given for skin disorders like acne. 
An important problem with the widespread use of the broad-spectrum antimicrobial agents, such as tetracyclines, for 
acne treatment is the development of resistant bacteria. Treatment regimens for acne are generally long, varying between 
8 to 24 weeks with an average of 12 weeks which strongly increases the selection for resistant bacteria.
Katrin G. Kuhn, Maja Laursen and Anette M. Hammerum
For further information: Anette M. Hammerum (ama@ssi.dk)
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Figure 1. Consumption of tetracyclines (J01A), penicillins (J01C) and other antimicrobial agents in 15–19 year olds and all 
age groups in Denmark, 2008–2011
Figure 2. Distribution (%) of indication codes for tetracycline prescriptions in 15–19 year olds in Denmark, 2008–2011
DANMAP 2012
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6. Resistance in zoonotic bacteria
Zoonoses are infectious diseases that can be transmitted 
between animals and humans, either through direct contact 
or indirectly by contaminated food. Zoonotic bacteria, such as 
Salmonella and Campylobacter, can develop resistance towards 
antimicrobial agents as a result of treatment of both animals 
and humans, which subsequently may lead to limited treatment 
possibilities or even treatment failure of human infectious 
diseases. A more detailed description of the trends and sources 
of zoonoses in Denmark and of national surveillance and 
control programmes can be found in the Annual Report on 
Zoonoses in Denmark 2012 [www.food.dtu.dk].
 
 
Salmonella is the second most important zoonotic bacterial 
pathogen in Denmark and can have a severe economic 
impact on both animal production and human productivity. 
 
In Denmark and the rest of European Union, S. Enteritidis 
and S. Typhimurium are the serovars most frequently 
associated with human illness. Human cases caused by 
S. Enteritidis are most commonly associated with the 
consumption of contaminated eggs or poultry meat, whereas 
S. Typhimurium cases are mostly associated with the 
consumption of contaminated pork, beef or poultry meat. 
 
For Salmonella, DANMAP 2012 includes isolates from broiler, 
layer and cattle farms reported infected during 2012 as well as 
isolates from Danish and imported broiler meat, turkey meat, 
beef and pork collected as part of national surveillance and 
control programmes. From pigs, Salmonella isolates recovered 
from sow herds as well as multiplier and breeding herds as 
part of the Salmonella control programme are included. In 
addition, faecal samples from healthy pigs were collected at 
the slaughterhouses and cultured for Salmonella as part of 
the DANMAP programme. Isolates from all reported human 
cases are included. Only one isolate per farm, meat sample or 
human case was included, and data are presented in the report 
where a sufficient number of isolates were obtained (>15). For 
details on methodology see Chapter 10, Material and Methods. 
In DANMAP 2012, we primarily present resistance among 
S. Typhimurium. During the last ten years, the numbers of 
S. Enteritidis isolates from infected poultry flocks and meat 
thereof have been decreasing, and therefore resistance in 
S. Enteritidis will not be presented in this report. This year 
however, the occurrence of resistance among Salmonella spp. 
from pigs and Danish pork is presented (Table 6.1). 
Among all the Salmonella isolates from Danish pigs (n = 374) 
and pork (n = 120), we observed high levels (28% to 41%) 
of resistance to ampicillin, streptomycin, sulfonamide, and 
tetracycline. None of the isolates were resistant to cephalosporins 
(ceftiofur, cefotaxime) or quinolones (ciprofloxacin, nalidixic 
acid).
The most common serotypes from Danish pigs and pork 
were S. Derby (47% and 38%, respectively), S. Typhimurium 
including the monophasic variants (39% and 34%, 
respectively) and S. Infantis (5% and 7%, respectively).
Note that the isolates from pigs i Table 6.1 and 6.2 include 
isolates from pen feacal samplings from the national control 
programme as well as isolates from the DANMAP sampling of 
healthy pigs. Thus the serotype distributions is not excatly as 
presented for the slaughter pig herds in Textbox 6.
  
As the majority of the S. Derby isolates were fully sensitive, 
the overall occurrences of resistance among Salmonella spp. in 
pigs and Danish pork were lower than observed among the S. 
Typhimurium isolates only. 
Even though S. Derby is very common among pigs, relatively 
few human S. Derby cases are reported in Denmark [Annual 
Report on Zoonoses in Denmark 2012].
Table 6.1. Resistance (%) among Salmonella Spp. from pigs and 
Danish pork, Denmark DANMAP 2012
Antimicrobial agent
Pigs Pork
% Danish         %
Tetracycline 41 33
Chloramphenicol 5 2
Florfenicol 3 2
Ampicillin 31 28
Ceftiofur 0 0
Cefotaxime 0 0
Sulfonamide 36 35
Trimethoprim 9 7
Apramycin 2 0
Gentamicin 3 1
Neomycin 2 2
Spectinomycin 11 8
Streptomycin 37 34
Ciprofloxacin 0 0
Nalidixic acid 0 0
Colistin 1 2
Fully sensitive 46 52
Multi-resistant 34 32
Number of isolates 374 120
Note: An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel and  multi-resistant if 
resistant to three or more of the ten antimicrobial classes (see Table 
10.3)
6.1 Salmonella
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6.1.1  S. Typhimurium in pigs and pork 
S. Typhimurium isolated from pigs (n = 144) had very high 
levels of resistance to ampicillin (65%), streptomycin (67%), 
sulfonamide (67%), and tetracycline (65%, Table 6.2), and 
the occurrence of resistance for all four antimicrobial agents 
increased compared with 2011 (Figure 6.1). Co-resistance 
of these four antimicrobial agents is often called the 
ASSuT resistance-profile, also when resistant to additional 
antimicrobial agents. 
Since 2007, ASSuT resistance among S. Typhimurium in pigs 
has been increasing, partly due to an increase in the prevalence 
of the monophasic variants of S. Typhimurium often carrying 
the ASSuT resistance-profile (Figure 6.2). In 2012, 73% of the 
monophasic variants were ASSuT resistant compared with 27% 
among the generic (e.g. non-monophasic) S. Typhimurium 
isolates. 
In 2012, the monophasic S. Typhimurium variants constituted 
56% of the total number of S. Typhimurium isolates from pigs, 
representing 72% of the multi-resistant isolates.
In DANMAP, S. Typhimurium includes the monophasic 
variants with antigenic formulas S. 4,5,12:i:- and S. 4,12:i:-, as 
recommended by the European Food Safety Authority [EFSA 
journal 2010. 8(10): 1826]. In the text, generic S. Typhimurium 
indicates results only covering isolates of the non-monophasic 
variants. Since 2012, routine analyses of S. Typhimurium 
phage types are no longer performed in Denmark. 
MIC distributions for S. Typhimurium from pigs, Danish 
pork and humans, as well as for Salmonella spp. from pigs and 
Danish pork in 2012 are presented in the web annex (Tables 
A6.1-A6.5). Data for each of the figures are also presented in 
the web annex.
An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel, and  multi-
resistant if resistant to three or more of the ten included 
antimicrobial classes (see Table 10.3).
Table 6.2. Resistance (%) among Salmonella Typhimurium(a) from pigs, Danish pork and human cases(b), Denmark
Antimicrobial agent
Pigs Pork Human
% Danish         %
Domestic
sporadic 
%
Domestic 
outbreak 
%
Travel 
abroad
%
Unknown 
origin 
%
Tetracycline 65 51 54 92 73 64
Chloramphenicol 9 2 9 0 20 11
Florfenicol 8 2 4 0 19 6
Ampicillin 65 56 58 92 71 61
Ceftiofur 0 0 1 0 5 2
Cefotaxime 0 0 - - - -
Sulfonamide 67 61 65 92 71 64
Trimethoprim 6 5 6 0 12 9
Apramycin 5 0 1 0 0 0
Gentamicin 5 0 2 0 7 2
Neomycin 3 0 2 0 2 2
Spectinomycin 13 2 8 0 17 11
Streptomycin 67 59 62 94 71 60
Ciprofloxacin 0 0 2 0 24 6
Nalidixic acid 0 0 1 0 14 5
Colistin 0 0 1 0 2 1
Fully sensitive 22 29 25 6 20 24
Multi-resistant 66 59 62 92 76 62
Number of isolates 144 41 177 48 59 127
DANMAP 2012
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and  multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3)
a) Include isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:-
b) An isolate was categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of the disease and 
was not reported as being part of an outbreak
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The prevalence of S. Typhimurium infected slaughter pig 
herds was 7.6% in 2012 (Textbox 6.), and as 66% of the S. 
Typhimurium isolates were multiresistant, the prevalence of 
pig herds with multi-resistant S. Typhimurium amounts to 
approximately 5%.
In Danish pork (n = 41), 56% of the isolates were of the mono-
phasic variants and high levels (34%) of ASSuT resistance 
were observed. Levels of resistance were comparable among 
S. Typhimurium isolates from pigs and Danish pork (Table 
6.2). Thus, the unexplained differences in resistance levels 
among isolates from pigs and pork observed in 2011 were 
not observed in 2012.  
Resistance to the other tested antimicrobial agents was 
similar to levels reported in 2011. However, results showed a 
decrease in resistance to neomycin in isolates from pigs and 
to spectinomycin in pork, compared with 2011. None of the 
S. Typhimurium isolates from Danish pigs and pork were 
resistant to cephalosporins (ceftiofur, cefotaxime), quinolones 
(ciprofloxacin, nalidixic acid) or colistin (Table 6.2). 
It is also important to note that the occurrence of S. Typhi-
murium isolates fully sensitive to all included antimicrobial 
agents have been decreasing since 2008, this is the case for 
isolates both from pigs and Danish pork.  
Among the generic S. Typhimurium isolates from pigs, 48% 
of the isolates were fully sensitive isolates, a level comparable 
to previous years, whereas the proportion have been slightly 
decreasing in the monophasic isolates, and only one (4%) of 
the monophasic isolates from pigs were fully sensitive in 2012.
 
The increased occurrence of monophasic S. 4,[5],12:i:- are 
not an isolated Danish phenomenon, but these variants are 
considered new pandemic strains of Salmonella in Europe 
[Hopkins et al. 2010, Eurosurveillance 3;1]. 
In the EFSA Summary Report on antimicrobial resistance 
2011 [EFSA, 2013], four to seven Member states, including 
Denmark, report resistance in generic S. Typhimurium and 
the monophasic variants S. 4,[5],12:i:- from pigs and pork. 
The levels of ASSuT resistance are comparable between the 
Member States.
In 2004, monophasic variants constituted 3% of the S. Typhi-
murium from pigs and pork in the EU but 20% in 2011 [EFSA, 
2013]. Likewise, in 2010 monophasic variants accounted for 
1.7% of all human cases in EU, increasing to 4.7% in 2011 
[EFSA, 2013].
Figure 6.1. Resistance (%) in Salmonella Typhimurium in(a) pigs, pork and human cases(b), Denmark
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human cases: n = 98–269 and travel related human cases: n = 55–117). Data for imported pork in 2011 and 2012 are not presented due to 
insufficient number of isolates
a) Include isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:-
b) An isolate is categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of disease and was 
not reported as being part of an outbreak
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6.1.2  Salmonella in humans
In 2012, Salmonella continued to be the second most 
frequent cause of bacterial intestinal infections in Denmark. 
A total of 1,198 human laboratory-confirmed cases of 
salmonellosis were reported (21.4 cases per 100,000 
inhabitants) [Annual report on Zoonoses in Denmark 
2012]. This year, S. Enteritidis isolates from humans have 
not been susceptibility tested. A total of 242 confirmed 
S. Enteritidis cases were reported (4.3 cases per 100,000 
inhabitants), of which more than 75% were associated with 
travel outside Denmark.
As in previous years, SSI collected information on travel 
history through phone interviews. Patients were asked about 
the date of disease onset and whether they had travelled 
abroad within a seven-day period prior to the onset of the 
disease. Furthermore, patients who had been abroad were 
asked about their destinations. Cases were categorised as 
“domestically acquired” if the patients had not travelled 
within the last week prior to the onset of the disease. Patients 
were categorised as of ‘unknown origin’ if no telephone 
interview was conducted and travel information had not 
been reported to the general practitioners. In 2012, travel 
information was obtained for 69% of the Salmonella cases.
Outbreaks of human salmonellosis are reported in the 
Annual Report on Zoonoses in Denmark in 2012 [www.food.
dtu.dk]. All human cases associated with a detected outbreak 
were considered ‘outbreak-related’ and all other domestic 
cases were considered ‘sporadic domestic’ in this report.
Salmonella Typhimurium in humans
S. Typhimurium was the most common serotype among the 
human cases (415 cases), and isolates with valid results from 
susceptibility testing of all antimicrobial agents included in 
the test panel were included (n = 411).
Among the reported human S. Typhimurium isolates 
included in DANMAP, 14% of the cases were categorised as 
travel-associated and whereas 55% most likely had acquired 
their infection in Denmark as sporadic incidences or as part 
of detected outbreaks (Table 6.2). Among the cases where 
the origin of infection was unknown (31%), the occurrence 
of resistance was for most antimicrobial agents comparable 
with the levels found among domestic cases.   
Figure 6.2. Occurrence (%) of multi-resistance(a b) and monophasic variants (c) in Salmonella Typhimurium in pigs, pork and human 
cases(d), Denmark
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Note: The number of isolates varies between years (pigs: n = 144–563, Danish pork: n = 26–103, domestic sporadic human cases: n = 98–269)
a) An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and  multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3). Data on resistance to colistin and trimethoprim are not available for 2007, thus 
the proportions of multi-resistant or fully sensitive are not calculated
b) ‘ASSuT’ isolates are resistant to ampicillin, streptomycin, sulfonamide and tetracycline, but can include resistant to other antimicrobial agents 
also chloramphenicol
c) Recording of the monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:- in the database was not fully implemented 
in 2007 and 2008, thus data are not presented
d) An isolate is categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of disease and was 
not reported as being part of an outbreak
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Among the S. Typhimurium isolates from domestic as well 
as travel-associated cases, we observed very high levels of 
resistance to ampicillin, streptomycin, sulfonamide, and 
tetracycline. High levels of ASSuT resistance occurred 
among isolates from sporadic domestic cases (42%, n = 177) 
as well as and travel-associated cases (63%, n = 59). 
Among the domestic sporadic cases, resistance to 
fluoroquinolones (ciprofloxacin) and amphenicols 
(florfenicol) increased compared with 2011, whereas 
resistance to spectinomycin decreased. Occurrences of the 
resistance to the other antimicrobial agents were similar to 
levels reported in 2011 for the domestic sporadic cases and 
similar for all antimicrobial agents for the travel-associated 
cases (Figure 6.1). The increase in flouroquinolone 
(ciprofloxacin) resistance among the sporadic domestic cases 
is probably linked to an undetected outbreak, as there was a 
cluster of cases with similar resistance and MLVA profiles. 
In general, the levels of resistance for the domestic cases 
were similar to those of Danish pork, except for the low 
occurrence of flouroquinolone resistance, a resistance not 
observed among the isolates from Danish pork.
Since 2008, the proportion of multi-resistant isolates 
from sporadic domestic cases has increased from 36% in 
2008 to 62% in 2012, again probably as a consequence of 
an increasing occurrence of multi-resistant monophasic 
variants of S. Typhimurium (Figure 6.2). The monophasic 
variants represented 36% of all domestic sporadic isolates 
and 48% of all multi-resistant isolates. Also in line with this, 
the proportion of fully sensitive S. Typhimurium isolates of 
domestic sporadic origin decreased from 59% in 2008 to 
25% in 2012, and as for the pigs, only 2% of the monophasic 
isolates was fully sensitive. 
There were several domestic foodborne outbreaks with S. 
Typhimurium detected, and most of the cases (n = 48) were 
of the multi-resistant monophasic variants (92%). 
Among the S. Typhimurium from travel-associated cases, 
resistance to cefotaxime, chloramphenicol, ciprofloxacin, 
florfenicol, nalidixic acid, spectinomycin and tetracycline, 
as well as multi-resistance was more frequent than among 
isolates of domestic sporadic origin. This is reflecting 
that a relatively larger proportion of the cases were of the 
monophasic variants among the travel-associated cases 
(51%) compared with the domestic sporadic cases (36%). 
Resistance to cephalosporins (ceftiofur) was low and only 
found in isolates from three travel-associated cases, two 
sporadic domestic cases and three cases of unknown origin. 
As also observed in 2011, a marked difference in 
fluoroquinolon (ciprofloxacin) resistance was found between 
domestically acquired infections (2%) and travel-associated 
infections (24%). The higher level of ciprofloxacin resistance 
in the travel-associated S. Typhimurium infections may reflect 
a higher prescription of fluoroquinolones in production 
animals in the countries of destination. In Denmark, 
fluoroquinolones are rarely used in animal husbandry 
(except for pet animals) since the implementation of legal 
restrictions in 2002-2003 [DANMAP 2010].
Although the MIC of the observed fluoroquinolone resistant 
isolates was below the clinical breakpoint, it should be noted 
that ciprofloxacin or other fluoroquinolones are often used for 
empiric treatment of adults with severe bacterial gastroenteritis. 
Karl Pedersen, Vibe Dalhoff Andersen, 
Helle Korsgaard, Lars Stehr Larsen and Mia Torpdahl
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Surveillance of Salmonella and Campylobacter in Denmark
Background: In Denmark, all flocks of laying hens, broilers and turkeys, including breeder flocks, are monitored 
for Salmonella according to the EU requirements and the Danish legislation. A Salmonella surveillance and control 
programme is also running in the Danish pig production, and S. Dublin in cattle is monitored on a voluntary basis. Since 
January 2010, a mandatory surveillance of Campylobacter in broiler flocks at the farm has also been in place. Salmonella 
and Campylobacter in fresh meat are surveyed at the slaughterhouses and at the retail level and finally, an intensified 
control of Salmonella and Campylobacter in fresh meat, based on a case-by-case risk assessment, has been in place for 
Danish and imported meat ready for retail, since 2007. Human salmonellosis and campylobacteriosis are notifiable 
illnesses in Denmark, and all cases are reported to SSI and recorded in a national database. More information regarding 
trends and sources of zoonotic infections in humans and animals is available in the Annual Reports on Zoonoses at 
www.food.dtu.dk.
Salmonella: In broiler and layer flocks, the Salmonella prevalence has been low for more than a decade and only 0.8% and 
0.6% of flocks were positive in 2012. A level well below the EU targets [Regulation (EC) No 1168/2006 and 646/2007]. 
From 2008, all Danish broiler flocks that test positive at the farm are heat treated at slaughter, and none of the slaughter 
batches tested at slaughter were Salmonella positive in 2012.
The prevalence of Salmonella in cattle is low, and in 2012 only 0.3% of the cattle carcasses tested at slaughter were 
positive. Furthermore, 94% of the non-milk producing herds and 92% of the milk-producing herds were, according 
to  the monitoring programme, classified as “probably S. Dublin free”. Among pig herds sampled prior to slaughter, 
24% were found Salmonella positive, while 1.2% of the pig carcasses tested at slaughter were positive (Figure 1). As in 
previous years, the most common serotype in pigs and pork in 2012 was S. Derby (60% and 38%, respectively) followed 
by S. Typhimurium (32% and 35%, respectively) when including the monophasic variants with antigenic formulas S. 
4,[5],12:i- (Figure 1).     
In 2012, the number of cases of human salmonellosis (21.4 cases per 100,000 inhabitants) increased slightly after several 
years of decrease. The increase in cases is mainly due to an increase in monophasic variants of S. Typhimurium. Cases 
due to S. Enteritidis continue to decrease. In total, 11 Salmonella outbreaks were reported, and 7 of these were caused 
by S. Typhimurium, primarily the monophasic variants. Two of the outbreaks were caused by Danish beef and one 
by Danish pork. As in previous years, the Salmonella source account estimated that almost half of the human cases of 
salmonellosis were acquired during international travel. More than 75% of the S. Enteritidis cases were acquired abroad 
whereas the majority of the S. Typhimurium cases were acquired in Denmark. For the sporadic cases not related to 
travel, Danish pork was estimated to be the most important source, which is similar to previous years. Danish beef was 
the second most common source in 2012. This is unusual and a result of an increased number of sporadic cases as well 
as the two outbreaks related to Danish beef. As in 2011, no human cases were attributed to Danish broiler meat in 2012 
(Figure 2).
Figure 1. Occurrence (%) of Salmonella serovars in pigs at farm(a) and in Danish pork, Denmark
a) Faecal samples from healthy pigs collected at the slaughterhouses and cultured for Salmonella as part of the 
DANMAP programme
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Figure 3. Occurrence of Campylobacter in broilers(a) and fresh 
chilled and frozen broiler meat(b), Denmark
a) Boot swabs collected in the stable 7-10 days before slaughter 
(detection limit: <10 cfu/g)
b) Non-heat treated chilled and frozen broiler meat at retail 
(detection limit:  <10 cfu/g). The prevalence was calculated as a mean 
of quarterly prevalences
DANMAP 2012
Figure 2. Estimated sources(a) of 1,198 cases of human salmonellosis, Denmark
Source: Danish Zoonosis Centre, National Food Institute
a) Sporadic and outbreak-related cases with unknown source include all sources not in the model
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Campylobacter: The proportion of Campylobacter positive 
broiler flocks has decreased significantly since 2010, and 
12% of all broiler flocks tested Campylobacter positive 
in 2012. At retail, Campylobacter was detected in chilled 
(10%) and frozen (6%) fresh broiler meat (Figure 3). 
The most common Campylobacter species in broilers are 
C. jejuni (94% in 2012). Campylobacter is also found in 
cattle and pigs, where C. jejuni is dominant in cattle and C. 
coli is dominant in pigs.   
Campylobacter is the most frequently reported foodborne 
pathogen in Denmark, however, the number of human 
campylobacteriosis cases in 2012 (66.5 cases per 100,000 
inhabitants) was 8% lower than in 2011. Since 2007, 
approximately one-third of the cases have been associated 
with travel outside Denmark. Three Campylobacter 
outbreaks were reported during 2012, where the suspected 
food source was broiler meat and raw milk. Consumption 
and handling of broiler meat is assumed to be the most 
important source of human campylobacteriosis (estimated 
source for more than 50% of domestic sporadic cases), 
however other sources such as contaminated water, 
vegetables and direct contact to farm animals exist.
Helle Korsgaard and Birgitte Helwigh
For further information: Birgitte Helwigh (bhel@food.dtu.dk)
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6.2 Campylobacter
Thermotolerant Campylobacter are the most commonly 
reported causes of gastrointestinal bacterial infections in 
humans in Denmark as well as in the European Union 
[ECDC, 2013]. The species most commonly associated with 
human infections is C. jejuni, but other species may also cause 
infections in humans. In Denmark, 85%-95% of the human 
campylobacteriosis cases are caused by C. jejuni. 
Campylobacter are widespread in nature and the most important 
reservoirs are the alimentary tract of wild and domesticated 
birds and mammals. Among sporadic human cases, broilers 
have been identified as a primary source of infection, though 
other sources also exist, e.g. water from untreated water 
sources, and other infected animals.
 
For Campylobacter, DANMAP 2012 includes randomly 
collected isolates from healthy pigs, broilers and cattle at 
slaughter and from fresh broiler meat sold at wholesale and 
retail outlets. Isolates from human cases originates from three 
out of five geographical regions in Denmark. Only one isolate 
per farm, meat sample or human case is included, and data are 
only presented if a sufficient number of isolates were obtained 
(>15). For details see Chapter 10, Materials and Methods.
MIC distributions for C. jejuni from broilers and cattle, 
broiler meat and humans, as well as for C. coli from pigs and 
broiler meat in 2012 are presented in the web annex (Tables 
A6.6-A6.10). Data for each of the figures are also presented in 
the web annex. 
An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel, and  multi-
resistant if resistant to three or more of the six included 
antimicrobial classes (see Table 10.3).
6.2.1  C. jejuni in broilers and Danish broiler 
meat
In 2012, we observed moderate levels of resistance (15%) to 
both fluoroquinolones (ciprofloxacin) and tetracycline among 
C. jejuni isolates from broilers (n = 41, Table 6.3). 
The consumption of antimicrobial agents in broilers is generally 
low, and tetracycline has been one of the most commonly 
used antimicrobial agents in Danish broilers over the last five 
years (Figure 4.6). The consumption of tetracycline increased 
considerably from 2008 to 2010, but decreased from 2011 
to 2012. Nonetheless, for C. jejuni isolates from broilers, the 
resistance and consumption patterns for tetracycline appear 
to follow each other (Figure 4.6 and Figure 6.3). We did not 
observe a similar agreement between the consumption and 
resistance patterns for fluoroquinolones (ciprofloxacin) in C. 
jejuni broiler isolates. Even though fluoroquinolones have not 
been used in the broiler production since 2009, the resistance 
level has remained at a moderate-to-high level (12%-23%) 
during the last five years. However, the increasing trend 
observed since 2007 does not appear to continue (Figure 6.3).
In C. jejuni isolates from Danish broiler meat (n = 65), we 
observed high levels of resistance to ciprofloxacin (29%) and 
moderate (14%, Table 6.3) levels of resistance to tetracycline 
in 2012. The resistance to ciprofloxacin and tetracycline has 
fluctuated over the last five years, however the ciprofloxacin 
resistance level observed in 2012 is the highest since 2007. 
Macrolide (erythromycin) resistance has remained at a very 
low level for a decade. The levels of antimicrobial resistance 
were comparable between C jejuni isolated from Danish 
broilers and Danish broiler meat (Figure 6.3).
 
Antimicroial agent
Cattle Broilers Broiler meat Humans
Danish Danish Danish Import Domestic Travelabroad
% % % % % %
Tetracycline 1 15 14 58 20 52
Chloramphenicol 0 0 0 0 0 0
Erythromycin 1 0 0 4 1 2
Gentamicin 0 0 0 0 3 4
Streptomycin 0 0 0 0 5 9
Ciprofloxacin 16 15 29 46 35 80
Nalidixic acid 16 15 29 46 36 80
Fully sensitive 84 78 64 31 61 17
Multiresistant 1 0 0 4 4 7
Number of isolates 89 41 66 26 80 46
DANMAP 2012
Table 6.3. Resistance (%) in Campylobacter jejuni from animals, meat of Danish and imported origin and human cases(a), Denmark
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the six antimicrobial classes (see Table 10.3)
a) An isolate is categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of disease
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Figure 6.3. Resistance (%) in Campylobacter jejuni from broilers, broiler meat and human cases(a), Denmark 
Note: The number of isolates varies between years (broilers: n = 41–94, Danish broiler meat: n = 26–113, imported broiler meat: n = 26–152, 
domestic sporadic human cases: n = 52–185 and travel-associated human cases: n = 31–79)
a) An isolate was categorised as ‘domestic’ if the patient did not travel outside Denmark one week prior to the onset of the disease
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6.2.3  C. jejuni in cattle
In C. jejuni isolates from cattle (n= 89), we observed moderate 
levels (16%) of resistance to flouroquinolones (ciprofloxacin) 
and low levels of resistance to tetracycline (Table 6.3).
Resistance to fluoroquinolones (ciprofloxacin) among C. jejuni 
from cattle has remained at a moderate-to-high level (16%-20%) 
since 2008 (Figure 6.4). As described in previous DANMAP 
reports, we observed an increase in the level of fluoroquinolone 
resistance in 2005 despite low consumption of fluoroquinolones 
in cattle. In 2012, only one of the fluoroquinolone-resistant 
isolates was also resistant to tetracycline, indicating that co-
selection by tetracycline (one of the major drugs for treatment 
of calves) was not the explanation for the observed levels of 
fluoroquinolone resistance. It has been discussed [DANMAP 
2007] that clonal spread, particularly between farms, could be 
an explanation for the observed resistance to fluoroquinolones. 
6.2.2  C. jejuni from imported meat
In C. jejuni isolates from imported broiler meat (n = 26), 
the levels of resistance to tetracycline (58%) and quinolones 
(nalidixic acid and ciprofloxacin, 46%, Table 6.3) remained 
high, and from 2007 to 2012 there has been an overall decrease 
in the proportion of fully sensitive C. jejuni isolates among 
isolates from imported broiler meat. Also, over the past five 
years, the level of resistance to tetracycline and ciprofloxacin 
has generally been higher in isolates from imported broiler 
meat compared with Danish broiler meat. This corresponds 
with the data reported by EFSA, where Denmark has reported 
the lowest proportions of resistance among C. jejuni isolates 
from broiler meat [EFSA, 2013].
Initially, fluoroquinolone-resistant C. jejuni isolates came 
from cattle farms in Southern Jutland, but in 2012 isolates 
were obtained from farms distributed throughout Jutland and 
Funen.
From 2003 to 2010, we observed a general increase in the 
resistance to tetracycline. However, this trend was discontinued 
in 2011, and in 2012 the level of tetracycline resistance was very 
low (1%, Figure 6.4).
6.2.4  C. coli in pigs
In C. coli isolates from pigs (n = 103), we observed very high 
levels (57%) of resistance to the aminoglycoside streptomycin. 
The level of streptomycin resistance in C. coli isolates from pigs 
has remained at the same high level since 2009 and may reflect 
that isolates originated from producers with high occurrence of 
diseases typically treated with streptomycin (limb, joint, CNS 
and skin). While the increase in streptomycin consumption 
represents only a very small fraction of the total consumption, 
it is still noteworthy that the consumption of penicillin-
streptomycin combinations for finisher has increased 
continuously from 2009-2012 (web annex, Table A4.2).
In 2012, we observed moderate (12%) levels of resistance to 
fluoroquinolones (ciprofloxacin) in C. coli isolates from pigs. 
Since 2007 there has been an increasing trend in the level of 
tetracycline resistance in C. coli isolates from pigs, and in 2012 
the resistance level was moderate (15%, Figure 6.5 and web 
annex, Table A4.2). The increasing trend in the tetracycline 
resistance has generally complied well with the development in 
consumption of tetracycline over the past years. However, the 
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Figure 6.4. Resistance (%) in Campylobacter jejuni from cattle, 
Denmark
Note: The number of isolates varies between years (n = 41–98)
DANMAP 2012
Among the domestically acquired infections, 61% were 
fully sensitive to the antimicrobial agents tested, while the 
percentage of fully sensitive isolates was much lower (17%) 
among isolates from travel associated cases (Table 6.3). Among 
the cases with resistant C jejuni, more than 90% were resistant 
to flouroquinolones (ciprofloxacin), while multi-resistance 
was found in 3% of the isolates from infections acquired in 
Denmark and in 7% of the infections associated with travel.
The occurrence of resistance to ciprofloxacin and tetracycline 
continued to be significantly higher in travel-associated C. 
jejuni isolates (80% and 52%, respectively) compared with 
isolates from domestically acquired infections (35% and 
20%, respectively, Table 6.3 and Figure 6.3). For the other 
antimicrobial agents tested, resistance levels were comparable. 
Ciprofloxacin or other fluoroquinolones are often used for 
empiric treatment of adults with severe bacterial gastroenteritis, 
and the level of resistance to these antimicrobial agents is 
therefore of major importance. In Denmark, fluoroquinolones 
are rarely used in animal husbandry (except for pet animals) 
since the implementation of legal restrictions in 2002-2003 
[DANMAP 2010]. Travelling to, or eating meat from countries 
where fluoroquinolone restrictions are not implemented can 
be associated with a higher risk of acquiring infection with 
ciprofloxacin-resistant C. jejuni.
Birgitte Borck Høg, Lars Stehr Larsen, 
Mia Torpdahl and Anne Mette Seyfarth
Figure 6.5. Resistance (%) in Campylobacter coli from pigs, 
Denmark 
Note: The number of isolates varies between years (n = 98–113)
DANMAP 2012
dramatic decrease (27%) in the use of tetracycline in the pig 
production in 2011 is not reflected in the tetracycline resistance 
levels of C. coli isolates from pigs. 
Until 2007, a continuous decrease in macrolide (erythromycin) 
resistance in C. coli was observed following the withdrawal of 
the macrolide growth promoter tylosin from the Danish pig 
production in 1998–1999. However, since then the resistance 
to erythromycin has fluctuated, but remains at a low level (7%, 
Figure 6.5). 
6.2.5  C. jejuni in humans 
In 2012, Campylobacter continued to be the most frequent 
cause of bacterial intestinal infections in Denmark. A total of 
3,728 human laboratory confirmed cases of campylobacteriosis 
were reported (66.5 per 100,000 inhabitants) [Annual report 
on Zoonoses in Denmark 2012]. 
A subset (n = 126) of the C. jejuni isolates submitted to SSI were 
selected for susceptibility testing continuously over the year. The 
isolates were randomly selected from all of the Campylobacter 
isolated from stool samples in the three geographical regions 
included in the surveillance. Among the tested isolates, 37% 
were from travel-associated cases and 63% were considered to 
be domestically acquired. As in previous years, SSI collected 
information on travel history through phone interviews. Travel 
history was collected only for patients where isolates had been 
submitted to susceptibility testing. Patients were asked about 
the date of disease onset and whether they had travelled 
abroad within a seven-day period prior to the onset of disease. 
Furthermore, patients who had been abroad were asked about 
their destinations. Cases were categorised as “domestically 
acquired” if the patients had not travelled within the week prior 
to the onset of disease.
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Occurrence of Clostridium difficile in Danish pig farms, cattle at slaughter and meat 
Background: Clostridium difficile is causing intestinal infection in humans and have caused outbreaks in hospitals in 
Denmark and other countries [DANMAP 2009]. In, 2010, C. difficile was isolated from pig farms (15% (15/99)), cattle 
at slaughter (15% (29/192)) and broiler flocks at slaughter (3% (6/197)). Isolates from broiler flocks contained the toxin 
genes tcdA and tcdB. Isolates from cattle and pigs were more virulent as some contained toxin genes, tcdA and tcdB, and 
the cdtA and cdtB genes encoding the binary toxin. Moreover, among isolates with all four toxin genes deletions of either 
39 bp or 54 bp in the tcdC gene were observed. These deletions are used as evolutionary markers and indicate highly 
virulent types. In both cattle and pigs these suspected highly virulent isolates belonged to PCR ribotypes previously 
involved in human infections (see DANMAP 2010, Textbox 3).
Even though C. difficile can be isolated from animals and meat its role as a zoonotic agent is not fully understood 
[Rupnik. 2007. Clin. Microbiol. Infect. 13:457-9]. The aim of this study was to investigate the occurrence of C. difficile in 
pig farms, cattle at slaughter and in meat samples collected from retail and outlets to determine if humans are exposed 
through meat to virulent C. difficile isolates originating from production animals.
Materials and Methods: During February through October 2011, 71 stool samples from primarily slaughter pig pens 
at 71 farms and 186 faecal samples from cattle at slaughter were tested for C. difficile in the same way as in 2010. One 
gram of faecal sample were added to 9 ml CDMN broth supplemented with 0.1% natrium taurocholate and incubated 
anaerobically  at 37°C for 7 days. Two ml were transferred to 2 ml 99% ethanol and left at room temperature for one 
hour. After centrifugation, 10 µl of pellet was transferred to a CDMN agar plate. The plate was incubated for 44 to 48 
hours anaerobically at 37°C. Presumptive C. difficile were re-streaked at CDMN agar plates. C. difficile toxin genes (tcdA, 
tcdB and the binary toxin genes cdtA and cdtB) were identified by PCR as previously described [Persson et al. 2008. Clin. 
Microbiol. Infect. 14: 1057-64]. Isolates positive for all four toxin genes were furthermore typed using Tandem Repeat 
Sequence Typing (TRST) (http://pubtrst.org/) and tested for deletions in tcdC. C. difficile isolates with no toxin genes 
were verified by 16s sequencing.
During February through December 2012 meat samples were randomly collected from retail and outlets in all regions 
of Denmark; a total of 972 meat samples were collected: Broiler meat (205 Danish and 179 imported), beef (121 Danish 
and 100 imported) and pork (188 Danish, 179 imported). The same procedure as for faecal samples was followed for 
isolation of C. difficile except that 15 gram of meat was added to 50 ml CDMN broth supplemented with 0.1% natrium 
taurocholate. 
Results and discussion: Two (2.8%) of the pig farm samples were positive for C. difficile. One isolate had all four toxin 
genes (not TRST typed) and one had tcdA and tcdB. The occurrence of C. difficile was significantly lower than in 2010, 
where 15% of the samples from pig farms were positive. C. difficile are intrinsic resistant to several classes of antimicrobial 
agents including cephalosporins, therefore the reduction in cephalosporin consumption in the pig production close to 
zero since July 2010 and to some extent the total reduction of antimicrobials in pigs, may be the reason for the reduction 
of C. difficile in pig farms as suggested for cephalosporinase producing E. coli in the same period [Agersø and Aarestrup. 
2013. J. Antimicrob. Chemother. 68: 569-72]. The occurrence in cattle was at the same level as in 2010 (15% (27/186)) 
and no major changes in the cephalosporin consumption or in the total consumption has been observed in cattle in this 
period. All isolates were tested for toxin genes and 23 had the toxin genes tcdA and tcdB, one had in addition cdtA, two 
had in addition both genes (cdtA and cdtB) encoding the binary toxin, and in one isolate no toxin genes were detected. 
One of the isolates containing all toxins was tr070 with a 39 bp deletion in tcdC and one was tr016 with a 54 bp deletion. 
Isolates with these deletions are previously observed in cattle [DANMAP 2010]. The TRST types found in isolates from 
cattle are types found in humans in Denmark and tr070 are commonly involved in human infections [DANMAP 2010].
From the meat samples, the highest occurrence was observed in broiler meat, where C. difficile was found in 7% of the 
tested samples from both Danish (14/205) and imported (13/179) broiler meat. In Danish pork an occurrence of 2% 
(4/188) was observed and no C. difficile was found in imported pork (n = 179), or in Danish (n = 121) and imported beef 
(n = 100). Thirteen isolates from Danish broiler meat, eight isolates from imported broiler meat and two isolates from 
Danish pork contained tcdA and tcdB toxin genes. Five from imported broiler meat, one from Danish broiler meat and 
two from pork did not contain any toxin genes.
Most of the isolates from animals and from meat samples contained tcdA and tcdB, but whether these are of  zoonotic 
importance is unknown. In 2009 approx. 1/3 of the human cases were caused by C. difficile with these toxins [DANMAP 
2009].  
Conclusion: In conclusion, the decrease of C. difficile in pig farms may be explained by a reduction close to zero of 
cephalosporin consumption in the same period. The occurrence of C. difficile was generally low in meat and none of the 
most virulent types containing the binary toxin were observed in the meat although present in cattle and pigs. The highest 
occurrence in meat was observed in the broiler meat, but whether this was due to differences in the slaughter processes 
for broilers compared to pigs and cattle or differences in occurrence in the animals requires further investigation. 
Although none of the most virulent types were detected in the meat samples, the types observed with tcdA and tcdB  may 
contribute to human infections so the zoonotic importance of these types should be further investigated.
Yvonne Agersø, Mia Torpdahl and Katharina E. P. Olsen 
For further information: Yvonne Agersø ( yvoa@food.dtu.dk)
Textbox 7 
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7. Resistance in indicator bacteria
Indicator bacteria (Enterococcus faecium, Enterococcus faecalis 
and Escherichia coli) have been included in the DANMAP 
programme since 1995. Enterococci are included to monitor 
resistance in Gram-positive bacteria and E. coli as representative 
of Gram-negative bacteria. These bacteria were selected as 
indicators for occurence of antimicrobial resistance for several 
reasons: they are ubiquitous and present as major commensals 
in both the animal and human reservoirs, they can acquire 
antimicrobial resistance as response to selective pressures and 
finally they have the potential for transferring resistance to 
pathogenic bacteria and between reservoirs. 
7.1  Enterococci
For Enterococci, DANMAP 2012 includes randomly collected 
isolates from healthy pigs and broilers at slaughter and from 
domestic fresh broiler meat, pork and beef sold at wholesale 
and retail outlets. In addition, enterococci from imported 
broiler meat, beef and pork were included. We included only 
one isolate per farm or meat sample, and data are presented in 
the report where a sufficient number of isolates were obtained 
(>15). For details on methodology, see Chapter 10, Materials 
and Methods. 
An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel, and  multi-
resistant if resistant to three or more of the ten included 
antimicrobial classes (see Table 10.3).
 
The MIC distributions and occurrence of resistance among E. 
faecium and E. faecalis are presented in the web annex (Tables 
A7.1 - A7.4).
7.1.1  E. faecium from Danish broilers and 
broiler meat  
In the E. faecium isolates from broilers (n = 107), we found very 
high levels (71%) of salinomycin resistance in 2012 (Table 7.1), 
a deviation from the decreasing trend 2007-2011 (Figure 7.1). 
Salinomycin is a coccidiostat commonly used in the broiler 
production, but information on consumption is not currently 
available and we could, therefore, not relate the occurrence of 
resistance to the usage. The levels of resistance were similar 
to levels reported in 2011(Figure 7.1); however since 2007, 
resistance to the aminoglycoside streptomycin has been 
decreasing. Resistance to the growth promoter virginiamycin 
(quinupristin/dalfopristin resistance) persisted at a low level 
(1%), even though the usage has been banned for more than 
a decade. The majority of resistant isolates (72%) were only 
resistant to salinomycin, and only four isolates were multi-
resistant.
We also observed a very high occurrence of salinomycin 
resistance (55%) in E. faecium isolates from broiler meat (n 
= 128, Table 7.1). The antimicrobial resistance to macrolides 
(erythromycin) decreased from 19% in 2011 to 8% in 2012 
(Figure 7.1). Most of the resistant isolates from broiler meat 
were only resistant to salinomycin (76%), and only one isolate 
was multi-resistant. 
None of the isolates from broilers or domestic broiler meat 
were resistant to fluoroquinolone (ciprofloxacin). In general, 
the levels of antimicrobial resistance were comparable between 
E. faecium isolated from Danish broilers and broiler meat. 
However, in isolates from Danish broiler meat the level of 
salinomycin resistance was lower than in isolates from Danish 
broilers. 
Figure 7.1. Resistance (%) in Enterococcus faecium from broilers and broiler meat, Denmark 
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Note: The number of isolates varies between years (broilers: n = 43–119, Danish broiler meat: n = 82–145, imported broiler meat: n = 64–115). 
Data from broiler meat are not available from 2007
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Table 7.1. Resistance (%) among Enterococcus faecium from animals and meat of Danish and imported origin, Denmark
Antimicrobial agent Broilers Broiler meat Beef meat Pigs Pork meat Pork meat
Danish  
 %
Danish
%
Imported
%
Danish
%
Danish
%
Danish
%
Imported
%
Tetracycline 7 7 40 7 62 3 14
Tigecycline 0 0 0 0 0 0 0
Chloramphenicol 0 0 0 0 0 0 0
Penicillin 2 3 16 0 20 6 0
Ampicillin 1 3 15 0 12 6 0
Erythromycin 14 8 61 13 24 3 0
Gentamicin 0 0 1 0 2 0 0
Kanamycin 0 2 13 7 21 16 0
Streptomycin 4 0 28 7 42 6 0
Ciprofloxacin 0 0 1 0 0 0 0
Vancomycin 0 0 0 0 0 0 0
Quinupristin/dalfopristin 1 0 16 0 12 0 0
Salinomycin 71 55 29 0 0 0 0
Linezolid 0 0 0 0 0 0 0
Teicoplanin 0 0 0 0 0 0 0
Fully sensitive 23 35 20 87 37 84 86
Multi-resistant 4 1 34 7 37 6 0
Number of isolates 107 128 82 15 112 32 22
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3)
DANMAP 2012Table 7.2. Resistance (%) among Enterococcus faecalis from animals and meat of Danish and imported origin, Denmark
Antimicrobial agent Broilers Broiler meat Beef Pigs Pork meat
Danish
%
Danish
%
Imported
%
Danish
%
Imported
%
Danish
%
Danish
%
Imported
%
Tetracycline 43 47 69 13 33 87 11 46
Tigecycline 0 0 0 0 0 0 0 0
Chloramphenicol 1 3 3 3 2 21 3 1
Penicillin 0 0 0 0 0 0 0 0
Ampicillin 0 0 0 0 0 0 0 0
Erythromycin 20 21 54 3 7 56 5 6
Gentamicin 0 0 1 0 0 9 1 3
Kanamycin 2 3 29 3 5 26 3 5
Streptomycin 3 11 34 8 9 34 5 5
Ciprofloxacin 0 0 2 0 0 0 0 0
Vancomycin 0 0 0 0 0 0 0 0
Salinomycin 0 1 1 0 0 0 0 0
Linezolid 0 0 0 0 0 0 0 0
Teicoplanin 0 0 0 0 0 0 0 0
Fully sensitive 52 49 22 87 67 12 88 54
Multi-resistant 4 8 35 3 7 37 4 6
Number of isolates 100 75 93 38 43 119 104 108
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3)
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Figure 7.2. Resistance (%) in Enterococcus faecium from pigs, 
Denmark 
DANMAP 2012
Note: The number of isolates varies between years (Pigs: n = 112–
153). Data from pork are not presented due to insufficient number 
of  isolates
7.1.2  E. faecium from Danish pigs and pork  
Among the E. faecium isolates from pigs (n = 112), we found 
high occurrences of resistance to tetracycline (62%) and 
streptomycin (42%). Tetracycline has been the most frequently 
used antibiotic in Danish pig production for a decade. Beta-
lactam (ampicillin and penicillin) resistance in E. faecium 
isolates from pigs stayed at the level found in 2011, whereas 
macrolide (erythromycin) resistance has declined since 2007 
and now stands at 24% (Figure 7.2), a trend that does not 
correlate to changes in usage of macrolides (Figure 4.5). All 
isolates resistant to streptomycin and/or erythromycin were 
also resistant to tetracycline, and overall 37% of the isolates 
were multi-resistant (Table 7.1).   
Even though virginiamycin (quinupristin/dalfopristin) has 
not been used as growth promoter for more than a decade, 
resistance remained among E. faecium isolated from pigs, and 
even increased, compared with 2011. None of the isolates were 
resistant to glycopetides (vancomycin) in 2012 (Table 7.1).
Among the five resistant E. faecium isolates (16%) from Danish 
pork, all were resistant to kanamycin (aminoglycosid) and two 
isolates were multi-resistant (Table 7.1). Occurrences of the 
resistance were similar to levels reported in 2011.
Fluoroquinolone (ciprofloxacin) resistance was not observed 
in E, faecium isolates from Danish pigs or pork. Resistance to 
tetracycline, erythromycin and streptomycin, as well as multi-
resistance was more frequent in E. faecium from Danish pigs 
compared with isolates from Danish pork.
7.1.3  E. faecium from imported meat
Compared with Danish broiler meat, resistance to tetracycline, 
penicillin, ampicillin, erythromycin, kanamycin, streptomycin, 
quinupristin/dalfopristin as well as multi-resistance was more 
frequent in E. faecium from imported broiler meat (n = 82), 
while resistance to salinomycin was higher in Danish broiler 
meat compared with imported (Table 7.1). Overall, 34% of 
the isolates were multi-resistant, and among the resistant 
isolates, 18% of the isolates were resistant to erythromycin and 
tetracycline. Only 20% of the E. faecium isolates from imported 
broiler meat were fully sensitive to the antimicrobial agents 
tested (Table 7.1). 
In imported pork, 86% of the E. faecium isolates (n = 22) were 
fully sensitive to the tested antimicrobial agents (Table 7.1), and 
only resistance to tetracycline (14%) was detected. Occurrences 
of resistance were similar between Danish and imported pork.
7.1.4  E. faecalis from Danish broilers and 
broiler meat
In E. faecalis isolates from broilers (n = 100), antimicrobial 
resistance to tetracycline increased from 17% in 2011 to 43% 
in 2012, contradictory to the reduced usage of tetracycline for 
broilers (Figures 7.3 and 4.7). Only four isolates were multi-
resistant (Table 7.2).
As in previous years, the level of salinomycin resistance was 
significantly lower in E. faecalis than in E. faecium isolates 
from broilers, while antimicrobial resistance to tetracycline 
and erythromycin was higher in E. faecium than in E. faecalis.
The levels of resistance in E. faecalis isolates from broiler meat 
were similar to E. faecalis isolates from broilers (Figure 7.3).
7.1.5  E. faecalis from Danish pigs and pork  
We found very high occurrences of resistance to tetracycline 
(87%) and erythromycin (56%) in E. faecalis isolates from 
pigs (n = 119), and only 12% of the isolates was fully sensitive 
to all the antimicrobial agents tested. The levels of resistance 
were comparable with 2011, except for resistance to the 
aminoglycoside gentamicin, which declined from 21% in 2011 
to 9% in 2012 . This decrease did not correlate with the general 
trend in usage of aminoglycosides (Figure 4.5). 
Since 2010 the occurrence of macrolide (erythromycin) 
resistance among E. faecalis isolated from pigs has increased 
from 44% to 56%, in contrast to a decline among the E. faecium 
isolates (Figures 7.2 and 7.4). We can offer no explanation for 
this with the information available. 
All the chloramphenicol resistant isolates from pigs (n = 25) 
were resistant to both tetracycline and erythromycin, while 
all kanamycin resistant isolates (n = 31) were also resistant to 
erythromycin, 97% to tetracycline and 94% to streptomycin. 
All gentamicin resistant isolates (n = 11) were resistant to 
kanamycin, tetracycline and erythromycin. Overall, 37% of the 
isolates were multi-resistant (Table 7.2). 
Most of the E. faecalis isolates from Danish pork (n = 104) 
were fully sensitive to all of the antimicrobial agents tested 
(Table 7.2), and the proportion of fully sensitive isolates have 
increased since 2007. Among the 12 resistant isolates, 92% 
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were resistant to tetracycline, and only 4 isolates were multi-
resistant. Occurrences of the resistance were similar to levels 
reported in 2011. 
Fluoroquinolone (ciprofloxacin) resistance was not observed 
in E. faecalis isolates from Danish pigs or pork. The levels of 
resistance were much lower in the E. faecalis isolates from 
Danish pork compared with isolates from Danish pigs (Figure 
7.4).
7.1.6  E. faecalis from imported meat
Compared with Danish broiler meat, E. faecalis from imported 
broiler meat (n = 93) had higher levels of resistance to 
tetracycline, erythromycin, kanamycin and streptomycin 
and were more often multi-resistant (Figure 7.3). Among the 
resistant isolates, only one isolate was not resistant to either 
tetracycline or erythromycin, and 58% of the resistant isolates 
were resistant to at least both antimicrobial agents. 
Overall, 35% of the E. faecalis from imported broiler meat were 
multi-resistant (Table 7.2).
Compared with Danish pork, E. faecalis isolates from imported 
pork (n = 108) were more frequently resistant to tetracycline 
(Table 7.2), whereas resistance levels to the other antimicrobial 
agents were comparable. Approximately half of the E. faecalis 
isolates from imported meat were fully sensitive to all of the 
antimicrobial agents tested, and all resistant isolates were at 
least resistant to tetracycline. Only 6% were multi-resistant 
(Table 7.2). 
 
The levels of resistance in E. faecalis isolates in Danish (n = 
38) and imported beef (n = 43) were comparable. The highest 
occurrence of resistance was found for tetracycline, where 13% 
and 33%, respectively, were resistant. The majority of isolates 
were fully sensitive to the antimicrobial agents tested, and only 
a few isolates were multi-resistant (Table 7.2).
Figure 7.3. Resistance (%) in Enterococcus faecalis from broiler and broiler meat, Denmark
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Note: The number of isolates varies between years (broilers: n = 49–112, Danish broiler meat: n = 34–75, imported broiler meat: n = 
69–143). Data from meat is not available from 2007, and broiler data from 2009 are not presented due to insufficient number of  isolates
DANMAP 2012Figure 7.4. Resistance (%) in Enterococcus faecalis from pigs and pork, Denmark
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Note: The number of isolates varies between years (Pigs: n = 117–157, Danish pork: n = 72–133 and imported pork: n = 45–125). Data 
from meat are not available from 2007
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7.1.9  One Health perspective
Occurence of antimicrobial resistance in enterococci isolated 
from production animals and food are used as indicators 
for prevalence and transmission of antimicrobial resistance 
through the food chain to the consumer. Changes in 
occurrences of antimicrobial resistance in enterococci from 
production animals are thought to be directly related to the 
use of antimicrobial agents.
The level of resistant enterococci is generally higher in pigs 
than in broilers, indicating that pig production is a potential 
greater reservoir for resistance genes. 
The higher level of resistance to salinomycin in E. faecium from 
broilers compared to pigs is expected since these coccidiostats 
are only used in the poultry production. Salinomycin is not used 
for treating humans, so salinomycin resistance in itself does 
not pose a public health problem. However, co-resistance with 
other antimicrobial agents can be of importance, and in 2012, 
27% of the salinomycin-resistant isolates were also resistant to 
other antimicrobial agents, especially erythromycin.
We do not always find close associations between trends in 
usage of specific antimicrobials and resistance. One possible 
explanation for this observed discrepancy could be cross- and 
multi-resistance as indicated above. It is, however, clear that the 
occurence of antimicrobial resistance in enterococci from pigs 
is significantly higher than in enterococci from poultry, and 
that these significant differences in resistance occurence reflect 
differences in usage of specific antimicrobial agents. 
When looking at trends in antimicrobial resistance in E. 
faecalis from Danish broilers and broiler meat, the levels of 
antimicrobial resistance are comparable, and in E. faecium 
they follow the same tendencies for most used antimicrobials 
(salinomycin, erythromycin and tetracycline). In contrast, we 
see much lower levels of antimicrobial resistance in enterococci 
in pork compared with pigs. 
These results may indicate that enterococcal populations in the 
live animal and on pork constitute different sub populations. 
Pork cuts for sampling are collected from wholesale and retail 
outlets. Possibly, enterococci on the product may reflect the 
processing environment, rather than direct contamination of 
the meat during slaughter and dressing. In contrast, cutting of 
broilers is done in slaughter plants, which may explain why the 
enterococcal populations from live broilers and from broiler 
meat do not appear too dissimilar. 
Lars Bogø Jensen and Lars Stehr Larsen
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7.2  Indicator Escherichia coli
For indicator E. coli, DANMAP 2012 includes randomly 
collected isolates from healthy pigs, broilers and cattle at 
slaughter and from fresh broiler meat, beef and pork sold 
at wholesale and retail outlets. We included only one isolate 
per farm or meat sample, and present only data where a 
sufficient number of isolates were obtained (>15). For details 
on methodology see Chapter 10, Materials and Methods.
The MIC distributions and occurrence of resistance among E. 
coli are presented in the web annex (Tables A7.5 and A7.6). 
Data for each of the figures are also presented in the web annex.
An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel, and  multi-
resistant if resistant to three or more of the ten included 
antimicrobial classes (see Table 10.3). 
 
7.2.1  Indicator E. coli from broilers and broiler 
meat
E. coli isolates from broilers (n = 115) were most often resistant to 
sulfonamide (21%) and ampicillin (20%, Table 7.3). Resistance 
to ampicillin and streptomycin has increased compared to 
2011, whereas the occurrence of the other resistances was 
comparable to the levels observed in 2011 (Figure 7.5).
Ampicillin resistance conveys cross-resistance to amoxicillin 
which has been the most frequently used antimicrobial agent 
in the broiler production for at least a decade. 
Figure 7.5. Resistance (%) in Escherichia coli from animals and meat of Danish and imported origin, Denmark
Note: The number of isolates varies between years (broilers: n = 114–152, Danish broiler meat: n = 113–197, imported broiler meat:
n = 140–304, pigs: n = 150–160, Danish pork: n = 66–106, imported pork: n = 30–96)
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Sulfonamides have only been used in the last 2-3 years, but 
resistance to sulfonamide has been high the past decade 
(Figure 7.5). Historical use of sulfonamide and co-selection 
by ampicillin may partly explain the high occurrence of 
sulfonamide resistance. Among the sulfonamide resistant 
isolates, 42% were also resistant to ampicillin. 
Among E. coli isolates from broilers, the majority of multi-
resistant isolates (10/15) were resistant to both ampicillin and 
sulfonamide, often in combination with tetracycline and/or 
streptomycin resistance. It is noteworthy that the level of multi-
resistance has more than doubled within the past five years, 
while the level of fully sensitive strain has remained stable 
(Figure 7.6). 
In addition, we found 8% of the E. coli broiler isolates resistant 
to both nalidixic acid and ciprofloxacin (fluoroquinolone). 
During the period 2003-2007, fluoroquinolone consumption 
in poultry was significantly higher than for the other 
production animal species in Denmark, because antimicrobial 
agents approved for poultry were limited to amoxicillin and 
fluoroquinolones. However, since 2008, the fluoroquinolone 
usage in the broilers has been very low (Figure 4.6). 
Fluoroquinolone (ciprofloxacin) resistance in E. coli from 
broilers has varied between 7% and 13% over the past decade 
with a decreasing trend in recent years. The majority of 
fluoroquinolone resistant isolates (78%) were not resistant to 
the more frequent resistance types. 
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Figure 7.6. Occurence (%) of multi-resistant and fully sensitive Escherichia coli (a) from animals and meat of Danish and imported origin, 
Denmark 
Note: The number of isolates varies between years (broilers: n = 114–152, Danish broiler meat: n = 113–197, imported broiler meat:
n = 140–304, pigs: n = 150–160, Danish pork: n = 66–106, imported pork: n = 30–96)
a) An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3)
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7.2.2  Indicator E. coli from cattle and beef
In cattle, we found similar levels of resistance in E. coli isolates 
(n = 98) as in 2011. The highest levels of resistance was found for 
tetracycline (7%), sulfonamide (6%) and streptomycin (6%), 
and among the resistant isolates 86% (4/7) were resistant to all 
three (Table 7.3). The level of multi-resistance has remained 
at the same level, fluctuating between 2% and 7% during the 
past five years. 
As in cattle, the levels of resistance in E. coli isolates (n = 46) 
from Danish beef were very low, and at the same level as in 
2011.
We found 91% of the isolates were fully sensitive whereas 
only two isolates were multi-resistant (Table 7.3). None of 
the E. coli isolates from cattle or Danish beef were resistant 
to cephalosporins (ceftiofur and cefotaxime). We detected 
one flouroquinolone  (ciprofloxacin) resistant isolate in 
Danish beef, while no isolate from cattle was resistant to 
fluoroquinolones. The use of fluoroquinolones in cattle has 
been close to zero since 2003, and the use of cephalosporins 
has been gradually decreasing since 2008 (Figure 4.6).
Among E. coli isolates (n = 197) from domestic broiler meat, we 
found the highest levels of resistance for ampicillin (22%) and 
sulfonamide (17%) while the occurrence of fluoroquinolone 
(ciprofloxacin) resistance remained at a low level (4%). The 
levels of resistance in E. coli from Danish broiler meat were 
similar to what was found among isolates from Danish broilers, 
except for lower levels of resistance to spectinomycin in the 
isolates from broiler meat (Table 7.3).
Resistance to cephalosporin (ceftiofur) was observed in two 
E. coli isolates from broilers and two isolates from Danish 
broiler meat. Based on a more sensitive selective enrichment 
method high level of cephalosporinase producing E. coli was 
also observed in broiler meat (see Textbox 8).
During the period 2007–2012, we have observed increasing 
trends in resistance to ampicillin, while resistance to 
spectinomycin decreased. The increasing trend in sulfonamide 
resistance observed from 2009 through 2011 (8%–22%) did not 
appear to continue in 2012 (Figure 7.5). 
The occurrence of multi-resistance increased from 2008 to 
2011, however this trend was discontinued in 2012 (Figure 
7.6). This appears to reflect increasing total antimicrobial 
consumption (mainly ampicillin and tetracycline) in 2009 and 
a decrease in 2012 (Figure 4.6). The majority (91%) of multi-
resistant isolates were resistant to ampicillin, sulfonamide and 
trimethoprim, frequently in combination with tetracycline 
resistance.
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Table 7.3. Resistance (%) among Escherichia coli from animlals and meat of Danish and imported origin, Denmark
DANMAP 2012
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3)
Broilers Broiler meat Cattle Beef Pigs Pork meat
Antimicrobial agent Danish%
Danish
%
Imported
%
Danish
%
Danish
%
Imported
%
Danish
%
Danish
%
Imported
%
Tetracycline 8 12 51 7 7 10 36 27 57
Chloramphenicol 0 1 10 2 0 2 3 1 15
Florfenicol 0 1 1 2 0 2 1 0 2
Ampicillin 20 22 51 5 4 10 29 33 49
Ceftiofur 2 1 8 0 0 0 1 1 2
Cefotaxime 2 1 9 0 0 0 1 1 2
Sulfonamide 21 17 48 6 4 8 35 30 42
Trimethoprim 10 12 37 2 2 8 22 22 34
Apramycin 0 0 1 0 0 0 0 0 2
Gentamicin 0 0 2 0 0 2 1 0 2
Neomycin 1 2 7 0 2 6 3 3 4
Spectinomycin 4 1 24 1 0 2 14 18 21
Streptomycin 11 8 31 6 4 8 42 36 45
Ciprofloxacin 8 4 36 0 2 2 1 0 9
Nalidixic acid 8 4 36 0 2 2 1 0 6
Colistin 0 1 3 0 0 0 0 0 2
Fully sensitive 57 62 23 93 91 87 41 47 32
Multi-resistant 13 11 51 7 4 8 32 29 47
Number of isolates 115 197 166 98 46 52 152 73 53
7.2.3 Indicator E. coli from pigs and pork
Resistance to ampicillin (29%), streptomycin (42%), 
sulfonamide (35%) and tetracycline (36%) was common in 
E. coli isolates (n = 152) from pigs (Table 7.3). We found 86% 
of streptomycin resistant isolates co-resistant to tetracycline 
and/or sulfonamides in 2012. Streptomycin, sulfonamide 
and tetracycline resistance increased compared to 2011, and 
trend analysis over the period 2007-2012 shows an increasing 
occurrence of resistance to ampicillin and sulfonamide (Figure 
7.5). Resistance to spectinomycin decreased compared to 2011, 
however the level has been fluctuating between 14% and 25% 
during the past five years.
Overall, we found 32% of the isolates from pigs were multi-
resistant (Table 7.3), and most of multi-resistant isolates (78%) 
were co-resistant to ampicillin, sulfonamide and streptomycin 
(ASSu) and more than half of these (21/38) were also resistant 
to tetracycline (ASSuT). Thirteen isolates were only resistant 
to tetracycline (9% of all isolates). The level of multi-resistance 
in E. coli from Danish pigs has been similar during 2007-
2012. The level of fully sensitive isolates in 2012 was similar to 
the level in 2010, with a temporary increase (not statistically 
significant) of fully sensitive isolates in 2011, coinciding with 
the low consumption of antimicrobial agents in 2011. Prior 
to 2011, the proportion of fully sensitive E. coli decreased 
significantly (Figure 7.6). 
The occurrence of resistance in the E. coli isolates (n = 73) from 
Danish pork was comparable to 2011 (Figure 7.5), and the 
highest occurrence of resistance was found for streptomycin 
(36%), tetracycline (27%), ampicillin (33%) and sulfonamide 
(30%, Table 7.3). Multi-resistance was seen among 29% of the 
isolates, and of the multi-resistant isolates, 67% where ASSu 
and more than half of these were also ASSuT. The occurrence of 
resistance in E. coli from Danish pork and pigs was comparable 
to 2011.
The level of fluoroquinolone (ciprofloxacin) resistance 
remained low, only one isolate from pigs and none from Danish 
pork was observed. This likely reflects the low consumption 
of fluoroquinolones since 2002–2003 (web annex, Table 
A4.2), when the use in production animals was restricted by 
legislation. Also, occurrence of cephalosporin (ceftiofur and 
cefotaxime) resistance remained very low; we observed only 
one isolate from pigs and one isolates from Danish pork. The 
use of cephalosporins in pigs has been close to zero since July 
2010, when a voluntary ban was adopted by the industry. 
Surveillance based on selective methods has shown a decrease 
in the number of cephalosporin resistant (ESC) in samples 
from pigs at slaughter in 2011–2012 compared to 2009–2010 
(see Text box 8).
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7.2.4 Indicator E. coli from imported meat 
The level of multi-resistance (51%) in imported broiler meat 
was considerably higher compared to Danish broiler meat 
(11%, Table 7.3), and also compared to other Danish meat 
types included in the DANMAP programme. The observed 
level of multi-resistance in imported pork in 2012, reached a 
level similar to that of imported broiler meat (Figure 7.6). 
The highest occurrences of resistance in E. coli isolates (n = 
166) from imported broiler meat were found for ampicillin 
(51%), sulfonamide (48%) and tetracycline (51%). Resistance to 
colistin was observed in 3% of the isolates, however in contrast 
to previous years, this level was not higher than observed in the 
Danish broiler meat (1%). Compared to Danish broiler meat, 
we found a higher occurrence of resistance for 13 of the 16 
antimicrobial agents in the test panel in E. coli from imported 
broiler meat (Figure 7.5, Table 7.3). 
In imported beef, 87% of the E. coli isolates (n = 52) were 
fully sensitive and four isolates (8%) multi-resistant (Table 
7.3). The level of fully sensitive and multi-resistance has not 
changed during the past 5 years, and is not higher than what 
we find in Danish beef. One isolate was resistant to quinolones 
(ciprofloxacin and nalidixic acid) and none of the isolates were 
resistant to cephalosporins (ceftiofur or cefotaxime).
 
The highest occurrence of resistance in E. coli isolates (n = 
53) from imported pork was for tetracycline (57%), ampicillin 
(49%), sulfonamide (42%), trimethoprim (34%) and 
streptomycin (45%, Table 7.3). Overall, 47% of the isolates were 
multi-resistant, and during the past five years the occurrence 
of multi-resistance has been increasing in E. coli isolates from 
imported pork (Figure 7.6). 
Resistance to fluoroquinolones (ciprofloxacin) was found 
in three isolates and cephalosporin (ceftiofur) resistance 
was observed in one isolate only. Compared to Danish pork, 
resistance to ampicillin, chloramphenicol, ciprofloxacin and 
tetracycline was higher in imported pork (Figure 7.5). In 
contrast to prior years, we detected resistance to all of the 16 
antimicrobial agents in the test panel in E. coli from imported 
pork meat, including resistance to apramycin, gentamycin and 
colistin.
7.2.5  One Health Perspective
We use E. coli as an indicator organism for antimicrobial 
resistance because it is a commensal in both mammals and 
birds and commonly present on raw meat. Using phenotypic 
resistance as a marker, our data indicate that, E. coli in slaughter 
animals and in the derived meat constitute overlapping bacterial 
populations (Table 7.3). Therefore, meat has the potential to 
act as a vehicle transferring antimicrobial resistance from food 
animals to humans. Furthermore, some of these E. coli strains 
are virulent with a zoonotic potential for disease in humans 
[DANMAP 2010, Textboks 6].
Transfer of genes coding for antimicrobial agents that are 
critically important in human medicine such as 3rd generation 
cephalosporins is especially worrisome, as is transmission 
through food of E. coli resistant to fluoroquinolones. 
Resistance to fluoroquinolones is generally low in Danish 
animals, but higher in imported meats (Figure 7.5). Resistance 
to cephalosporins is presently increasing internationally in 
the animal reservoir, causing great concern both nationally 
and internationally (see further in Textbox 8). Cephalosporin 
resistance commonly resides on mobile genetic elements, e.g. 
plasmids, and therefore may be transferred between bacteria, 
in addition to clonal spread of E. coli strains.
Multi-resistance is of importance, because high levels of 
resistance decrease the number of good first choice antibiotics 
available for humans to treat infections and because it increases 
the risk of selection of antimicrobial resistance. As an example, 
if resistance to fluoroquinolone (chromosomal) or ESBL 
(plasmid) develops, the risk of co-selection through use of “old 
antimicrobial agents” (such as tetracycline, sulfonamide and 
penicillin) in the same bacterium increases with the occurrence 
of multi-resistance. Resistance to these antimicrobial agents 
is common in E. coli from Danish pigs and pork, as well as 
imported broiler meat, where we also observed high levels 
(>20%) of multi-resistance (Figure 7.5 and 7.6). 
With co-resistance to critically important antimicrobial agents, 
the risk of maintenance and spread of the critical important 
antimicrobial resistance through use of un-related antimicrobial 
agents increases markedly. High levels of resistance and multi-
resistance contribute to a reduced number of antimicrobial 
agents available for use in human medicine, thus limiting the 
solutions for treating human illness.
Vibeke Frøkjær Jensen, Vibe Dalhoff Andersen
and Lars Stehr Larsen
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Occurrence of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli in 
meat and slaughter pigs after selective enrichment with ceftriaxone, but no sign of 
carbapenemase producing E. coli
Background: Extended spectrum beta-lactamase (ESBL)-producing bacteria is one of the fastest emerging resistance 
problems worldwide in both humans and production animals. Lately, several studies have found the same ESBL genes, 
plasmids and clones of E. coli isolates originating from animals and involved in human infections, suggesting a zoonotic 
link. The occurrence of Enterobacteriaceae resistant to carbapenems is a growing threat in human medicine as carbapenems 
are the last line antimicrobial agents for treatment of infections caused by multidrug resistant Gram-negative bacteria in 
humans; this has been pointed out by both EFSA and ECDC. The presence of carbapenemase producing bacteria in food-
producing animals is not known, but lately carbapenemase producing E. coli has been detected in livestock pigs in Germany, 
and carbapenemase producing Salmonella enterica subsp. enterica has been detected in both livestock pigs and poultry in 
Germany [Fischer et al. 2012. J. Antimicrob Chemother. 67:1793-5]. The presence and possible spread of carbapenemase 
producing bacteria in production animals is thus considered extremely important for the assessment of potential zoonotic 
risks.
Carbapenems are not used in the Danish animal production. Both ESBL and carbapenem resistance can be driven by usage 
of cephalosporins. In July 2010, the use of cephalosporins in the Danish pig production was discontinued, but it is still used 
for systemic and intramammary treatment in cattle. Cephalosporins have not been used in the Danish broiler production 
for at least a decade. The aim of this study was to investigate the occurrence of ESBL-producing E. coli in pigs and in meat 
at retail and to investigate if carbapenemase producing E. coli could be present in meat and production animals (see section 
11. for definition of ESBL).
Materials and methods: During February through December 2012, faecal samples were taken from pigs at slaughter (n 
= 787). One animal represented one herd and no herds were sampled more than once in the same month. In the same 
period, broiler meat (Danish: n = 206, imported: n = 178), beef (Danish: n = 121, imported: n = 98) and pork (Danish: n 
= 188, imported: n = 178) samples were collected randomly in retail stores and outlets in all regions of Denmark. E. coli 
was isolated from 1 g of faecal sample or 5 g of meat after selective enrichment in McConkey media with ceftriaxone (1 µg/
ml). The genetic background for ESBL-resistance was revealed by use of whole genome sequencing (WGS). The reads were 
assembled de novo prior to prediction of genes. The web-server ResFinder (www.genomicepidemiology.org.) was used to 
identify acquired ESBL and carbapenemase genes in the WGS data. For isolates where no genes were detected, the sequences 
were investigated for up-regulation of chromosomal ampC by use of CLC bio 6. Moreover, a study of extended spectrum 
cephalosporinase (ESC)-producing E. coli collected from pigs (n = 28) and cattle (n = 19) at slaughter and from meat (n = 
138) collected in 2011 (see textbox 7, DANMAP 2011) were tested for reduced susceptibility towards carbapenems by use 
of discs containing meropenem, ertapenem and imipenem, respectively. 
Results: For pigs at slaughter, 8% (64/787) contained ESC-producing E. coli, which was significantly higher than in 2011 
but significantly lower than in 2010. The most commonly detected gene was, as in previous years, CTX-M-1. One TEM-
55 producing E. coli and one TEM-135 producing E. coli were detected in pigs at slaughter which has not previously been 
detected. CTX-M-14 and CTX-M-15 producing E. coli were detected in a few isolates (n = 5 and n = 1, respectively) 
from pigs as well (Figure 1). From meat samples, the highest prevalence of ceftriaxone resistant E. coli was found among 
imported broiler meat (61%, 110/178) and had increased significantly compared with 2011. The prevalence (36%, 75/206) of 
ceftriaxone resistant E. coli in Danish broiler meat was at the same level as in 2011. The occurrence of ceftriaxone resistant 
E. coli was significantly higher in imported broiler meat when compared to Danish broiler meat. The most commonly detected 
gene in Danish broiler meat was, as found in previous years, CMY-2, whereas CTX-M-1 and CMY-2 were almost equally present 
in imported broiler meat. Eight isolates of the ESBL-producing isolates from broiler meat contained two ESBL genes. In the 
other meat types, the prevalence was generally low (0-2%, Figure 2). None of the isolates from 2012 contained any known 
carbapenemase genes and none of the isolates from 2011 that were phenotypically tested showed reduced susceptibility 
towards any of the three carbapenems tested.
Discussion: Despite a usage of cephalosporins close to zero (approximately 1 kg), the results showed that even though the 
prevalence of cephalosporinase producing E. coli in slaughter pigs was significantly higher than in 2011, it is still significantly 
lower than in 2010 where the voluntary ban of cephalosporin usage in the Danish pig production was effectuated. 
The prevalence of cephalosporinase producing  E. coli in Danish and imported broiler meat was still high. The occurrence 
of cephalosporinase producing  E. coli in Danish broiler meat has not decreased significantly although the consumption of 
amoxicillin, which may select for ESBL-producing E. coli, has decreased in the broiler production. This is probably due to 
continuous introduction of ESBL-producing E. coli from imported parent animals, but other factors such as horizontal gene 
transfer, persistence of certain clones or cross contamination at slaughter may influence the occurrence of ESC-producing 
E. coli in the meat. An increasing trend of ESBL-producing E. coli from human infection has been observed the last years. 
CTX-M-15 is the most commonly gene detected in E. coli isolates from human infections, but CTX-M-1 occur in 7-8% 
of the ESBL-producing E. coli from human infections and to a lesser extent AmpC enzymes [Textbox 9, DANMAP 2011; 
Textbox 9, DANMAP 2012].
Testing for reduced susceptibility to carbapenems among isolates from food and food-producing animals has not been 
included as part of DANMAP until now. The detection of carbapenem resistance is not straightforward since carbapenemases 
belong to several different classes of beta-lactamases and no single test is likely to give high sensitivity as well as high 
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Figure 1.  Occurrence (%) of ESBL Escherichia coli and genes in pig from samples collected at farm and slaughterhouse 
level, Denmark DANMAP 2012
Note: E. coli was isolated after selective enrichment in McConkey media with ceftriaxone (1 μg/ml). The genetic background 
for ESBL resistance was revealed by use of PCR, micro array and DNA sequencing
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Figure 2. Occurrence (%) of ESBL Escherichia coli and genes in meat(a), Denmark
Note: E. coli was isolated after selective enrichment in McConkey media with ceftriaxone (1 μg/ml). The genetic background 
for ESBL resistance was revealed by use of PCR, micro array and DNA sequencing
a) Each year approximately 1,000 samples are collected evenly distributed between the six categories of meat
specificity for all types of enzymes. Moreover, several types are not always expressed phenotypically. Since none of the tested 
ESC-producing E. coli isolates showed reduced susceptibility towards any of the three tested carbapenems or contained 
known carbapenemase genes, meat or food-producing animals in Denmark are most likely not a source to carbapenemase 
producing bacteria causing human infections in Denmark, but monitoring of carbapenemase producing bacteria in animals 
and meat is still important as the situation may change over time.  
Conclusion: In conclusion, it is important to maintain the voluntary ban of cephalosporins in the pig production to limit 
occurrence of ESBL-producing E. coli. ESBL genes found in ESBL-producing E. coli from human infections are still present 
in meat and pigs, and broiler meat from both Danish and imported origin still seems to be the most important meat sources 
to ESBL-producing E. coli. Carbapenemase producing E. coli from meat or food-producing animals are considered a low if 
any risk to human health. 
Yvonne Agersø, Rolf Sommer Kaas, Henrik Hasman
For further information: Yvonne Agersø (yvoa@food.dtu.dk)
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8. Resistance in human clinical bacteria
8.1  Escherichia coli
Escherichia coli is part of the normal intestinal flora of both 
humans and animals but also cause infections. In humans, E. 
coli is the most frequent cause of bacteraemia and community- 
and hospital-acquired urinary tract infections. For E. coli, 
DANMAP 2012 includes data from 12 out of 13 Departments 
of Clinical Microbiology (DCM), representing 95% of the 
Danish population. Eleven of the 12 DCM working with 
primary health care isolates contributed data on antimicrobial 
resistance in urine isolates of E. coli from primary health care 
(Table 8.1). 
Blood isolates from hospital patients
DANMAP received data on the antimicrobial susceptibility of 
approximately 3,900 E. coli isolates from blood (Table 8.1 and 
Figure 8.1).
In 2012, resistance to 2nd generation cephalosporins 
(cefuroxime) was 9% and resistance to 3rd generation 
cephalosporins 7%. Both levels are similar to the levels reported 
in 2011.
One carbapenem (meropenem) resistant E. coli blood isolate 
was reported in 2012. The mechanism behind the carbapenem 
Substance
Blood isolates, hospitals Urine isolates, hospitals Urine isolates, primary health care
% % %
Ampicillin 45 # 41 40 #
Mecillinam 9 7 6
Sulfonamide 33 # 33 #
Gentamicin 7 5 *
Ciprofloxacin 14 12 # 10
Cefuroxime 9 6 * 4 *
3rd generation cephalosporins(a) 7 6 * 4 *
Meropenem <1 <1 <1
Max. number of isolates tested 3916 38610 36475
Table 8.1. Resistance (%) in Escherichia coli isolates from humans, Denmark DANMAP 2012
Figure 8.1. Resistance (%) in Escherichia coli blood isolates from humans, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2012
*) An asterisk indicates a significant increase from 2011 to 2012
#) A number sign indicates a significant decrease from 2011 to 2012
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime
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resistance in this isolate is not known since the isolate was 
not sent to SSI for further analysis, but another meropenem 
resistant E. coli isolate from the same patient was analysed at 
SSI. The carbapenem resistance in this isolate was due to ESBL-
production and reduced permeability in combination [Textbox 
11].
In 2012, ciprofloxacin resistance was 14%, which is similar 
to the level reported in 2011. The level of quinolone and 3rd 
generation cephalosporin resistance in Denmark was above the 
level reported to EARS-Net by the other Nordic countries and 
corresponded to the occurrence reported by other European 
countries in 2011 [EARS-Net 2011].
Aminoglycoside (gentamicin) resistance was 7%, similar to the 
level in 2011. Again, this was higher than the level reported to 
EARS-Net by the other Nordic countries in 2011 [EARS-Net 
2011]. Mecillinam resistance was 9% in 2012, which is at the 
same level as in 2011.
The occurrence of ampicillin resistance decreased from 48% in 
2011 to 45% in 2012.
Since 2003, resistance in E. coli blood isolates has increased 
steadily: resistance to 2nd generation cephalosporins from 2% 
to 9%; ciprofloxacin resistance from 3% to 14%; aminoglycoside 
(gentamicin) resistance from 1% to 7%. These increases parallel 
the increased antimicrobial consumption which has been seen 
until 2012 (Table 5.4).
Urine isolates from hospital patients
DANMAP received data on the antimicrobial susceptibility 
of approximately 38,000 E. coli isolates from hospital patients 
with a urinary tract infection (Table 8.1 and Figure 8.2).
Figure 8.2. Resistance (%) in Escherichia coli urine isolates from humans in hospitals, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2012
DANMAP 2012
The occurrence of resistance to both 2nd generation 
cephalosporin (cefuroxime) and 3rd generation cephalosporin 
increased from 5% in 2011 to 6% in 2012 [Textbox 9]. 
In 2012, carbapenem (meropenem) resistance was observed 
in six E. coli urine isolates from hospitalised patients. One of 
these isolates produced Verona integron-encoded metallo-
β-lactamase (VIM)-4, however the mechanism behind the 
carbapenem resistance in the remaining five isolates is not 
known, since the isolates were not further analysed [Textbox 
11].
The occurrence of ciprofloxacin resistance decreased from 13% 
in 2011 to 12% in 2012. This is a change to the steady increase 
seen in ciprofloxacin resistance from 2% in 2003 to 12% in 
2012 (Figure 8.2). 
Aminoglycoside (gentamicin) resistance increased from 4% in 
2011 to 5% in 2012. 
The occurrence of sulfonamide resistance decreased from 35% 
in 2011 to 33% in 2012.
Urine isolates from primary health care
DANMAP received data on the antimicrobial susceptibility 
of approximately 36,000 E. coli isolates from urinary tract 
infection in patients from primary health care (Table 8.1 and 
Figure 8.3).
The occurrence of resistance to both 2nd generation 
cephalosporin (cefuroxime) and 3rd generation cephalosporin 
increased from 3% in 2011 to 4% in 2012 [Textbox 9]. 
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Since 2003, the level of ciprofloxacin resistance has increased 
steadily from 2% in 2003 to 10% in 2012 (Figure 8.3), which 
parallels the increasing trend observed in the consumption of 
fluoroquinolones during the last decade (Table 5.2).
The occurrence of ampicillin resistance decreased from 41% in 
2011 to 40% in 2012. Sulfonamide resistance decreased from 
35% in 2011 to 33% in 2012, which follows the decreasing trend 
observed in the consumption of sulfonamides during the last 
years (Table 5.2). 
DANMAP 2012
Figure 8.3. Resistance (%) in Escherichia coli urine isolates from humans in primary health care, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2011
In 2012, carbapenem (meropenem) resistance was observed in 
nine E. coli urine isolates from primary health care. The isolates 
were not further investigated [Textbox 11]. 
Line Skjøt-Rasmussen, Stefan S. Olsen 
and Anette M. Hammerum
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Increased occurrence of 3rd generation cephalosporin resistance among Escherichia coli 
isolates from urinary tract infections  
Background: Extended Spectrum Beta-Lactamase (ESBL)-producing bacteria are not reportable in Denmark. However, 
3rd generation cephalosporin resistance can be used as a marker for ESBL-producing bacteria, since 3rd generation 
cephalosporin resistance is most often due to production of ESBL-enzymes and to a lesser extent AmpC enzymes.
Methods: Data on 3rd generation cephalosporin (ceftriaxone, cefpodoxime and cefotaxime) resistance in E. coli urine 
isolates from hospitalised patients in 2011 and 2012 were collected from 9 of 13 Departments of Clinical Microbiology 
(DCM) in Denmark; 8 DCM working with primary health care isolates contributed data on 3rd generation cephalosporin 
resistance in urine isolates of E. coli. 
Results: In 2012, 938 out of 26,633 (4%) tested patients from primary health care had a UTI with a 3rd generation 
cephalosporin resistant E. coli, as compared to 835 out of 25,344 (3%) tested patients in 2011. In 2012, 1,573 out of 26,449 
(6%) tested hospitalised patients had a urinary tract infection (UTI) with a 3rd generation cephalosporin resistant E. 
coli, as compared to 1,539 out of 29,451 (5%) tested patients in 2011. The increases observed from 2011 to 2012 in 3rd 
generation cephalosporin resistance in E. coli from UTI in both primary health care and hospitalised patients were 
statistically significant (Table 8.1).
Discussion: An increasing trend has been observed for 3rd generation cephalosporin resistant E. coli from UTI during 
the last years. In 2012, 2,511 patients had a UTI with 3rd generation cephalosporin resistant E. coli. Furthermore, 235 
patients had a bloodstream infection with a 3rd generation cephalosporin resistant E. coli in 2012, which was at the 
same level as in 2011 (Table 8.1). The genes encoding the 3rd generation cephalosporin resistance were not detected 
in the isolates from 2012, but earlier studies have shown that the ESBL-production is most often due to production of 
CTX-M-15, and to a lesser extent CTX-M-14, CTX-M-1 and other enzymes [Focus Area, DANMAP 2009; Textbox 9, 
DANMAP 2011]. The epidemiology behind the increasing trend in 3rd generation cephalosporin resistant E. coli from 
UTI is not known. Further studies are needed to investigate why 3rd generation cephalosporin resistant E. coli isolates 
from UTI episodes are detected with increasing frequency.
Anette M. Hammerum, Stefan S. Olsen and Line Skjøt-Rasmussen
For further information: Anette M. Hammerum (ama@ssi.dk)
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Figure 8.4. Resistance (%) in Klebsiella pneumoniae blood 
isolates from humans, Denmark
DANMAP 2012
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2012
8.2  Klebsiella pneumoniae
Klebsiella pneumoniae is part of the normal intestinal flora 
in humans but also cause infections such as urinary tract-, 
respiratory tract-, wound- and bloodstream infections. Many of 
these infections are hospital acquired and can be life threatening, 
especially if the strains are resistant to antimicrobial agents. K. 
pneumoniae is intrinsically resistant to aminopenicillins (e.g. 
ampicillin). Therefore, infections caused by K. pneumoniae 
are treated with broad spectrum antimicrobial agents such as 
ciprofloxacin, gentamicin, cephalosporins and carbapenems. 
For K. pneumoniae, DANMAP 2012 includes data from 12 
out of 13 DCM, representing 95% of the Danish population. 
Eleven of the 12 DCM working with primary health care 
isolates contributed data on antimicrobial resistance in urine 
isolates of K. pneumoniae from primary health care (Table 8.2). 
Blood isolates from hospital patients
DANMAP received data on the antimicrobial susceptibility of 
approximately 900 K. pneumoniae isolates from blood (Table 
8.2 and Figure 8.4).
In general, the level of antimicrobial resistance in 2012 was 
similar to 2011 (Figure 8.4). 
Resistance to 2nd generation cephalosporins (cefuroxime) was 
14% and resistance to 3rd generation cephalosporins 9%. Both 
levels were similar to the levels reported in 2011 (14% and 10%, 
respectively). In 2011, 3rd generation cephalosporin resistance 
was above the level reported to EARS-Net by the other Nordic 
countries and corresponded to the occurrence reported by 
other European countries in 2011 [EARS-Net 2011]. Third 
generation cephalosporin resistance can be due to production 
of ESBL or AmpC enzymes. The genetic background was 
not reported for the 3rd generation cephalosporin resistant 
K. pneumoniae isolates in 2012. The prevalence study from 
October 2011 showed that most of the ESBL production was 
due to production of CTX-M-15 [Textbox 9, DANMAP 2011]. 
In 2012, two carbapenem (meropenem) resistant K. 
pneumoniae blood isolates were detected. One of these isolates 
was sent to SSI for further analysis; the reduced susceptibility 
to carbapenems was due to production of ESBL and reduced 
permeability. The mechanism behind the carbapenem 
resistance in the other isolate was not known [Textbox 11].
Ciprofloxacin resistance decreased from 12% in 2011 to 9% in 
2012 (Figure 8.4). From 2011 to 2012, a decreased consumption 
of fluoroquinolones has been observed (Table 5.4). Resistance 
to aminoglycoside (gentamicin) was 6%, similar to the level in 
2011. The levels of resistance to ciprofloxacin and gentamicin 
were both above the levels reported from the other Nordic 
countries and the same as reported to EARS-Net by other 
European countries in 2011 [EARS-Net 2011]. 
Substance Blood isolates, hospitals
%
Urine isolates, hospitals
%
Urine isolates, primary health care
%
Mecillinam 9 11 11 #
Sulfonamide 24 # 26 #
Gentamicin 6 6
Ciprofloxacin 9 # 9 # 8
Cefuroxime 14 11
3rd generation cephalosporins(a) 9 8 5
Meropenem <1 <1 <1
Max. number of isolates tested 938 5982 3142
Table 8.2. Resistance (%) in Klebsiella pneumoniae isolates from humans, Denmark 
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime
#) A number sign indicates a significant decrease from 2011 to 2012
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Table 8.3. Resistance (%) in Klebsiella pneumoniae urine isolates from humans in hospitals, Denmark
a) Susceptibility to mecillinam was tested in 5971 isolates, sulfonamide susceptibility in 3115 isolates, gentamicin susceptibility in 4469 isolates, 
ciprofloxacin susceptibility in 5982 isolates, cefuroxime susceptibility in 4943 isolates, and 3rd gen. cephalosporin susceptibility in 4106 isolates
b) Tested 3rd generation cephalosporins were cefpodoxime and cefotaxime
Substance 2009%
2010
%
2011
%
2012(a)
%
Mecillinam 13.3 14.3 11.9 11.1
Sulfonamide 27.0 28.6 33.4 24.3
Gentamicin 7.3 6.4 5.7
Ciprofloxacin 17.3 13.9 11.5 9.1
Cefuroxime 12.8 10.9 10.6
3rd gen. cephalosporins(b) 12.8 12.0 9.6 8.3
Max. number of isolates tested 6394 5740 5746 5982
a) Susceptibility to mecillinam was tested in 3,142 isolates, sulfonamide susceptibility in 2,825 isolates, ciprofloxacin susceptibility in 2,968 
isolates, and 3rd geneneration cephalosporin susceptibility in 2,163 isolates
b) Tested 3rd generation cephalosporins were cefpodoxime and cefotaxime
Substance 2009%
2010
%
2011
%
2012(a)
%
Mecillinam 15.1 16.3 12.5 10.6
Sulfonamide 30.2 33.9 34.9 25.7
Ciprofloxacin 13.2 11.9 8.6 7.8
3rd gen. cephalosporins(b) 8.1 7.0 5.3 4.7
Max. number of isolates tested 3200 3200 3489 3142
Table 8.4. Resistance (%) in Klebsiella pneumoniae urine isolates from humans in primary health care, Denmark
DANMAP 2012
Urine isolates from hospital patients
DANMAP received data on the antimicrobial susceptibility 
of approximately 5,900 K. pneumoniae isolates from hospital 
patients with a urinary tract infection (Table 8.2 and Table 8.3).
Resistance to 2nd generation cephalosporins (cefuroxime) 
was 11% and resistance to 3rd generation cephalosporins 8%. 
Both levels were similar to the levels reported in 2011 (11% 
and 10%, respectively). The level of resistance to 3rd generation 
cephalosporins has decreased from 13% in 2009, when it was 
first reported to DANMAP, to 8% in 2012.
In 2012, carbapenem (meropenem) resistance was observed in 
three K. pneumoniae urine isolates from hospitalised patients. 
One of the three isolates was sent to SSI for further analysis; the 
reduced susceptibility to carbapenems was due to production 
of ESBL and reduced permeability. The mechanism behind the 
carbapenem resistance in the other two isolates was not known 
[Textbox 11]. 
Ciprofloxacin resistance decreased from 11% in 2011 to 9% in 
2012.
Sulfonamide resistance decreased from 33% in 2011 to 24% 
in 2012. Mecillinam resistance (11%) was at the same level as 
reported in 2011. 
Urine isolates from primary health care
DANMAP received data on the antimicrobial susceptibility of 
approximately 3,100 K. pneumoniae isolates from urinary tract 
infection in patients from primary health care (Table 8.2 and 
Table 8.4).
In 2012, resistance to 3rd generation cephalosporins was 5%, 
which is similar to the level reported in 2011. Resistance to 
3rd generation cephalosporins in K. pneumoniae from urinary 
tract infection in patients from primary health care was lower 
than the occurrence of resistance detected in isolates from both 
blood and urine from hospital patients.
In 2012, two carbapenem (meropenem) resistant K. pneumoniae 
urine isolates from patients in primary health care were found. 
Both isolates were sent to SSI for further analysis; the reduced 
susceptibility to carbapenems was probably due to production 
of ESBL and reduced permeability.
Resistance to ciprofloxacin was 8%, which is similar to the level 
reported in 2011. Ciprofloxacin resistance in K. pneumoniae 
from urinary tract infections in patients from primary health 
care was lower than the occurrence of resistance detected in 
isolates from urine from hospital patients.
Sulfonamide resistance decreased from 35% in 2011 to 26% in 
2012, and mecillinam resistance decreased from 12% in 2011 
to 11% in 2012. 
Line Skjøt-Rasmussen, Stefan S. Olsen 
and Anette M. Hammerum
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Reduced susceptibility in the Bacteroides fragilis group isolated from blood cultures in 
Denmark
Background: Bacteraemia with Bacteroides fragilis group species is associated with high mortality rates if appropriate 
antimicrobial therapy is not administered. Increasing resistance in the B. fragilis group has been reported worldwide, 
especially towards clindamycin and piperacillin-tazobactam. Lately, resistance towards the carbapenems and 
metronidazole have been reported in Europe [Nagy et al. 2011. Clin. Microbiol. Infect. 17: 371-9; Hartmeyer et al. 
2012. J. Med. Microbiol. 61: 1784-8]. At Odense University Hospital, 10.2% (9 of 88) of B. fragilis group blood culture 
isolates from a 3-year period (November 2007 to November 2010) had reduced susceptibility (intermediate susceptible 
or resistant) towards meropenem (MIC >2 mg/L). 
The antimicrobial susceptibility of the B. fragilis group in Denmark was until recently largely unknown. We are here 
reporting on the antimicrobial susceptibility of piperacillin-tazobactam, meropenem, metronidazole and clindamycin 
in the B. fragilis group isolated from blood cultures in Denmark [Justesen et al. 2013. Int J Antimicrob Agents, 42: 
188-90].
Methods: A national survey was performed from January to the end of May 2012, including 11 of 13 Departments of 
Clinical Microbiology in Denmark. The study included 118 consecutive blood culture isolates (Table 1) from the B. 
fragilis group. EUCAST clinical breakpoints were used for SIR categorization.
Results: None of the isolates were resistant to metronidazole. Overall, high rates of reduced susceptibility towards 
piperacillin-tazobactam and clindamycin were seen in B. thetaiotaomicron and towards meropenem in B. fragilis (Table 
1).
Conclusion: The perspectives from this study are worrying, as the blood culture isolates from our study only represent 
“the-tip-of-the-tip of the iceberg”. Considering the astronomical numbers of Bacteroides fragilis group bacteria in the 
gut, the percentage of patients that are harbouring isolates with decreased susceptibility could be much higher than the 
percentages reported from this study. This study emphasizes the need for more simple and inexpensive antimicrobial 
susceptibility testing methods for anaerobic bacteria, especially the B. fragilis group. It is no longer enough to rely on 
local surveillance data to treat patients with serious infections with the B. fragilis group. Metronidazole is still the drug 
of choice for anaerobic infections. However, although no resistant strains were detected in this study, the emergence of 
resistant strains is a concern and should be monitored closely.
Ulrik Stenz Justesen
For further information: Ulrik Stenz Justesen (Ulrik.Stenz.Justesen@rsyd.dk)
Table 1. Bacteroides fragilis group isolates from the study and percentage with reduced susceptibility (I or R) according to 
the EUCAST clinical MIC breakpoints
Note: I: intermediate susceptible. R: resistant
a) Numbers of I/R
b) There is no intermediate susceptible category for clindamycin
MIC breakpoint (mg/L)
Piperacillin-tazobactam
S≤8 and R>16
Meropenem
S≤2 and R>8
Clindamycin
S≤4 and R>4
Total (118) 8.5% (9/1)(a) 3.4% (3/1) 24.6% (-/29)(b)
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Carbapenemase producing bacteria in Denmark
Background: Carbapenems comprise one of the only classes of antimicrobial agents that can be used for treatment 
of infections with multi-resistant bacteria like Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, 
and Acinetobacter baumannii. Treatment options for infections with carbapenem resistant bacteria are often none 
or suboptimal. Resistance can be caused by the presence of various carbapenemases, of which the most frequently 
occurring are K. pneumoniae carbapenemase (KPC), Oxacillinase β-lactamase (OXA), Verona integron-encoded 
metallo-β-lactamase (VIM), and New Delhi metallo-β-lactamase (NDM).
Currently there is no systematical monitoring of carbapenemase producing bacteria in Denmark and these bacteria are 
not mandatory reportable. In recent years, Danish Departments of Clinical Microbiology (DCM) have, on a voluntary 
basis, submitted carbapenem resistant isolates for verification and genotyping at the Antimicrobial Resistance 
Reference Laboratory at Statens Serum Institut. The results of these investigations have been reported in Textbox 11 in 
DANMAP 2011 where attention was given to the emergence of carbapenemase producing Enterobacteriaceae (CPE) 
including K. pneumoniae and E. coli. The present textbox describes the carbapenemase producing P. aeruginosa and A. 
baumannii in addition to Enterobacteriaceae.
Enterobacteriaceae: During 2008–2011, 15 CPE cases were detected in Denmark [Textbox 11, DANMAP 2011]. In 
2012 four new cases were detected, among these the first NDM-4 producing E. coli in Denmark [Jakobsen et al. in 
press]. Prior to detection the patient had been to Vietnam. Furthermore, an NDM-1 producing Citrobacter freundii 
and two VIM-4 producing E. coli were detected. None of these patients had a prior history of travel and the origin of 
these carbapenemase producing isolates was unknown.
When comparing the number of CPE cases registered at the Antimicrobial Resistance Reference Laboratory with 
DANMAP 2012 resistance data collected from the Danish DCM, it was clear that not all carbapenem resistant E. coli 
and K. pneumoniae isolates detected at the hospitals had been submitted to SSI. In addition to the four isolates received 
at the Antimicrobial Resistance Reference Laboratory, nine carbapenem resistant isolates were reported (eight E. coli 
from urinary tract infections and one K. pneumoniae isolate).  
A. baumannii: During 2012, the Antimicrobial Resistance Reference Laboratory received 20 carbapenem resistant A. 
baumannii isolates from an outbreak at one of the major hospitals in the Capital Region. All isolates tested positive for 
the presence of the OXA-23 carbapenemase. In previous years the hospital has had outbreaks with OXA-23 producing 
A. baumannii isolates. It is under investigation if the outbreak seen in 2012 could be related to earlier outbreaks. 
Furthermore, three OXA-23 producing A. baumannii were received from three other hospitals, one was from a patient 
who had been in Egypt prior to the detection and the other two were from patients who had been hospitalized in 
Turkey. 
P. aeruginosa: In most studies, P. aeruginosa carbapenem resistance mechanisms have been shown primarily to include 
loss of outer membrane porin channels and increased drug-targeted efflux pump activity with consequential reduced 
permeability of antimicrobial agents, but carbapenemases such as VIMs can also be detected in P. aeruginosa. In recent 
years, an increasing trend has been observed for carbapenem resistance in P. aeruginosa from bloodstream infections 
in Denmark. A Danish study of 116 P. aeruginosa carbapenem non-susceptible (R+I) isolates from 2011 showed that 
carbapenemases (VIM-2) were present in 7% of the isolates [Hansen et al. 2012, ECCMID, P1697]. During 2012, 
four VIM producing P. aeruginosa isolates were detected at four different hospitals. One of the patients with a VIM 
producing P. aeruginosa had been in Pakistan prior to the detection of the isolate, whereas none of the other patients 
had a prior travel history. The origin of these VIM producing isolates was unknown.  
Conclusion: Currently, surveillance of carbapenemase producing bacteria in Denmark is not mandatory and not all 
isolates are sent to the Antimicrobial Resistance Reference Laboratory for investigation. The increasing occurrence 
of CPE and carbapenemase producing A. baumannii and P. aeruginosa in Denmark is worrying. The carbapenemase 
producing bacteria detected in Denmark were all multi-resistant which makes infections caused by these bacteria 
extremely difficult to treat with antimicrobial agents. 
 
Anette M. Hammerum, Lotte Jakobsen and Frank Hansen 
For further information: Anette M. Hammerum (ama@ssi.dk)
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Figure 8.5. Resistance (%) in Pseudomonas aeruginosa blood 
isolates from humans, Denmark
DANMAP 2012
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2012
8.3  Pseudomonas aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen of 
immunocompromised individuals. P. aeruginosa typically 
infects the pulmonary tract, urinary tract, burns, wounds, and 
also causes other bloodstream infections. It is the most frequent 
coloniser of medical devices (e.g. catheters). P. aeruginosa 
infection is a serious problem in patients hospitalised with 
cancer, cystic fibrosis and burns. The case fatality rate in these 
patients is high. P. aeruginosa is intrinsically resistant to the 
majority of antimicrobial agents. The antimicrobial classes 
which can be used for treatment include some fluoroquinolones 
(e.g. ciprofloxacin and levofloxacin), aminoglycosides (e.g. 
gentamicin, tobramycin and amikacin), some beta-lactams 
(piperacillin-tazobactam, ceftazidime, and carbapenems) and 
colistin.
P. aeruginosa blood isolates obtained from hospitalised 
patients
For P. aeruginosa, DANMAP 2012 includes data from 12 out of 
13 Departments of Clinical Microbiology (DCM), representing 
95% of the Danish population. DANMAP received data on the 
antimicrobial susceptibility of approximately 370 P. aeruginosa 
isolates from blood. Resistance to all the tested antimicrobial 
agents was not significantly different from the level  in 2011, but 
an increasing trend has been observed for gentamicin during 
2007–2012 and for meropenem during 2007–2011 (Figure 8.5). 
The occurrence of resistance to fluoroquinolones, carbapenem, 
ceftazidime and piperacillin/tazobactam was at the same level 
or lower than most of the other countries reporting to EARS-
Net in 2011 [EARS-NET 2011].
Meropenem resistance was observed for 4% (n = 13) of the P. 
aeruginosa isolates in 2012. A Danish study of P. aeruginosa 
carbapenem non-susceptible isolates from 2011 showed that 
carbapenemases were present in a minority of the isolates (7%) 
[Textbox 11]. As in previous years, presumable carbapenemase 
producing P. aeruginosa isolates were sent on a voluntary 
basis from the DCM to SSI for national surveillance on 
carbapenemase producing bacteria, including not only isolates 
from bloodstream infections but also from other origins. 
During 2012, 4 Verona integron-encoded metallo-β-lactamase 
(VIM)-producing P. aeruginosa isolates were identified at SSI 
[Textbox 11]. 
Anette M. Hammerum, Stefan S. Olsen 
and Line Skjøt-Rasmussen
8.4  Streptococci 
Streptococci are part of the normal commensal flora of 
the mouth, skin, intestine, and upper respiratory tract of 
humans, but streptococci also cause infections such as otitis 
media, tonsillitis, bacterial pneumonia, bacteraemia/sepsis, 
endocarditis and meningitis.
In this report, data on resistance in invasive (from blood or 
cerebrospinal fluid) streptococcal isolates were obtained from 
the Neisseria and Streptococcus Reference laboratory covering 
all DCM in Denmark. In Denmark, penicillins and macrolides 
are often used for treatment of infections caused by streptococci. 
All invasive non-duplicate Streptococcus pneumoniae and 
group A, B, C and G streptococci were susceptibility tested 
against erythromycin and penicillin. 
Streptococcus pneumoniae
Streptococcus pneumoniae is a leading cause of bacterial 
pneumonia, otitis media, bacteraemia and meningitis. In 2012, 
susceptibility testing was performed on 872 non-duplicate S. 
pneumoniae isolates from invasive infections (Figure 8.6).
Erythromycin resistance in S. pneumoniae isolates from blood 
and cerebrospinal fluid was 5.4% (n = 47) in 2012 compared 
to 4.9% in 2011 (Figure 8.6). These 47 isolates belonged to 12 
different serotypes and the most commonly found resistant 
serotypes were type 15A (n = 10), 19A (n = 9), 33F (n = 8) and 
6C (n = 5). 
The percentage of S. pneumoniae invasive isolates being non-
susceptible (resistant and intermediary resistant) to penicillin 
was 5.1% (n = 44) in 2012 compared to 4.8% in 2011 (Figure 
8.6). These 44 isolates belonged to 15 different serotypes and 
the most commonly found penicillin non-susceptible serotypes 
were type 15A (n = 10), 19A (n = 9), 23B (n = 17) and 6C 
(n = 5). Two of the 872 tested isolates (0.2%) were resistant to 
penicillin (MIC > 2 μg/ml) and both of these were serotype 14.
As can be seen from above, four serotypes were particularly 
non-susceptible to either penicillin or erythromycin. These were 
serotypes 6C, 14, 15A and 19A. Of the six received serotype 14 
isolates, four were resistant to either penicillin, erythromycin 
or both. All of the erythromycin resistant isolates of serotypes 
6C, 15A and 19A were also non-susceptible to penicillin.
The level of erythromycin and penicillin resistance in Denmark 
was similar to the level reported to EARS-Net by the other 
Nordic countries but lower than reported by other European 
countries in 2011 [EARS-Net 2011]. 
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Figure 8.6. Nonsusceptibility (%) in Streptococcus pneumoniae 
blood and spinal fluid isolates from humans, Denmark
DANMAP 2012
8.5 Enterococci
Enterococci are part of the normal intestinal flora of both 
humans and animals but also cause infections. Important clinical 
infections caused by Enterococcus species include urinary 
tract infections, bacteraemia and bacterial endocarditis. E. 
faecalis and E. faecium can cause life-threatening infections in 
humans, especially in the hospital environment. The naturally 
high level of antimicrobial resistance found in E. faecalis and 
E. faecium makes infections difficult to treat. Antimicrobial 
therapy for serious enterococcal infections requires the use 
Group A streptococci
In 2012, 160 invasive GAS (Streptococcus pyogenes) isolates 
were susceptibility tested. As in previous years, no resistance to 
penicillin in GAS isolates from invasive infections was reported 
in 2012. Erythromycin resistance was detected in one isolate 
(0.6%) as compared to two of 164 (1.2%) in 2011.
Group B, C and G streptococci
Two isolates (2.7%) were reported resistant to penicillin from 
group C invasive infections in 2012, while as in previous years 
no resistance to penicillin was reported in isolates from group 
B or G invasive infections in 2012.
In 2012, 134 invasive group B streptococci (Streptococcus 
agalactiae) isolates from invasive infections were tested. 
Erythromycin resistance was detected in 17 isolates (12.7%) 
compared to 20.2% in 2011. Seventy-three isolates of invasive 
group C streptococci were tested in 2012. Four isolates (5.5%) 
were resistant to erythromycin compared to one isolate (2.0%) 
in 2011. Seventeen (10.6%) of the tested 160 invasive group G 
streptococci were resistant to erythromycin compared to 8.0% 
in 2011.
Tine Dalby, Hans-Christian Slotved and Steen Hoffmann
of synergistic combinations of a cell-wall-active agent such as 
penicillin (ampicillin) and an aminoglycoside (gentamicin) or 
a glycopeptide (vancomycin). 
For E. faecalis and E. faecium, data from 12 of the 13 DCM were 
obtained, representing 95% of the Danish population. 
Enterococcus faecium and Enterococcus faecalis blood isolates 
obtained from hospitalised patients
DANMAP received data on the antimicrobial susceptibility of 
647 E. faecium isolates and 595 E. faecalis isolates from blood.
As in previous years, most of the E. faecium isolates from 
bloodstream infections were ampicillin resistant. In 2012, 94% 
of the E. faecium isolates were resistant to ampicillin. Treatment 
with fluoroquinolones, cephalosporins or carbapenems has 
been described as a risk factor for development of an E. faecium 
infection. An increasing consumption of these antimicrobial 
agents has been observed in hospitals in Denmark during the 
last decade. The antimicrobial selection pressure in a hospital 
environment might be a reason for the high level of ampicillin 
resistant E. faecium as a cause of bloodstream infections.
 
Two of the DCM (Aalborg and Aarhus) tested all enterococcal 
blood isolates for high-level gentamicin resistance (HLGR). 
Among the tested E. faecalis isolates from the two DCM, 27% 
were HLGR, whereas 62% of the tested E. faecium isolates 
were HLGR. The occurrence of HLGR E. faecalis and HLGR E. 
faecium was similar to or higher than the occurrence detected 
in many countries reporting to EARS-Net in 2011 [EARS-Net 
2011].
In 2012, vancomycin resistance was detected in 1.8% of the E. 
faecium isolates (n = 11) and 0.2% (n = 1) of the E. faecalis 
isolates from bloodstream infections. Six of the vancomycin 
resistant E. faecium isolates were detected at DCM Aarhus and 
three at DCM Hvidovre. These bloodstream isolates were part 
of outbreaks with vancomycin resistant (vanA) E. faecium. The 
occurrence of vancomycin resistant E. faecium and vancomycin 
resistant E. faecalis was at the same level or lower compared to 
most other European countries [EARS-Net 2011].
Since 2005, presumable vancomycin resistant enterococcal 
isolates from invasive and non-invasive infections and 
screening samples for national surveillance on vancomycin 
resistant enterococci have been sent from the DCM the 
Antimicrobial Resistance Reference Laboratory at SSI. During 
2012, 50 vanA E. faecium, two vanB E. faecium and one vanB 
E. faecalis isolates were received at SSI. 
As described above, most of the E. faecium isolates from 
bloodstream infections were resistant to ampicillin; these 
infections can therefore not be treated with ampicillin but will 
often be treated with vancomycin or linezolid instead. This 
might in part, together with the increased number of MRSA 
infections, explain the increased consumption of glycopeptides 
(vancomycin) and linezolid in hospitals which has been 
observed during the last years. 
Anette M. Hammerum, Stefan S. Olsen, Lotte 
Jakobsen and Line Skjøt-Rasmussen
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Neisseria gonorrhoeae 2012
Background: Neisseria gonorrhoeae is the causative agent of the sexually transmitted infection gonorrhoea, which is 
usually located in the urethra in males and cervix in females and sometimes the pharynx or rectum. Infection in the 
two latter sites is usually asymptomatic.  Complicated cases include prostatitis, orchitis, epididymitis, and salpingitis. 
Conjunctivitis may occur in newborns after transmission from the mother during labour and rarely in adults, e.g. 
following auto-inoculation. 
Methods: Through decades, all Departments of Clinical Microbiology in Denmark have submitted their isolates of 
N. gonorrhoeae (gonococci) to the Neisseria and Streptococcus Reference (NSR) laboratory at Statens Serum Institut 
for national surveillance of antimicrobial resistance. Most of the received isolates are from urethra or cervix, while 
specimens from rectum and pharynx are only rarely obtained by clinicians. Occasionally, the NSR laboratory receives 
strains isolated from other anatomical sites, such as conjunctivae, joint fluid, blood, Bartholin’s abscess, etc.
At the NSR laboratory, antimicrobial susceptibility testing towards ceftriaxone and ciprofloxacin is performed by a 
gradient diffusion technique, and the isolates are tested for penicillinase production. 
Since 2009, as part of NSR’s participation in ECDC’s surveillance of sexually transmitted infections, approximately 60 
consecutive gonococcus isolates are investigated twice yearly for susceptibility to an expanded panel of antimicrobial 
agents. In addition to ceftriaxone and ciprofloxacin, this panel includes azithromycin, cefixime, spectinomycin, and 
gentamicin. 
Results and discussion: The number of strains received in the years 2008, 2009, 2010, 2011, and 2012 were 357, 445, 
370, 339, and 505, respectively.
The ciprofloxacin resistance rate increased steadily from 30% in 2003 reaching a peak of 75% in 2009, followed by a 
decrease to 57% in 2012 (Figure 1). The percentage of strains producing penicillinase fluctuated between 12% and 24%. 
Occurrence of ceftriaxone resistant gonococci (MIC ≥ 0.25 mg/L), as well as ceftriaxone treatment failure in patients 
with gonorrhoea, has been reported from several countries during recent years. No cases from Denmark have been 
reported. However, since 2008 the ceftriaxone MIC distribution has shown a drift towards higher values than previously 
(Figure 2).
Results obtained by examining strains against an expanded panel of antimicrobial agents are shown in Table 1. In 2012, 
azithromycin resistance in gonococci was 12%, a decrease since 2009 where 46% of the isolates were resistant. Resistance 
to cefixime increased from 15% in 2009 to 21% in 2011, and it was 11% in 2012. Cefixime is an oral cephalosporin which 
has never been used in Denmark. Throughout 2009–2012 all strains were susceptible to spectinomycin; however, this 
parenteral drug is not marketed in Denmark and is not readily accessible in most countries. Gentamicin has been used 
successfully for the treatment of gonorrhoea in several countries in Africa but no randomized clinical trials have been 
published. Gentamicin breakpoints for gonococci have not been determined. In 2011 and 2012, 99% of the examined 
strains from Denmark had gentamicin MIC ≤ 4 mg/L. 
Conclusions:
The centralised national surveillance of antimicrobial resistance in gonococci should be continued.
Steen Hoffmann
For further information: Steen Hoffmann (hof@ssi.dk)
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Table 1. Resistance rates (%) against azithromycin, cefixime and spectinomycin in gonococci, Denmark 2009–2012
2009 2010 2011 2012
(n  = 119) (n = 111) (n = 126) (n = 114)
Azithromycin 46 23 12 12
Cefixime 15 18 21 11
Spectinomycin 0 0 0 0
DANMAP 2012
Figure 1. Ciprofloxacin resistance and penicillinase production in gonococci, Denmark 2003–2012
Figure 2. Distribution of ceftriaxone MIC values (mg/L) in gonococci, Denmark 2003–2012
DANMAP 2012
DANMAP 2012
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8.6  Staphylococcus aureus 
Staphylococcus aureus is part of the normal flora from skin and 
mucosa in approximately 50% of humans. Some people only 
carry S. aureus intermittently whereas others carry S. aureus 
for longer time. However, in addition S. aureus also cause 
infections ranging from superficial skin infections i.e. impetigo 
and boils, to invasive infections such as post-operative wound 
infections, infections related to intravenous catheters and 
prosthetic devices, bacteraemia, osteomyelitis, endocarditis 
and arthritis. 
In Denmark, a voluntary surveillance programme of all S. 
aureus bacteraemia cases was established in 1957. Methicillin-
resistant S. aureus (MRSA) has been both laboratory and 
clinical notifiable since November 2006. MRSA belonging 
to clonal complex 398 (CC398) has in recent years attracted 
special attention as this type has been closely connected to 
livestock animals, especially pigs, and increasingly affects 
people in direct contact with pigs. The cases have in the 
past years constituted an increasing part of the community-
acquired (CA) cases and due to these increasing numbers, 
cases belonging to CC398 will be treated as a separate group as 
both epidemiology and exposition are different. 
Surveillance of bacteraemia
In 2012, 1,528 S. aureus bacteraemia cases corresponding to 27.4 
per 100,000 inhabitants were reported from the Departments 
of Clinical Microbiology (DCM) in Denmark. Nineteen (1.2%) 
of the cases were caused by MRSA. This is at the same level as in 
previous years and very low compared to most other countries 
participating in EARS-Net [EARS-Net 2011]. Antimicrobial 
resistance in S. aureus bacteraemia isolates from 2007–2012 
is presented in Table 8.5. The highest frequency of resistance 
other than to penicillins was observed for fusidic acid (14%), 
erythromycin (6%), clindamycin (6%) and norfloxacin (4%). 
Susceptibility to all tested antimicrobials was at the same level 
as in 2011. Resistance to at least 1, 2 or 3 other antimicrobials 
in addition to penicillin was demonstrated in 25%, 9% and 2% 
of the cases, respectively. 
Figure 8.7. Number of MRSA cases, with a three years moving average, Denmark
DANMAP 2012
Table 8.5. Resistance (%) in isolates from Staphylococcus aureus bacteraemia cases, Denmark
Antimicrobial agent 2007%
2008
%
2009
%
2010
%
2011
%
2012
%
Methicillin 0.6 1.3 1.6 1.4 1.4 1.2
Penicillin 78 77 77 75 77 74
Erythromycin 4 5 7 5 7 6
Clindamycin 3 4 6 4 6 6
Tetracycline 2 3 2 3 2 2
Fusidic acid 9 9 9 13 13 14
Rifampicin <1 <1 <1 <1 <1 <1
Norfloxacin 1 2 2 3 4 4
Kanamycin <1 1 1 1 <1 1
Linezolid 0 0 0 0 0 0
Mupirocin <1 <1 <1 <1 <1 <1
Trimethoprim-sulfamethoxazole nt nt nt nt <1 1
Number of isolates 1345 1344 1480 1418 1525 1528
DANMAP 2012
Note: nt = not tested
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DANMAP 2012Table 8.6. Epidemiological classification of new MRSA cases, Denmark
Note: Numbers shown in bold are totals
Epidemiologic classification Exposure
2011 2012
No. of cases  
(% of total)
No. (%) of 
cases with 
infections 
No. of cases  
(% of total)
No. (%) of 
cases with 
infections 
Imported (IMP) 252 (20) 145 (58) 324 (21) 218 (67)
Hospital-acquired (HA) 58 (4) 29 (50) 67 (4) 42 (63)
Health-care associated, 
community onset (HACO) with health care risk 182 (14) 178 (11)
      with known exposure 44 10 (23) 60 24 (40)
      without known exposure 138 117 (85) 118 88 (75)
Health care worker 40 (3) 7 (18) 29 (2) 5 (17)
Community-acquired (CA) without health care risk 596 (46) 726 (47)
      with known exposure 311 64 (21) 378 69 (18)
      without known exposure 285 246 (86) 348 300 (86)
CC398 164 (13) 63 (38) 232 (15) 92 (40)
Figure 8.8. Number of MRSA infections according to epidemiological classification, Denmark
DANMAP 2012
Surveillance of methicillin-resistant S. aureus 
In 2012, 1,556 new MRSA cases were detected (27.9 per 100,000 
inhabitants). This is the highest number of cases observed in 
over 25 years (Figure 8.7).  A case was a person found positive 
for the first time with a specific MRSA strain regardless whether 
the patient was infected or colonised. 
In 2012, the number of MRSA increased by 20% compared to 
2011. The number of new cases has more than doubled (135%) 
since 2007. In 2012, fourteen persons were found with their 
second case of MRSA (i.e. MRSA of a new subtype). At the 
time of diagnosis, 838 (54%) of the new cases were found due 
to infection which is similar to 2011 (53%). The proportion 
of bloodstream infections with MRSA was 1.2% in 2012 (see 
surveillance of S. aureus bacteraemia). 
The total number of cases and the number of cases presenting 
with infection according to epidemiological classification are 
shown in Table 8.6. Most of the cases (79%) were acquired 
in Denmark. The epidemiological classification of MRSA 
infections 2007–2012 is shown in Figure 8.8. The figure has 
been updated from 2007 to include CC398 infections. Twenty-
seven of the healthcare-associated with a community onset 
(HACO) infections (22%) could be associated with a known 
exposition, 16 from hospitals, 5 from nursing homes and the 
remaining 6 from other social institutions. The remaining 99 
cases of infection classified as HACO were registered with a 
possible association to health-care institutions (within the 
last 12 months) but without known exposition; of these, 68 
cases were with an association to hospitals and 24 cases with 
an association to nursing homes and private home care. The 
remaining 7 cases could not be associated to any particular 
institution. The number of infections classified as CA was 369 
in 2012 (Figure 8.8). The proportion of CA infections with 
known exposure was at the same level (19%) as in 2011 (both 
years adjusted for CC398 cases). CC398 cases constituted 15% 
of new MRSA cases in 2012 (Table 8.6). See also Textbox 13.
DANMAP 2012  
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Molecular typing of the MRSA strains
In total, spa typing revealed 232 different strain types. The 
number of isolates belonging to the 10 dominating spa types 
isolated in 2012 is shown in Table 8.7. They constituted 
57% of the total number of MRSA isolates. Seven spa types 
constituted 49% of the 838 clinical infections with MRSA (out 
of 180 different spa types associated with clinical infection). 
Most prevalent spa types causing clinical infections at time of 
presentation were t002 (n = 88), t034 (n = 75), t019 (n = 74), 
t008 (n = 73), t032 (n = 45), t044 (n = 34) and t304 (n = 23). 
The PVL gene was demonstrated in 42% of the infections and 
in 20% of the asymptomatic carriers.
Resistance among MRSA isolates
The resistance pattern varied considerably between spa types 
(Table 8.8). In 2012, 100% of CC398 spa type t034 isolates 
were resistant to tetracycline and 100% of CC22 spa type t032 
were resistant to norfloxacin. In contrast, the majority of t019, 
a primarily community-acquired spa type, and t304 were 
susceptible to all tested antimicrobial agents except for beta-
lactams. 
Table 8.7. The ten most prevalent spa types demonstrated in 
MRSA cases, Denmark 
a) CC = Clonal complex
spa type CC group(a) No. of cases No. causing infections (%)
t034 CC398 185 75 (41)
t002 CC5 141 88 (62)
t008 CC8 130 73 (56)
t019 CC30 97 74 (76)
t032 CC22 89 45 (51)
t304 CC8 74 23 (31)
t044 CC80 45 34 (76)
t127 CC1 42 19 (45)
t024 CC8 42 20 (48)
t223 CC22 37 13 (35)
DANMAP 2012
DANMAP 2012
Table 8.8. Resistance (%) in the six most prevalent spa types demonstrated in MRSA cases compared with all MRSA 
cases, Denmark
spa type
Clonal complex
t034
CC398
%
t002
CC5
%
t008
CC8
%
t019
CC30
%
t032
CC22
%
t304
CC8
%
All cases
%
Erythromycin 33 31 58 1 79 0 38
Clindamycin 81 26 10 0 78 0 37
Tetracycline 100 6 10 2 0 0 31
Fusidic acid 2 23 9 2 3 1 15
Rifampicin 0 1 0 0 1 0 1
Norfloxacin 32 21 41 2 100 0 26
Kanamycin 1 13 49 1 0 0 23
Linezolid 0 0 0 0 0 0 0
Mupirocin 0 0 2 1 0 0 <1
Trimethoprim-sulfamethoxazole 1 0 1 0 0 0 2
Number of isolates 185 141 130 97 89 74 1556
DANMAP 2012
Table 8.9. Resistance markers in addition to cefoxitin 
demonstrated in MRSA cases, Denmark 
a) T = tetracycline, N = norfloxacin, F = fusidic acid, K = kanamycin, 
E = erythromycin, C = clindamycin, R = rifampicin
No. of 
markers No. of cases
Frequent patterns
(no of isolates)
Frequent spa type 
(no of isolates)
0 495 – t019(89), t002(57)
1 240 T(85) t034(28)
F(50) t002(18)
N(43) t032(18)
K(43) t4272(5)
2 269 E,C(78) t002(17), t024(15)
C,T(68) t034(58)
3 370 E,C,N(101) t032(67)
E,C,T(69) t034(33), t011(14)
E,N,K(59) t008(37)
T,F,K(37) t044(27)
4 149 E,C,T,K(36) t127(17), t437(8)
E,C,T,F(30) t1028(28)
E,C,N,K(28)
E,C,T,N(24) t034(23)
5 22 E,C,T,N,K(13) t189(6)
6 6 E,C,T,N,K,S(3)
7 4 E,C,T,F,N,K,S(2) t064(2)
E,C,T,R,N,K,S(2)
8 1 E,C,T,F,R,N,K,S(1) t2872(1)
Even though differences in antimicrobial resistance were 
demonstrated between spa types, the success of antimicrobial 
treatment cannot be predicted based on spa type or 
epidemiological classification. Resistance to at least 1, 2 or 3 
other antimicrobials in addition to cefoxitin/penicillin was 
demonstrated in 68%, 53% and 35% of the cases, respectively. 
In Table 8.9 are shown the most common resistance patterns 
and any frequent associated spa types. 
Andreas Petersen, Robert L. Skov
 and Anders Rhod Larsen
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Livestock associated methicillin-resistant Staphylococcus aureus (LA-MRSA) 
Background: Since 2003, livestock associated methicillin-resistant Staphylococcus aureus (LA-MRSA) has emerged 
worldwide. LA-MRSA primarily belong to clonal complex 398 and is especially associated with pigs. In addition, a 
new type of MRSA carrying a different resistance determinant mecC has been found associated to cattle and sheep in 
Denmark and internationally [García-Álvarez et al. 2011. Lancet Infect. Dis.11: 595–603; Petersen et al. 2013. Clin. 
Microbiol. Infect. 19: E16-22]. In humans, MRSA CC398 has especially been found in persons with contact to pigs. 
mecC positive isolates have been detected in bulk milk in the United Kingdom and  in swabs from  sheep and cows in 
Denmark [García-Álvarez et al. 2011. Lancet Infect. Dis.11: 595–603; Eriksson et al. 2013. Vet. Microbiol. 163: 110-5]. 
Despite  that transmission of  mecC  MRSA from colonized cows and sheep have been confirmed by whole genome 
sequencing, human  findings do not appear to have the same close relationship to animals as CC398  [Petersen et al. 
2013, Clin. Microbiol. Infect. 19: E16-22; Harrison et al. 2013. EMBO Mol. Med.  5: 509-15].
The prevalence of MRSA CC398 in Danish pigs at slaughter increased from 13% in 2009 to 44% in 2011[DANMAP 
2011]. The prevalence was also measured in pig herds in 2010 and 2011 and was in both years 16%. The higher preva-
lence found in pigs at the slaughterhouse is likely due to contamination during transport and handling of pigs [Broens 
et al. 2011. Vet. J. 189: 302–5], but could also be due to an increase in herd prevalence at positive farms. 
Prevalence studies in cattle at slaughter of MRSA performed in 2010 and 2011 did not detect any MRSA of either 
mecA or mecC type in cattle [DANMAP 2011]. 
In 2012, the prevalence and diversity of LA-MRSA was investigated in pigs at slaughter, in cattle bulk milk samples 
and in human samples as part of the national surveillance of MRSA.
Investigation of MRSA in pigs at slaughterhouses: Nasal swabs were collected from pigs at slaughter during Febru-
ary through December 2012. Presumptive MRSA was isolated in 555 out of 709 samples, as previously described 
[DANMAP 2009–2011]. A random subset (n = 235) of the presumptive MRSA were tested by PCR for the presence of 
mecA, 232 isolates were PCR positive, whereby the prevalence of MRSA in pigs at slaughter could be estimated to 77%. 
The prevalence in 2012 was significantly higher than in 2009 (13%) and in 2011 (44%). The high and increasing 
prevalence could have several explanations: It could be caused by a combination of truly infected/colonized pigs 
from positive pig herds and contamination of pigs originating from negative farms due to e.g. MRSA contaminated 
transport vehicles; MRSA in the surroundings where pigs were kept before slaughter or MRSA in the slaughter chain 
in general; but it could also be due to an increase of infected pig herds. 
A total of 110 MRSA isolates from pigs were spa typed. The detected spa types all corresponded to CC398 (t034 
(61.8%), t011 (34.5%), t1451 (2.7%) and t898 (0.9%)). All spa types have previously been found in pigs in Denmark.
Investigation of MRSA in bulk milk: The bulk milk samples were collected from 219 different farms from September 
2012 through January 2013. MRSA and S. aureus were isolated after freezing of the milk by adding 1 ml of milk to 4 
ml of Mueller-Hinton broth supplemented with 6.5% NaCl and incubated for 23-25 hours at 37°C. 50 µL of culture 
were spread on Brilliance MRSA 2 agar plates and Brilliance Staph 24 agar from Oxoid to isolate presumptive MRSA 
and S. aureus, respectively. MRSA was verified by multiplex PCR and spa typed. 
MRSA were detected in 1.8% (4/219) of the bulk milk samples and S. aureus in 70% of the samples (153/219). This 
corresponded to a MRSA prevalence among S. aureus of 2.6% (4/153). A follow-up sampling found MRSA in bulk 
milk samples from two out of four of the farms previously tested positive for MRSA. This could be due to these farms 
being transiently contaminated with MRSA or that MRSA is present at a concentration close to the detection level. 
This is the first finding of MRSA from bulk milk in Denmark. None of the bulk milk MRSA isolates were positive for 
mecC. All MRSA carried the mecA gene and belonged to CC398 (t011, t034) and CC1(t127), which have previously 
been detected in pigs. This might indicate transmission of MRSA from pig production to dairy cattle [Agersø et al., 
2012. Vet. Microbiol. 157: 246-50]. 
Livestock associated MRSA in humans: MRSA CC398 was found in 232 human cases in 2012 (42 in 2009, 111 in 2010 
and 164 in 2011). It should be noted that there was no targeted screening for CC398 in 2012. The most frequent spa 
type related to CC398 was type t034 (n = 185). The majority of CC398 cases (183, 79%) were in persons with docu-
mented close contact to pigs or being a household member. Ninety-two CC398 cases (40%) presented with infections. 
There were still no signs of significant spread of CC398 to urban areas. Thirteen (0.9%) bacteraemia (N = 1,528) cases 
in 2012 belonged to CC398 (two MRSA and 11 methicillin sensitive) and had no known contact to pig farming. The 
corresponding numbers were five in 2007, six in 2008, 10 in 2009, 11 in 2010 and 11 in 2011. 
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MRSA isolates carrying the new mecA homologue mecC, were demonstrated in 24 cases in 2012 (9 in 2009, 21 in 
2010 and 37 in 2011). Sixteen of the cases (67%) had infections, including one bacteraemia at the time of diagnosis. 
No livestock contact was registered for any of the 24 mecC cases. 
Conclusions: The prevalence of MRSA in pigs at slaughter has increased to 77%, but whether more herds are positive 
compared to previous years is unknown. Pigs still seem to be the most important reservoir for MRSA CC398, but 
detection of LA-MRSA CC398 in bulk milk depicts a spread possibly from the pig production. In 2012, CC398 was 
the second most common CC group among human MRSA cases. The number of MRSA isolates carrying the mecC 
gene seems to have stabilized.
Yvonne Agersø, Anne Mette Seyfarth, Andreas Petersen, Robert L. Skov and Anders Rhod Larsen
For further information on the veterinary studies: Yvonne Agersø, E-mail: yvoa@food.dtu.dk
For further information on the human cases: Robert L. Skov, E-mail: rsk@ssi.dk
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9. Resistance in diagnostic submissions from animals
DANMAP 2012
The DANMAP programme monitors antimicrobial 
susceptibility in Escherichia coli O149 via diagnostic 
submissions from pigs. Due to the low number of samples, 
Staphylococcus hyicus via diagnostic submissions from pigs 
as well as E. coli F5 (K99) via diagnostic submissions from 
cattle were not included in the analyses this year.
Most isolates from diagnostic submissions originated from 
animals in antimicrobial therapy. A higher frequency of 
resistance is therefore expected in the bacteria from these 
diagnostic submissions compared with the bacteria originating 
from healthy animals sampled at slaughter.
E. coli isolates resistant to three or more of the ten different 
antimicrobial classes included in the test panel were considered 
multi-resistant (see the definition of multi-resistance and the 
included antimicrobial classes in Section 10.5).
The distribution of MICs among E. coli O149 from pigs is 
presented in the web annex (Table A9.1). Data from the figure 
are also presented in the web annex.
9.1  Escherichia coli
Pigs
The available E. coli O149 isolates (n = 36) from pigs originated 
from diagnostic submissions of faecal samples mainly from 
weaners with diarrhea (about 7-30 kg bodyweight). The 
detection of E. coli O149 in piglets with neonatal diarrhea has 
decreased significantly during the last ten years, partly due to the 
general use of vaccination. Further, the prevalence of diarrhea 
caused by E. coli O149 is decreasing in all age groups apparently 
due to a breeding programme successively eliminating the F4 
(K88) receptors in the Danish pig population (E. coli O149 
possesses the fimbrial type F4).
Trends in resistance to the selected antimicrobial agents in 
E. coli O149 isolates from pigs are presented in Figure 9.1. 
Although the resistance pattern of individual isolates is variable, 
the average level of resistance to different antimicrobial agents 
has been quite stable during the surveillance period. Most 
(78%) of the isolates were multi-resistant; however the level 
decreased compared with 2011. Only one isolate (3%) was fully 
susceptible.
As in previous years, high levels of resistance were found to 
tetracycline (78%), sulfonamide (75%) and streptomycin (72%, 
Figure 9.1). Sulfonamide and streptomycin are not used for 
weaning pig diarrhea, and the consumption in weaners has 
been stable at a low level (Figure 4.4). The resistance to these 
agents may be co-selected with tetracycline resistance since 
tetracyclines are the most common antimicrobial agents used 
for weaned pigs (Figure 4.4).
The consumption of quinolones has been at a very low level 
in the pig production since 2003 due to legislative restrictions 
of the use for food-producing animals (web annex, Table 
A4.2) and the corresponding resistance to nalidixic acid has 
decreased during this period. A decrease in the proportion of 
isolates resistant to trimethoprim (77% to 50%) was observed 
from 2011 to 2012 (data not presented). 
In 2012, one of the 36 E. coli O149 isolates was resistant to 3rd 
generation cephalosporins (cefotaxime and ceftiofur) even 
though a voluntary ban on use of cephalosporins has been 
implemented in the pig production since 2010.
Vibe Dalhoff Andersen and Lars Stehr Larsen
Figure 9.1. Resistance (%) in Escherichia coli O149 from 
diagnostic submissions from pigs, Denmark
Note: The number of isolates varies between years (pigs: n = 31-
118)
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10. Materials and methods
10.1 General information
For the DANMAP 2012 report, population sizes and geographical 
data were obtained from Statistics Denmark [www.dst.dk] and 
data on general practitioners from the Danish Medical Association 
[www.laeger.dk]. 
The epidemiological unit for pigs and cattle was defined as the 
individual farm, meaning that only one isolate per bacterial species 
per farm was included in the report. The same epidemiological 
unit was applied for broilers, except for Salmonella where the 
individual flock of broilers was defined as the epidemiological unit. 
For food, the epidemiological unit was defined as the individual 
meat sample. For humans, the epidemiological unit was defined 
as the individual patient and the first isolate per patient per year 
was included. 
Unless stated specifically, all differences and temporal trends 
noted in the text are statistically significant (p<0.05) using either 
Chi-square tests or linear logistic regression (see Section 10.6.4).
10.2 Data on antimicrobial consumption
Antimicrobial agents used for humans and animals in Denmark 
are presented in Table 3.3.
10.2.1  Data on antimicrobial consumption in 
animals
Since 2001, consumption data presented in this report have been 
obtained from the national monitoring programme VetStat, 
which is a database hosted by the Danish Veterinary and Food 
Administration. Prior to 2001, data were based on national sales 
figures from the pharmaceutical industry.
Data registration
In Denmark, all therapeutic drugs are prescription-only and VetStat 
collects data on all medicines prescribed by veterinarians for use in 
animals, except in a few instances when medicines are prescribed 
on special license (i.e. medicines not approved for marketing in 
Denmark). In addition, data on consumption of coccidiostatics 
as feed additives (non-prescription) and antimicrobial growth 
promoters (not in use since 2000) are collected by VetStat. 
Until 2007, antimicrobial agents could only be purchased at the 
pharmacy or in medicated feed from the feed mills. From April 
2007, the monopoly was suspended and private companies (two in 
2011) were permitted - on certain conditions   (identical conditions 
as for pharmacies) - to sell prescribed veterinary medical products 
for animals. In addition, price setting was liberalised, which 
allowed for discounts corresponding to lower administration costs 
related to sale of large quantities to the veterinarians.
The pharmacy or company either sells the medicines to 
veterinarians for own use in practice or for re-sale to farmers, or 
sells the medicines directly to the animal holder on presentation 
of a prescription. By law, the profit that veterinarians may make 
on the sale of medicine is very small (5%), thereby limiting the 
economic incentive to sell medicine.
In 2012, the animal owners and veterinarians purchased the 
antimicrobial agents almost equally between the pharmacies 
and the veterinary drug trading companies, while only 2% was 
purchased from the feed mills. Sales from feed mills additionally 
comprised zinc chloride for the pig production on veterinary 
prescription, and non-prescription sales of coccidiostatic agents 
for domestic fowl (Gallus gallus).
Data on all sales of veterinary prescription medicine from the 
pharmacies, private companies, feed mills and veterinarians are 
sent electronically to VetStat. Veterinarians are required by law to 
report to VetStat all use and prescriptions for production animals 
(monthly submissions). For most veterinarians, the registration of 
data is linked to the writing of invoices. However, errors in the 
veterinarians invoice system sometimes cause errors in amounts 
reported, and these data are not validated at entry to Vetstat. The 
electronic registration of the sales at the pharmacies is linked to the 
billing process and stock accounts at the pharmacy, which ensures 
a very high data quality regarding amounts and identity of drugs.
The VetStat database contains detailed information about source 
and consumption for each prescription item:
date of sale, identity of prescribing veterinarian, source ID (identity 
of the pharmacy, feed mill, or veterinarian practice reporting), 
package identity code and amount, animal species, age-group, 
disease category and code for farm-identity (CHR - Danish 
Central Husbandry Register). The package code is a unique 
identifier, relating to all information on the medicinal product, 
such as active ingredient, content as number of unit doses (e.g. 
number of tablets), package size, and code of the antimicrobial 
agent in the Veterinary Anatomical Therapeutic Chemical 
(ATCvet) classification system.
Knowledge of the target animal species enables the presentation 
of consumption data in “defined animal daily doses” - a national 
veterinary equivalent to the international defined daily doses 
(DDDs) system applied in the human field [www.whocc.no]. See 
further description of the ADD system in the DANMAP 2009 
report [www.danmap.org].
Methods
In DANMAP we want to compare consumption of 
antimicrobials between different animal populations and 
between veterinary and human sectors. In order to do this we 
need to take into account the quantity of antimicrobials used, 
their potency, their formulation, the route of administration 
and – sometimes – the age of the animals in which they are 
used. We also need to know the size of the populations to which 
the antimicrobials are administered.
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The animal daily doses (ADDs) used in previous DANMAP 
reports, are an integrated part of the VetStat database and have 
been described elsewhere [DANMAP 2009; Jensen et al., Prev 
Vet Med. vol: 64, 201-215, 2004]. In principle, the ADD should 
be identical for all products within medicinal groups, and 
defined by the active compound, route of administration and 
the formulation. However, in VetStat, the ADDs are defined by 
the dosage level that was part of the product registration, and 
over time doses for products within the same medicinal group 
sometimes have changed. The greatest variation occurs when 
the ADD for some products have been defined solely based on 
the approved dosage. For example, the approved dosage of a 
product registered in 2011 may differ from a similar product, 
registered in 2001.
In DANMAP 2012, we therefore introduce two new metrics 
to follow trends in antimicrobial consumption to ensure 
robustness of the analyses over time. The new metrics, DADD 
and DAPD, are defined below. 
DADD - Defined animal daily dose
DADD is the average maintenance dose per day for a 
drug used for its main indication in the appropriate 
animal species. The DADD is not defined at product 
level but for each antimicrobial agent, administration 
route and animal species and when appropriate, also age 
group. DADD has been specifically defined for use in 
DANMAP and does not always completely match the 
“prescribed daily dose” or the recommended dosage in 
the Summaries of Product Characteristics (SPC).
The DADDs used in DANMAP 2012 are presented in the web 
annex.
The basic principles for the DADD are similar to the principles 
previously described for the ADD. The designation of the 
DADD is based on the VetStat ADDs, but re-defined for each 
group of antimicrobial agents, i.e. for each combination of active 
compound, administration route, formulation, considering the 
following principles:
1. Minor inconsistencies, e.g. due to rounding of numbers, 
have been corrected;
2. Approved dosage for the most widely used antimicrobial 
products were given priority above dosage for products 
that are rarely used;
3. Approved dosage for older products within the group are 
maintained as the common DADD even if a new product 
is approved with a higher dosage;
4. In determining the dosage for a group with large variation 
between approved dosages of the products, the dosages 
in accordance with the dose given in ”The Veterinary 
Formulary” [British Veterinary Association, 2005, 6th 
edition] are applied;
5. Dosages may vary within active compound and 
administration route, if different dosages have been 
approved for different age group/indication or formulation. 
When principle 2 and 3 are conflicting, principle 4 is applied.
Denominator
Trends in veterinary consumption, both within and across 
species, are presented in DADD per 1,000  animals per 
day – DAPD. The number of animals in a population (in 
epidemiological terms: the population at risk) is represented 
by their live biomass.  The biomass of a species is calculated, 
taking into account average live body-weight and the average 
life-span of the species.
DAPD - DADD per 1,000 animals per day
The number of DADDs administered to a specific animal 
species during a year (in thousands) divided by the 
number of standard animals at risk per day. The number 
of standard animals at risk per day takes into account 
species differences in average body-mass and life-span. 
When relevant, the numbers of DADDs and standard 
animals at risk are estimated for specific age groups, or 
simply as number of doses (DADDs) used to treat one 
kg of animal divided with the total estimated biomass (in 
tonnes).  
DAPD is a statistical measure, providing a rough estimate 
of the proportion (in thousands) of animals treated 
daily with an average maintenance dose of a particular 
antimicrobial agent. For example, 10 DAPDs indicate 
that an estimated 1% of the population, on average, 
receives a certain treatment on a given day. The DAPD is 
also referred to as the treatment proportion.
In principle, the metric DAPD is parallel to the metric 
used in pharmaco-epidemiology for the human sector, 
Defined daily dose per 1,000 inhabitants per day (DID), 
see Section 10.2.3.
Due to a relative high number of pigs exported around 30 kg 
(30% of pigs produced in 2012, Table 3.1), an adjusted measure 
of consumption per pig was calculated. The adjustment is based 
on the assumption that pigs exported at 30 kg, on average, 
received the same amount of antimicrobial agents before 
export, as other pigs from farrowing to 30 kg.
Antimicrobial use per pig produced (adjusted) = 
[DADDs +DADDw  + (1+Q)*DADDf ] / 
(biomass-days-total+ Nw* 5800(kg*days)), 
where DADDs = amount of antimicrobial agents used in sows; 
DADDw = amount of antimicrobial agents used in weaners; 
DADDf = amount of antimicrobial agents used in finishers; 
Q is the proportion of weaning pigs exported around 30 kg. 
Nw =  number of pigs exported at 30 kg bodyweight, and 
Nw*5800 is the number of biomass days the exported pigs 
would have contributed to the live biomass if not exported.
 
10.2.2  Estimation of live biomass of animals
The estimation of live biomass and thus the number of standard 
animals at risk per day depends on the available data sources 
for each species. The estimated live biomass for the animal 
species are presented in the web annex (table A4.1).  
Broiler and layer production (Gallus gallus). The live biomass 
is estimated based on number of broilers produced (Table 3.1), 
and an average live weight at slaughter of 1.97 kg [Statistics 
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Aquaculture. The estimation is based on data from the Danish 
AgriFish Agency (NaturErhvervstyrelsen) on produced 
amounts in each subtype of production, and information on 
the typical lifespan and entrance and exit body weights, and 
were calculated in cooperation with Danish Aquaculture [NH 
Henriksen, Danish Aquaculture]. Data from 2012 were not 
available at the time of publication.
10.2.3  Data on antimicrobial consumption in 
humans  
Data on consumption of antibacterial agents in humans were 
obtained from Statens Serum Institut (SSI), National Register of 
Medicinal Products Statistics. SSI has the legal responsibility for 
monitoring the consumption of all human medicinal products. 
This is performed by monthly reporting of consumption from 
all pharmacies in Denmark, including hospital pharmacies, 
to SSI. Data from the primary health care sector have been 
collected since 1994, whereas data on consumption in hospitals 
are available from 1997. 
Certain categories of hospitals were excluded when the 
consumption was measured by occupied bed-days and 
admissions. Data from private hospitals and clinics, psychiatric 
hospitals, specialised non-acute care clinics, rehabilitation 
centers and hospices were excluded from DANMAP 
(representing approximately 3% of the antimicrobial 
consumption at hospitals and of the number of bed-days).
In Denmark, all antimicrobial agents for human use are 
prescription-only medicines and are sold by pharmacies in 
defined packages. Each package is uniquely identified by a 
code which can be related to package size, content as number 
of unit doses (e.g. number of tablets), content as number of 
Defined Daily Doses (DDDs), code of the antimicrobial agent 
in the Anatomical Therapeutic Chemical (ATC) classification 
system, and producer. In addition, the following information 
is collected for each transaction: social security number (CPR 
number) of the patient, code identifying the prescribing 
physician, date and place (pharmacy, hospital pharmacy, 
institution) of the transaction, and information regarding 
reimbursement of cost, if applicable. The data are transferred 
monthly to SSI in an electronic format. 
For the first time since 1995, the consumption of certain 
infusion substances, such as cephalosporins, carbapenems 
and trimethoprim, has been directly reported by the hospital 
pharmacies to SSI. In previous DANMAP reports, the 
consumption of these substances was corrected by direct data 
collection from all Danish hospital pharmacies; however, in 
2012 all data were delivered only by SSI.
The present report includes data on the consumption of 
antibacterial agents for systemic use, or group J01, of the 2012 
update of the ATC classification, in primary health care and in 
hospitals. As recommended by the World Health Organization 
(WHO), consumption of antibacterial agents in primary health 
care is expressed as DIDs, i.e. the number of DDDs per 1,000 
inhabitants per day (DDD/1,000 inhabitants-day). Consumption 
in primary health care is also reported as a number of packages 
per 1,000 inhabitants. Consumption of antibacterial agents in 
hospitals is expressed as DIDs, for comparison with primary 
health care, and DBDs, the number of DDDs per 100 occupied 
beds per day (DDD/100 occupied bed-day). 
Denmark, 2013] after an estimated average life span of 30 days. 
The mean live biomass per broiler is assumed to be half of the 
weight at slaughter. In addition, the biomass of the parental 
animals (rearing and breeding) for the broiler production was 
estimated for 2011 based on number of hens per year (2,9 mill) 
annual rotations, length of the empty periods, percentage of 
cocks, and average weight of the cocks and hens in rearing and 
in breeding [DANHATCH, 2013; S. Kabell, Danish Agriculture 
and Food Council, personal communication]. For the other 
years, the biomass of rearing and breeders was assumed to be 
proportionately to the broiler production as in 2011.
In the layer production chain, the biomass of the parent flocks 
is estimated separately for each production type, based on 
number of eggs produced, eggs per hen, average production 
length [Danish Poultry Producers, Statistics Denmark]. We have 
assumed an average weight of 2.3 kg per hen, based on slaughter 
weight [Statistics Denmark, 2013].
Turkey production. The live biomass is estimated based on 
number of turkeys produced (Table 3.1) and an average live 
weight at slaughter of  21 kg for male turkeys and 11 kg for hens 
after an estimated average life span of 20 weeks and 15.5 weeks, 
respectively [Danish Agro; S. Astrup, personal communication]. 
The estimated mean live biomass per turkey is assumed to be 
half of the weight at slaughter.
Pig production. The estimation was based on number of pigs 
produced, including exports at different ages [Statistics Denmark; 
Danish Agriculture and Food Council], productivity data for 
each year [Danish Agriculture and Food Council] and census 
data for breeding animals [Statistics Denmark]. The average 
weight and life span for the growing animals (piglets, weaners 
and finishers) were estimated from the productivity number. 
The estimation methods were developed in cooperation with 
Danish Agriculture and Food Council. There are no statistics 
on average weight of breeding animals available, so an estimated 
average weight had to be assumed. However, the size of the 
breeding animals has probably increased over the last decade, 
but this could not be accounted for. 
Cattle production. The live biomass of the cattle population 
is estimated from census data [Statistics Denmark, 2013] and 
the average live weight of the different age groups. The Danish 
cattle population is mainly dairy, particularly Holstein Friesian, 
but also other breeds such as Jersey and a small population of 
beef cattle. Most of the cattle slaughtered are dairy cows and bull 
calves of dairy origin. The average live weight was estimated for 
10 different age and gender categories. 
Fur animals. The live biomass of mink is estimated from 
production data [Statistics Denmark, 2012; Kopenhagen Fur, 
2013] and the average weight at pelting was 2.45 kg [Kopenhagen 
Fur, 2013]. The progeny live for approximately 7 months. The 
biomass for the breeding animals (female) was estimated based 
on census data and an assumed average live weight of 2 kg.
Pet animals. Only dogs and cats are taken into account, as the 
other population sizes are negligible in Denmark, and relatively 
rare in veterinary practice. The 2011 population is based on 
census data [Statistics Denmark, 2000] estimating 650,000 cats 
and 550,000 dogs. The number of dogs in Denmark has been 
relatively stable during the last ten years [Danish Dog register, 
2012]. The average live weight for cats and dogs were estimated 
to 4 kg and 20 kg, respectively (based on pedigree registration 
data). 
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Since antimicrobial consumption expressed as DDD/100 occupied 
bed-days does not necessarily reflect changes in hospital activity 
and production, consumption in hospitals is also presented as 
DAD (the number of DDD/100 admitted patients).
The number of occupied bed-days is calculated as the date of 
discharge minus the date of admission (minimum one day), 
and the number of admissions is calculated as one admission 
whenever a patient is admitted to one specific ward (one patient 
can be registered as admitted multiple times if transferred between 
wards during one hospital stay). Data on the number of occupied 
bed-days (or patient-days) and number of admissions in each 
hospital were obtained from the National Patient Registry at the 
National Board of Health  [www.sst.dk].
10.3. Collection of bacterial isolates
10.3.1  Animals
Samples from animals are collected from healthy production 
animals randomly selected at slaughter. From pigs, isolates of 
Escherichia coli, Enterococcus faecium, Enterococcus faecalis, 
Campylobacter coli, Campylobacter jejuni and Salmonella spp. 
were collected. From cattle, isolates of E. coli, C. coli and C. 
jejuni were collected, and from broilers isolates of E. coli, C. coli, 
C. jejuni, E. faecalis and E. faecium were collected. In addition, 
isolates of E. coli O149, E. coli F5 (K99) and Staphylococcus 
hyicus were collected from diagnostic submissions.
Campylobacter, indicator E. coli and enterococci. Samples 
from healthy pigs, cattle and broilers were collected for the 
DANMAP programme at slaughter by meat inspection staff 
or company personnel and sent for examination at DTU 
National Food Institute. For broilers, cloacal swabs were 
collected weekly from May through October and the sampling 
programme represented 86% of all broiler farms in Denmark. 
A Danish broiler farm is typically comprised of more than one 
unit each generating several flocks per year, but even though 
a farm was sampled more than once through the sampling 
period, only one isolate per farm of each bacterial species was 
included.
For pigs and cattle, the slaughter plants included in the 
DANMAP programme accounted for 98% and 94% of the 
total number of animals slaughtered in Denmark during 2012, 
respectively. The number of pigs and cattle samples from each 
slaughter plant was proportional to the annual number of 
animals slaughtered at the plant. Samples were collected once 
a month from January through November as caecum samples 
from pigs and rectum samples from cattle. Only one isolate per 
farm of each bacterial species was included. 
Accordingly, the bacterial isolates from the Danish production 
animals may be regarded as representing a stratified random 
sample of the respective populations, and the observed prevalence 
of resistant isolates provides an estimate of the true occurrence in 
the population.
An overview of the number of samples analysed, isolates 
obtained and MIC determinations performed for pigs, cattle 
and broilers is presented in Table 10.1. The isolation rates of C. 
jejuni from pigs and C. coli from cattle and broilers were low 
and therefore MIC-analyses were not performed. 
Salmonella. DTU National Food Institute is the national 
reference laboratory for Salmonella in animals and food and 
receives all isolates for typing. Only one isolate per serotype 
per farm was selected for the DANMAP report, except for 
isolates from broilers, where one isolate per flock was included. 
Isolates of S. Typhimurium include the monophasic variants 
with antigenic formulas S. 4,5,12:i:- and S. 4,12:i:-. 
The Salmonella isolates from pigs originated both from 
the random sampling of healthy animals at slaughter for 
DANMAP and from the national Salmonella surveillance 
programme where the results of a serological surveillance at 
the slaughterhouses and in all breeding herds appoint risk 
herds to be further examined by microbiological analysis of 
pen-faecal samples.  
No Salmonella data from layers, broilers and cattle are 
presented in DANMAP 2012 due to the low findings of serotype 
S. Enteritidis and S. Typhimurium. Salmonella isolates from 
diagnostic submissions were not included in the DANMAP 
2012.
Further details on the sampling procedures and the findings of 
the Danish Salmonella surveillance programs are presented in 
Textbox 6, and in the Annual Report on Zoonoses in Denmark, 
2012 [www.food.dtu.dk].
Isolates from diagnostic submissions were specifically 
collected for the DANMAP programme at the Laboratory of 
Swine Diseases, the Danish Agriculture and Food Council, 
Kjellerup (E. coli O149 from diarrheic pigs and S. hyicus from 
skin infections) and at DTU National Veterinary Institute (E. 
coli F5 (K99) from diarrheic cattle). Only one isolate per farm 
was included. Due to low annual numbers of isolates, only 
results for E. coli O149 from diarrheic pigs are included in 
DANMAP 2012. 
10.3.2  Meat
Campylobacter, indicator E. coli and enterococci. The meat 
isolates originated from meat samples collected at wholesale 
and retail outlets by the Regional Veterinary and Food Control 
Authorities (RFCA) in all regions of Denmark. The samples 
were collected during the course of routine inspection by the 
authorities or on specific request from the Danish Veterinary 
and Food Administration (DVFA) for the DANMAP program. 
The sampling includes both Danish and imported meat. Only 
one isolate per bacterial species per meat sample was selected 
for DANMAP. 
Salmonella. The Salmonella isolates from Danish pork 
originated from the national Salmonella surveillance 
programme (swab samples from pork and beef carcasses taken 
at the slaughterhouse after cooling). Salmonella isolates from 
imported poultry meat and other imported fresh meats derived 
from a case-by-case risk assessment control programme 
(DFVA), are not presented due to the low number of isolates 
(<15). Further details on sampling and findings are presented 
in Textbox 6. Only one isolate per positive swab sample or batch 
of meat was included for DANMAP. Isolates of S. Typhimurium 
include the monophasic variants, antigenic formula S. 4,5,12:i:- 
and S. 4,12:i:-.
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Table 10.1. Number of DANMAP samples, number of isolates and MIC-tests from healthy production animals at slaughter, Denmark   
Note: Data in this table should not be used for reporting of prevalences of the bacterial species
a) From 2011, the DANMAP samples from pigs were also part of the surveillance programme for Salmonella
E. coli E. faecium E. faecalis C. jejuni  C. coli  
Pigs(a) No. of samples analysed (1 per farm) 300 807 807 300 300
No. of isolates obtained 266 216 191 19 141
No. of isolates MIC-tested/reported 152 112 119 0 103
Cattle No. of samples analysed (1 per farm) 149 0 0 172 172
No. of isolates obtained 134 0 0 110 3
No. of isolates MIC-tested/reported 98 0 0 89 0
Broilers No. of samples analysed (no. of flocks) 164 177 177 202 202
No. of farms represented  125 125 125 125 125
No. of isolates MIC-tested/reported 115 107 100 41 0
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10.3.3  Humans  
S. Typhimurium, S. Enteritidis and C. jejuni. Antimicrobial 
susceptibility was performed on human faecal isolates 
submitted to Statens Serum Institut (SSI). Campylobacter 
isolates were submitted from Departments of Clinical 
Microbiology (DCM) covering three geographical regions: 
Northern Jutland, Funen and Roskilde/Køge. Information on 
travel history was obtained for the patients. Salmonella isolates 
were submitted from all DCM in Denmark. Exact figures of the 
proportion tested and the sampling strategy for the different 
species can be found in Sections 6.1 and 6.2.
Staphylococcus aureus. All blood isolates were referred 
to the Staphylococcus reference laboratory at SSI on a 
voluntary basis. In November 2006, methicillin-resistant 
S. aureus (MRSA) became a notifiable disease in Denmark 
and it became mandatory to submit all MRSA isolates to the 
reference laboratory.
Invasive Streptococcus pneumoniae, Streptococcus pyogenes 
(group A streptococci), group B, C and G streptococci. 
Invasive pneumococcal disease is a notifiable disease in 
Denmark, and therefore all blood and spinal fluid isolates 
nationwide are sent to SSI for identification or confirmation as 
well as susceptibility testing and typing. Group A, B, C and G 
streptococcal isolates are referred to SSI on a voluntary basis.
E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
invasive E. faecium and invasive E. faecalis. Data were 
provided on all isolates recorded from either blood samples (E. 
coli, K. pneumoniae, P. aeruginosa, E. faecium and E. faecalis) 
or urine samples (E. coli and K. pneumoniae) submitted for 
susceptibility testing to the DCM at the following hospitals: 
Rigshospitalet, Hvidovre, Herlev, Hillerød, Region Sealand, 
Odense, Esbjerg, Vejle, Herning/Viborg, Aarhus and Aalborg.
No samples were collected from healthy humans.
10.4 Isolation and identification of bacteria
10.4.1  Animals
Salmonella. Examination of samples at DTU National Food 
Institute was performed by non-selective pre-enrichment of 
25 g material in a 1:10 dilution with buffered peptone water 
(BPW) incubated 16-20 hours at 37°C. A Modified Semi-solid 
Rappaport-Vassiliadis (MSRV) plate was inoculated with 
0.1 ml deposited as 3 drops. After incubation o/n at 41.5°C, 
material from swarming zones was inoculated onto Brilliant 
Green Agar (BGA). Incubation o/n at 37°C was followed by 
serotyping of suspect colonies by slide agglutination according 
to the White-Kauffmann-Le Minor Scheme. Salmonella 
isolates received at DTU National Food Institute for typing 
were isolated according to the standard methods at the 
submitting laboratory, and upon reception, inoculated onto 
BGA followed by serotyping. All isolates received for typing 
are stored at -80°C.
Campylobacter. The samples from broilers was inoculated 
directly onto mCCD agar (Oxoid, Denmark) and incubated 
in microaerophilic atmosphere for 2-3 days at 41.5°C. For 
samples from cattle, selective enrichment in Preston broth at 
a ratio of 1:10 incubated in microaerophilic atmosphere for 
24 h at 41.5°C was performed followed by inoculation of 10 µl 
of the enrichment broth to mCCD agar. Campylobacter-like 
colonies were verified by microscopy and identification was 
performed by a real-time PCR assay [Mayr et al. 2010, J Food 
Prot. 73(2):241-50]. All isolates of C. jejuni and C. coli were 
stored at -80°C. 
Indicator E. coli. The material was inoculated directly onto 
Drigalski agar (SSI Diagnostica, Denmark) and incubated o/n 
at 37°C. Yellow colonies were inoculated onto BBL CHROM 
agar Orientation Medium (Becton Dickinson, Germany) and 
red colonies were collected as E. coli after o/n incubation at 
37°C. All isolates were stored at -80°C.
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Table 10.2. Interpretation criteriae for MIC-testing by EUCAST epidemiological cut-off values (blue fields) and the corresponding 
EUCAST clinical breakpoints (white fields)
* EUCAST epidemiological cut-off values (ECOFFs) and EUCAST clinical breakpoints.  Changes in ECOFF values since DANMAP 2011 are 
highlighted by orange
a) The EUCAST ECOFF (>1) was not applied for quinopristin/dalfopristin (tradename synercid) according to investigations presented in 
DANMAP 2006
b) The EUCAST ECOFF (>4) was not applied for ciprofloxacin. The aim was to look for high level ciprofloxacin-resistance as described by Werner 
et al, 2010 (Int J Antimicob Agents;35:119-125)
c) The EUCAST ECOFF (>2) for colistin was applied for S. Typhimurium and other serotypes, except for S. Enteritidis and S. Dublin where 
ECOFF >8 was applied as recommended by Agersø et al., 2011 [DANMAP 2011, Textbox 6]
Antimicrobial 
agent Salmonella E. coli E. faecium E. faecalis C. jejuni  C. coli  
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
Ampicillin >8* >8* >8* >8* >4* >8* >4* >8*
Apramycin >16 >16
Cefotaxime >0.5* >2* >0.25* >2*
Cefoxitin
Ceftiofur >2* >1*
Chloram-
phenicol >16* >8* >16* >8* >32* >32* >16* >16*
Ciprofloxacin >0.06 * >1* >0.06* >1* >16(b) >8(b) >0.5* >0.5* >0.5* >0.5*
Colistin >2*/ >8(c) >2* >2* >2*
Erythromycin >4* >4* >4* >4* >8* >8*
Florfenicol >16* >16*
Gentamicin >2* >4* >2* >4* >32*  >32* >2* >2*
Kanamycin >1,024 >1,024
Linezolid >4* >4* >4* >4*
Nalidixic acid >16* >16* >16* >16*
Neomycin >4* >8*
Penicillin >16* >16*
Quinupristin/
dalfopristin >4
(a) >4*
Salinomycin >4 >4
Spectinomycin >64 >64*
Streptomycin >16* >16* >128* >512* >4* >4*
Sulfonamide >256 >64* 
Teicoplanin >2* >2* >2* >2*
Tetracycline >8* >8* >4* >4* >1* >2* >2* >2*
Tiamulin
Tigecycline >0.25* >0.5* >0.25* >0.5*
Trimethoprim >2* >4* >2* >4*
Vancomycin >4* >4* >4* >4*
DANMAP 2012
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Indicator enterococci. One drop of material suspended in 2 
ml of sodium chloride (0.9%) was spread on Slanetz Bartley 
agar and incubated two days at 42°C. Three colonies typically 
of E. faecalis and E. faecium were sub-cultivated on blood 
agar. Colonies were identified by colour, motility, arginine 
dihydrolase testing and the ability to ferment mannitol, 
sorbitol, arabinose and raffinose. All isolates of E. faecium and 
E. faecalis were stored at -80°C.
Veterinary pathogens. Diagnostic submissions were examined 
according to the standard methods at the Laboratory of Swine 
Diseases, the Danish Agriculture and Food Council, Kjellerup 
(E. coli O149 and S. hyicus) and at DTU National Veterinary 
Institute (E. coli F5 (K99)). 
10.4.2  Meat  
Salmonella was isolated by the regional laboratories at the 
DVFA according to the open reference methods issued by the 
NMKL (NMKL No. 187, 2007 or NMKL No. 71, 1999), the 
ISO 6579:2002 or alternative methods validated against the 
reference method according to ISO 16140:2001. Sero- and 
phage-typing was performed at DTU National Food Institute.
Campylobacter was isolated according to the guidelines 
for microbiological examination of food (NMKL No. 119, 
2007). Identification was performed by microscopy or test kit 
DRO150M (Oxoid), and by oxidase activity, catalase activity and 
the ability to hydrolyse indoxyl acetate and hippurate. Isolation 
and identification was performed by the regional laboratories 
at the DVFA. All isolates of C. jejuni, C. coli and C. lari were sent 
to DTU National Food Institute for MIC-testing and storage at 
-80°C.
Indicator E. coli was isolated by the regional laboratories at the 
DVFA by adding 5 g of the sample to 45 ml of MacConkey- 
or laurylsulphate-broth, which was incubated o/n at 44°C, 
subsequently streaked onto violet red bile agar and incubated 
for 24 h at 44°C. Presumptive E. coli was identified by 
CHROMagar Orientation Medium or by indole- and lactose 
testing in laurylsulphate-broth incubated o/n at 44°C. E. coli 
isolates were sent to DTU National Food Institute for MIC-
testing and storage at -80°C. 
Indicator enterococci were isolated by the regional 
laboratories at the DVFA by adding 5 g of the sample to 45 ml 
azide dextrose broth, incubated o/n at 44°C and subsequently 
streaked onto Slanetz-Bartley agar. After incubation at 44°C 
for 48 h, colonies typically for E. faecium and E. faecalis were 
identified by a real-time PCR assay, and finally sent to DTU 
National Food Institute for MIC-testing and storage at -80°C.
10.4.3  Humans 
Salmonella isolates were serotyped by slide agglutination 
according to the Kauffman-White Scheme.
Campylobacter. Species identification was performed using a 
species-specific PCR assay [Klena et al. 2004. J Clin Microbiol. 
42: 5549–5557].
Staphylococcus aureus. Sequencing of the S. aureus specific 
spa gene was performed for species confirmation and typing. 
Spa-negative isolates were confirmed as S. aureus by MALDI-
TOF. The spa-typing [Harmsen et al. 2003. J Clin Microbiol. 
41: 5442–5448] and additional typing by multi locus sequence 
typing (MLST) [Enright et al. 2000. J Clin Microbiol. 38: 
1008–1015] was annotated using eBURST v.3 software (www.
mlst.net). Based on the spa and MLST typing, each isolate 
was assigned to a clonal complex (CC). For MRSA isolates, 
presence of the mecA or mecC methicillin resistance genes 
was confirmed by PCR [Larsen et al. 2008. Clin Microbiol 
Infect. 14: 611–614; Stegger et al. 2012. Clin Microbiol Infect. 
18: 395–400]. For all isolates, presence of lukF-PV gene (PVL) 
was demonstrated by PCR [Larsen et al. 2008. Clin Microbiol 
Infect. 14: 611–614; Stegger et al.2012. Clin Microbiol Infect. 
18: 395–400].
10.5 Susceptibility testing
Antimicrobial susceptibility testing of Salmonella, Campylobacter, 
indicator E. coli, Enterococcus and the veterinary pathogens was 
performed as microbroth dilution MIC with Sensititre (Trek 
Diagnostic Systems Ltd., East Grinstead, UK). Inoculation 
and incubation procedures were in accordance with the CLSI 
guidelines [Clinical and Laboratory Standards Institute, USA] 
and the European standard ISO 20776-1:2006.
The quality control strains Staphylococcus aureus ATCC 29213, 
Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 
27853, Enterococcus faecalis ATCC 29212 and Campylobacter 
jejuni ATCC 33560 were used. 
Isolates from animals and meat were tested at DTU National 
Food Institute, and the Salmonella and Campylobacter isolates 
of human origin were tested at SSI. MIC-testing at DTU National 
Food Institute is accredited by DANAK (the national body for 
accreditation).
One isolate per bacterial species per farm, per meat sample or per 
patient was tested for antimicrobial susceptibility. For Salmonella 
isolates from poultry, one isolate per serotype per flock was 
tested. For isolates in excess numbers (e.g. isolates from healthy 
animals), a random selection was appointed to MIC. 
Table 10.2 presents the interpretation of MIC-values used for 
any combination of bacteria and antimicrobial agent. Since 
2007, data were interpreted by EUCAST epidemiological cut-off 
values (ECOFFs) with a few exceptions described in Table 10.2. 
The corresponding clinical breakpoints validated by EUCAST 
are presented both in Table 10.2 and in the MIC-distribution 
tables to visualize the impact of the use of ECOFFs contra clinical 
breakpoints. In general, if ECOFFs were re-validated and changed 
by EUCAST during the past year, all data presented from previous 
years were interpreted using the changed ECOFFs. All MIC-
distributions are presented in the web annex at www.danmap.
org. Each of the tables provides information on the number 
of isolates, the applied interpretation of MIC-values and the 
estimated level of resistance and confidence intervals.
Multi-resistance was defined as resistance to three or more of the 
antimicrobial classes listed in Table 10.3. Isolates were considered 
fully sensitive if susceptible to all the antimicrobial agents 
included in the test panel.
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Staphylococcus aureus from humans. Susceptibility testing was 
performed by disc diffusion according to EUCAST methodology 
using discs from Oxoid (Ballerup, Denmark) on Mueller-Hinton 
Agar (SSI, Copenhagen, Denmark). The following antimicrobial 
agents were tested: Erythromycin, clindamycin, kanamycin, 
rifampicin, penicillin, cefoxitin, fusidic acid, norfloxacin, linezolid, 
tetracycline, trimethoprim-sulfametoxazole and mupirocin. In 
addition, MRSA isolates were screened for resistance towards 
glycopeptides by spot test on Brain-Heart infusion (BHI) agar 
(Becton Dickinson, Germany) with teicoplanin (5 mg/L) and 
confirmed by Etest® (AB Biodisk, Solna, Sweden) on BHI 
with inoculum of McFarland 2.0. In case of MIC ≥ 8 mg/L for 
vancomycin or MIC ≥12 mg/L for teicoplanin, population analysis 
profile against vancomycin was performed [Wootton et al. 2001. J 
Antimicrob Chemother.47: 399–403].
Invasive Streptococcus pneumoniae from humans. Screening 
for penicillin- and erythromycin-resistant S. pneumoniae was 
performed with 1 μg oxacillin discs and 15 μg erythromycin discs 
(Oxoid, Roskilde, Denmark), respectively, on Müller-Hinton 
agar (Müller-Hinton plate, 5% blood, 20 mg beta-NAD, SSI 
Diagnostica, Hillerød, Denmark). Penicillin and erythromycin 
MICs were determined using STP6F plate, Sensititre (Trek 
Diagnostic Systems Ltd., East Grinstead, UK) as recommended 
by the manufacturer. All breakpoints used were defined by the 
EUCAST. Both fully and intermediary resistant isolates were 
defined as resistant. 
Invasive Streptococcus pyogenes (group A), group B, C and 
G streptococci from humans. Screening for penicillin- and 
erythromycin-resistant streptococci was performed with 1 unit 
penicillin G discs and 15 μg erythromycin discs (Oxoid, Roskilde, 
Denmark), respectively, on Müller-Hinton Agar (Müller-Hinton 
plate, 5% blood, 20 mg beta-NAD, SSI Diagnostica, Hillerød, 
Denmark). Erythromycin-resistant streptococci were tested with 
a 15 μg erythromycin disc and a 2 μg clindamycin disc (Oxoid) on 
Müller-Hinton agar. Erythromycin MICs were determined using 
the Etest® (AB Biodisk, Solna, Sweden) on Müller-Hinton agar 
incubated at 36°C in 5% CO2. The breakpoints used were defined 
by the EUCAST. Both fully and intermediary resistant isolates 
were defined as resistant.
 
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive E. 
faecium and E. faecalis from humans. The DCM performed 
either disk (Oxoid, Basingstoke, UK) or tablet (Neo-Sensitabs®, 
A/S Rosco) diffusion susceptibility testing on a number of 
media. As per September 2012, all DCM except Rigshospitalet 
used breakpoints defined by EUCAST. 
Data on antimicrobial resistance from private hospitals and 
clinics and from psychiatric hospitals were excluded. All 
submitting laboratories participate in national and international 
quality assurance collaborations such as the United Kingdom 
National External Quality Assessment Schemes (NEQAS).
Table 10. 3. Definitions of antimicrobial classes for calculation of multi-resistance (MR) in zoonotic and indicator bacteria, 
DANMAP 
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the panel for the selected bacterial species
a) An isolate is considered multi-resistant if  resistant to three or more of the ten antimicrobial classes
b) An isolate is considered multi-resistant if  resistant to three or more of the six antimicrobial classes
Antimicrobial
classes
Salmonella and 
E. coli(a) Campylobacter
(b) Enterococcus(a)
Tetracyclines Tetracycline Tetracycline Tetracycline
Phenicoles Chloramphenicol and/or florfenicol Chloramphenicol Chloramphenicol
Penicillins Ampicillin Ampicillin and/or penicillin 
Cephalosporins Ceftiofur and/or cefotaxime
Sulfonamides Sulfonamides  
Trimethoprim Trimethoprim  
Aminoglycosides I
 
Gentamicin Gentamicin   
Gentamicin and/or 
kanamycin and/or 
streptomycin 
Aminoglycosides II  Streptomycin Streptomycin 
Quinolones Ciprofloxacin and/or nalidixic acid  
Ciprofloxacin  and/or 
nalidixic acid  
Ciprofloxacin  and/or 
nalidixic acid  
Polymycins Colistin 
Macrolides Erythromycin Erythromycin
Glycopeptids Vancomycin and/or teicoplanin 
Ionophores Salinomycin
Oxazolidinones Linezolid
Glycylcyclines Tigecycline 
DANMAP 2012
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10.6 Data handling
10.6.1  Animal  
The results from the analysis of all animal samples - positive 
as well as negative findings - and of the bacteria isolated and 
the susceptibility testing were stored in an Oracle Database 
9i Enterprise Edition® at DTU National Food Institute. The 
susceptibility data were stored as continuous values as well as 
categorised as susceptible or resistant as defined by the relevant 
ECOFF. Each isolate was identified by the bacterial species, the 
subtype as applicable and by the date of sampling and species 
of animal. Information on the farm of origin was also recorded. 
All handling and evaluation of results were carried out using 
SAS®Software, SAS Enterprise Guide 4.3.
10.6.2  Meat 
Results from the analysis of food samples were reported via 
the database administrated by the DVFA, except for the data 
on Salmonella, which were reported to and extracted from 
the laboratory database at DTU National Food Institute. 
For each bacterial isolate, information was available on food 
type, bacterial species, date and place of sampling, date of 
examination, country of slaughter, the Regional Veterinary and 
Food Control Authorities collecting and processing the sample, 
and an identification number, which makes it possible to 
obtain further information about the isolate from the relevant 
authorities. Furthermore, information about the country of 
origin was recorded whenever possible.
10.6.3  Human  
Salmonella and Campylobacter. Data on Salmonella and 
Campylobacter infections are stored in the Danish Registry 
of Enteric Pathogens (SQL database) maintained by SSI. This 
register includes only one isolate per patient within a window 
of six months and includes data on susceptibility testing of 
gastrointestinal pathogens.
Staphylococcus aureus. For MRSA, data on the characteristics 
of the isolates and the clinical/epidemiological information were 
obtained from the Danish MRSA register at SSI (mandatory 
reportable). Patients were registered, regardless of whether it 
was colonisation or infection, the first time they were diagnosed 
with MRSA or when a new subtype was demonstrated. Based 
on the reported information, MRSA cases were classified 
as colonization/active screening (i.e. surveillance samples 
to detect nasal, throat, gut or skin colonization), imported 
infection (i.e. acquired outside Denmark), infection acquired 
in a Danish hospital, defined as diagnosed >48 hours after 
hospitalisation with no sign of infection at admittance (HA-
MRSA) or infection diagnosed outside hospitals (community 
onset).
MRSA cases with community onset were further classified 
according to risk factors during the previous 12 months as 
either health-care associated with community onset (HACO) 
or community-acquired (CA). Health-care associated risk 
factors included prior hospitalizations or stay in long-term care 
facilities within 12 months prior to MRSA isolation and being 
a health-care worker. Community risk factors included known 
MRSA-positive household members or other close contacts.
Streptococcus pneumoniae, Streptococcus pyogenes (group 
A streptococci), group B, C and G streptococci. Data on 
susceptibility testing of isolates were stored as MICs in a Microsoft® 
Access database placed on a SQL server at SSI. Analysis including 
selection of isolates from blood and spinal fluid samples and 
removal of duplicate isolates was performed in Microsoft® Access.
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive E. 
faecium and invasive E. faecalis. Twelve out of thirteen DCM 
in Denmark provided data on resistance levels in E. coli, K. 
pneumoniae, invasive P. aeruginosa, invasive E. faecium and 
invasive E. faecalis isolates. Data were extracted from the 
following laboratory information systems:
•	 ADBakt (Autonik AB, Skoldinge, Sweden) for the DCM at 
Hvidovre, Herlev and Aalborg Hospitals.
•	 MADS (DCM Skejby Hospital, Aarhus, Denmark) for 
the DCM at Rigshospitalet and Slagelse/Region Sealand, 
Odense, Esbjerg, Vejle, Herning/Viborg, and Aarhus 
(Skejby) Hospitals.
•	 SafirLIS Microbiology (Profdoc Lab AB, Borlänge, 
Sweden) for the DCM at Hillerød Hospital.
Resistance data on the first isolate per patient per year 
were included. Generally, resistance data were excluded if 
susceptibility to a certain antimicrobial agent was tested on 
only a selected number of isolates.
10.6.4  Statistical tests
Significance tests of differences between proportions of 
resistant isolates were calculated using SAS®Software, SAS 
Enterprise Guide 4.3 or StatCalc in EpiInfo™ v. 6. Difference in 
par-wise comparisons were tested using Chi-square, or Fisher’s 
Exact Test when the number of samples is low (<25). When 
appropriate, significance of temporal trends is tested using 
linear logistic regression using Proc LOGISTC procedure in 
SAS (Likelihood ratio test). 
In the text, commented differences imply statistically 
significant differences where p<0.05. 
When comparing proportions between years, the EUCAST
epidemiological cut-off values for 2012 were also used for 
interpretation of previous years MICs.
Anne Mette Seyfarth, Vibeke Frøkjær Jensen
and Line Skjøt-Rasmussen
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List of abbreviations
DADD  Defined animal daily dose
DAPD  Defined animal daily dose per 1,000 animals per day 
AGP  Antimicrobial growth promoter
ATC  Anatomical Therapeutic Chemical Classification System
ATCvet  Anatomical Therapeutic Chemical Classification System for veterinary medicines
CC  Clonal complex
CHR  Central Husbandry Register
CI  Confidence interval
CNS  Central nervous system
CPR  Danish Civil Registry, register for social security numbers
DAD  Defined Daily Doses per 100 admissions
DBD  Defined Daily Doses per 100 occupied bed-days
DCM  Department of Clinical Microbiology
DDD   Defined Daily Dose
DID   Defined Daily Doses per 1,000 inhabitants per day (DDD/1000 inhabitant-days)
DTU   Technical University of Denmark
DVFA  Danish Veterinary and Food Administration
EARS-Net The European Antimicrobial Resistance Surveillance Network
ECDC  European Centre for Disease Prevention and Control
EFSA  European Food Safety Authority
ESBL  Extended spectrum beta-lactamase
GI  Gastrointestinal
GP  General practitioner
HLGR  High-level gentamicin resistance
MIC  Minimum inhibitory concentration
MRSA  Methicillin-resistant Staphylococcus aureus
N  Number of samples
n   Number of isolates tested for antimicrobial susceptibility
OIE  World Organisation for Animal Health
RFCA  Regional Veterinary and Food Control Authorities
SSI  Statens Serum Institut
VetStat  Danish Register of Veterinary Medicines
VRE  Vancomycin resistant enterococci
WHO   World Health Organization
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Glossary
Anatomical Therapeutic Chemical (ATC) classification. 
International classification system for drug consumption 
studies. The ATC code identifies the therapeutic ingredient(s) 
of each drug for human use according to the organ or system on 
which it acts and its chemical, pharmacological and therapeutic 
properties. Antibacterials for systemic use are known as ATC 
group J01. The ATC classification is maintained by the WHO 
Collaborating Centre for Drug Statistics and Methodology 
(Oslo, Norway) (www.whocc.no/atcddd/indexdatabase/). 
The ATC classification for veterinary medicinal products, 
ATCvet, is based on the same main principles as the ATC 
classification system for medicines for human use and is 
also maintained by the WHO Collaborating Centre for Drug 
Statistics and Methodology (www.whocc.no/atcvet/database/).
Antibacterial agents. Synthetic (chemotherapeutics) or natural 
(antibiotics) substances that destroy bacteria or suppress 
bacterial growth or reproduction [Source: Dorland’s Illustrated 
Medical Dictionary]. Antimycobacterial agents are not 
included. In the section of human consumption, ‘antibacterial 
agents’ are referred to as ‘antimicrobial agents’ (see below).
Antimicrobial agents. The term ‘antimicrobial agents’ covers 
antibacterial, antiviral, coccidiostatic and antimycotic agents. 
In the section on veterinary consumption, the broad term 
‘antimicrobial agents’ is usually used because coccidiostats 
are included. Antiviral substances are not used in veterinary 
medicine, and antimycotics are only registered for topical 
veterinary use and used mainly in companion animals. 
Antimycobacterial agents are not included. The term 
’antibacterial agents’ is only used in the veterinary section 
for precision, to distinguish from use of coccidiostats as feed 
additives (poultry only). In the section of human consumption, 
the term ‘antimicrobial agents’ refers to all antibacterial agents 
for systemic use (J01 in the ATC system).
Broiler. A type of chicken raised specifically for meat 
production. In Denmark, the average weight after slaughter is 
1.66 kg.
Central Husbandry Register (CHR). This is a register of all 
Danish farms defined as geographical sites housing production 
animals. It contains information concerning ownership, 
farm size, animal species, age groups, number of animals and 
production type. Each farm has a unique farm identity number 
(CHR-number).
Defined animal daily dose (DADD). DADD is the average 
maintenance dose per day for a drug used for its main indication 
in the appropriate animal species. DADD has been specifically 
defined for use in DANMAP and does not always completely 
match the “prescribed daily dose” or the recommended dosage 
in the Summaries of Product Characteristics (SPC). In contrast 
to the ADD previously used in DANMAP, the DADD not has 
been defined for each antimicrobial agent, administration route 
and animal species but at product level. In DANMAP 2012, the 
DADD replaces the ADD (as defined in VetStat), which has 
been used since DANMAP 2003. For more details, see Chapter 
10, Materials and Methods. The DADDs used in DANMAP 
2012 are presented the web annex.
DADD per 1,000 animals per day (DAPD). Trends in 
veterinary consumption, both within and across species, are 
presented in DAPD, allowing for comparison between sectors 
and adjusting for changes in live biomass. The estimated live 
biomass is expressed as the number of standard animals with 
an estimated average weight and lifetime. This may also be 
referred to as the ‘standard-animals-at-risk’ and takes into 
account species differences in body-mass and life-span. DAPD 
is a statistical measure, providing an estimate of the proportion 
of animals (in thousands) treated daily with a particular 
antimicrobial agent. For example, 10 DAPDs indicate that an 
estimated 1% of the population, on average, receives a certain 
treatment on a given day (Section 4.3 and Chapter 10, Materials 
and Methods). 
Defined Daily Dose (DDD). This is the assumed average 
maintenance dose per day for a drug used for its main indication 
in adults. It should be emphasised that the Defined Daily Dose 
is a unit of measurement and does not necessarily reflect the 
recommended or prescribed daily dose. DDDs provide a fixed 
unit of measurement independent of price and formulation, 
enabling the assessment of trends in drug consumption and to 
perform comparisons between population groups. The DDDs 
are defined and revised yearly by the WHO Collaborating 
Centre for Drug Statistics and Methodology (www.whocc.no/
atcddd/indexdatabase). 
DDD per 1,000 inhabitants per day (DID). Consumption in 
both primary health care, hospital care and the overall total 
consumption is presented in DID, allowing for comparison 
between sectors and for illustration of the consumption in 
hospital care without taking account of hospital activity 
(discharges). Data presented in DID provide a rough estimate 
of the proportion of the population within a defined area treated 
daily with certain drugs. For example, 10 DIDs indicates that 
1% of the population on average gets a certain treatment daily. 
In figure presented as DDD/1,000 inhabitant-days.
ESBL. In the DANMAP report, ‘ESBL’ describes the clinically 
important acquired beta-lactamases with activity against 
extended-spectrum cephalosporins; including the classical 
class A ESBLs (CTX-M, SHV, TEM), the plasmid-mediated 
AmpC and OXA-ESBLs [Giske et al. 2009. J. Antimicrob. 
Chemother. 63: 1-4].
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Finishers. Pigs from 30-100 kg live weight, from after the 
weaner stage to time of slaughter.
Fully sensitive. An isolate will be referred to as fully sensitive if 
susceptible to all antimicrobial agents included in the test panel 
for the specific bacteria.
Intramammaria. Antimicrobial agents for local application in 
the mammary gland (udder) to treat mastitis.
Layer. A hen raised to produce eggs for consumption.
Minimum inhibitory concentration (MIC). This is the 
lowest concentration of antimicrobial agent in a given culture 
medium, e.g. broth or agar, below which growth of the bacteria 
is not inhibited.
Multi-resistant. A Salmonella, Campylobacter, Enterococcus 
or E. coli isolate is assumed multi-resistant if it is resistant 
to three or more of the antimicrobial classes. The number of 
antimicrobial classes and antimicrobial agent included therein 
depend on the test panel for each bacterium (See Table 10.3, 
Materials and methods).
Pet animals. Dogs, cats, birds, mice, guinea pigs and more 
exotic species kept at home for pleasure, rather than one kept 
for work or food. Horses are not included as pet animals. The 
live biomasses of Danish pets used for estimating veterinary 
consumption only include dogs and cat.
Piglet. The newborn pig is called a piglet from birth till they are 
permanently separated from the sow at 3-4 weeks of age. The 
weight of the piglet at weaning is approximately 7 kg.
Poultry. The major production species are fowl - Gallus gallus 
(broilers, layers, including breeding and rearing) and turkey. 
Regarding antimicrobial consumption, ‘poultry’ also includes 
domesticated ducks, geese, game birds and pigeons.
Sow.  Any breeding female pig on the farm.
Weaner. Any pig of 7–30 kg live weight after it has been weaned.
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